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The full references to the article and statements about contribution of the
author to each work are presented here:
1. SVM applications in bioinformatics
Byvatov E., Schneider G.
Appl. Bioinformatics. 2003;2(2):67-77.
Evgeny Byvatov contributed to this review by providing a comprehensive
discussion of the available applications of the Support Vector Machine in
Chemo- and Bioinformatics.
2. Comparison of support vector machine and artificial neural network
systems for drug/nondrug classification
Byvatov E., Fechner U., Sadowski J., Schneider G.
J. Chem. Inf. Comput. Sci. 2003; 43(6):1882-9
Evgeny Byvatov contributed to this paper by providing an extensive4
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4 Introduction
4.1 The Drug Discovery process
Drug discovery and development is a creative, complex and highly
regulated process. On average, it takes approximately 15 years to navigate a
medication through the progression from the researcher laboratory to the patient.
Although the development of new technologies has provided opportunities to
significantly shorten that timeline, the process remains scientifically complex, and
must be designed to take advantage of serendipity. [1]
Generating leads refers to the process of designing and synthesizing novel
compounds with desired properties. Traditionally, it begins in a research
laboratory by selecting and examining specific biological targets. These targets
are disease-relevant, which means they play an important role in the progression
of the disease or its symptoms. The desired targets should also be drugable, which
refers to the ability to design or find small molecules that act on the target. [2]
These chemical compounds, often referred to as “small molecules”, undergo
extensive laboratory testing to determine their activity on the target. Those with
biologically active structures, or structures that allow interaction with the
biological target, become potential candidates for further study. Multiple
compounds are usually identified and tested to determine which have the desired
profile. Lead candidates are those with promising characteristics that are selected
for further studies. Such molecules “lead the way” to develop new drugs.
The lead molecule is defined as a chemical entity that (a) already shows
some of the desired properties, and (b) is small enough to be the core structure for
the various chemical variations and additions to build analogs. [3]
In the past, researchers were limited by the number of leads they had
access to and the speed that leads could be assessed.[4] With the advent of high-
throughput technologies, the number of compounds and speed of assessment has
significantly increased.
“Optimizing” the lead refers to the process used to manipulate the
compound to improve its biological or therapeutic properties. Compounds are
transformed into chemical structures that can be produced as the dosage forms for
use in preclinical studies, which confirm the compound biological activity, safety,
toxicology and pharmacokinetic profile. [5] Chemical leads are molecules with
known structures which possess many, but not all of the properties described in
the target product profile. The process of optimizing leads concludes with the
selection of an Early Development Candidate (EDC), which is the drug candidate
selected for more intense study. If a compound passes this step, applications are
made to governmental regulatory authorities to request permission for human
clinical testing. [6]
During clinical trials, test medication is administered to healthy volunteers
and patients. (Phase I) This step is highly regulated by government agencies.
Instructions for the conduct of clinical trials are specifically outlined in official
documents, such as the Code of Federal Regulations in the US. [7]7
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The clinical trial process is separated into different phases, each with a
specific objective. Initial human tests, called phase I studies, usually involve a
small number (20 to 80) of healthy volunteers, and are conducted to determine
dosing levels and assess the safety, tolerability, dose response and metabolic
properties of the compound in humans.
In phase II studies, the drug is administered to a larger number (50 to 500)
of subjects. Unlike phase I trials which involve healthy volunteers, phase II
studies confirm the drug safety profile in patients diagnosed with the disease
being studied. Phase II studies can be divided into two categories: phase IIa
studies usually examine a variety of doses to identify the initial dosing regimen.
Larger phase II studies, often referred to as phase IIb, confirm the safety in a
larger patient population, and define the optimal dosing regimen. Because they
are often double blinded, they may also provide preliminary data on the drug
efficacy.
Phase III studies are much larger in scale, and gather additional
information about the drug safety and effectiveness in the intended patient
population. Depending on the therapeutic area, thousands of patients may be
enrolled in studies that compare the drug being tested to one or more currently
available therapies. The objective is to show statistical superiority via either
improved efficacy or safety over current treatments. This critical endpoint is
needed to obtain regulatory approval to market the drug.
In spite of the fact that phase III trials are one of the last important steps
before requesting marketing approval, drug candidates are discontinued if the
study results are negative. Discontinuing drug development at such a late stage in
the process contributes to the enormous cost of bringing drugs to market. [7]
We have described above overview of the drug development process,
focusing on the Lead Identification and Preclinical Development. These are the
main areas relevant for our research. Figure 1 shows an overview of the early
drug discovery process.
Computers have become much more powerful and cheaper over the last
years, thereby allowing in silico screening using larger databases and more
Target
Validation
Lead
Identification
Preclinical
Development
Target
Identification
Hit
Identification
Lead
Optimization
Drug
Bioinformatics
Chemoinformatics
Figure 1. Overview of the early drug discovery process8
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sophisticated algorithms. Using appropriate virtual screening techniques, it might
become possible to predict properties like affinity to the target, absorption,
distribution, metabolism, excretion or toxicity (ADME/Tox) at an earlier stage of
the research pipeline, reducing expenditure per successful compound. Only the
most promising compounds will then be synthesized and screened, potentially
yielding a higher fraction of active structures in the selected subset and higher
survival rates. Virtual screeining can allow reevaluation of the already existing
databases. Some of these compounds might already possess the desired properties,
which could be detected by, for instance, similarity searching. [8]
In this thesis I present the successful application of Machine Learning to the
early virtual screening. Machine Learning existed as a separate field for many
years. The first connection between this mathematical area and Life Science was
done recently by Bioinformatics. The similar connection between Chemistry and
Machine Learning was done after the first attempts to describe molecules with the
help of descriptors.
In the beginning of this thesis I gave a short introduction to the drug
discovery process. Virtual Screening can be applied in almost every
pharmaceutical project: from the choice of the hits till ADME (Absorption,
Distribution, Metabolism and Toxicity) filter. With virtual screening it is possible
to significantly speed up these projects.
There is an introduction to the techniques that are used for describing
molecules as a descriptor vector in Chapter 4.2. Descriptor vectors are the typical
input for the Learning Machines like a Neural Network or the Support Vector
Machine. We focus on the representations applied in our research. We have
mostly calculated descriptors based on the 2D molecular graph. The typical
examples are physicochemical properties, atom and bond counts, etc. (Chapter
4.2.1) as well as CATS descriptors (Chapter 4.2.2). The other types of descriptors
are 3D based descriptors. Their success strongly depends on the conformer that is
used during calculation of the 3D descriptors.
We have also applied molecular fingerprints as a method to describe
molecules. Normally fingerprints are a poor choice, when a Neural Network is to
be trained. The fingerprint vector is simply too long. In our case it was an
exception. We applied fingerprints together with SVM. (Support Vector
Machine). The advantage of the SVM in comparison to other methods is: it can be
trained in a very high-dimensional space. We were the first who introduced this
consecutive application of fingerprints and SVM in Chemoinformatics. (Chapter
7.7)
In Chapter 4.3 I focus on the on the SVM itself. Our predictions were
almost always based on the trained SVM. SVM was our main tool. Due to the
space limitation we usually made only brief introduction to SVM in all published
articles. In order to compensate that we are giving here (in Chapter 4.3) the
complete description of the SVM: SVM theory, optimal hyperplane, soft-margin
hyperplane, quadratic programming as a technique to find the optimal hyperplane.
We also include a discussion of the kernel functions that influence exact form of
the separating surfaces.
In Chapter 4.4 we introduced Feature Selection methods that we used in
our research. In this section we emphasise the difference between Filter and9
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Wrapper based approaches to the Feature Selection. In our article (Chapter 7.3)
we compared advantages and disadvantages of the both methods in application to
the Virtual Screening.
Chapter 7 contains publications that constitute the basis of this thesis.
Our first publication was a review article. (Chapter 7.1) In this article we
give an overview of the applications of the SVM in Bio- and Chemoinfromatics.
We performed a detailed comparison of SVM and Neural Networks in the next
publication in order to justify usage of this method in our research. (Chapter 7.2)
Development of the new methods is described in Chapters 7.3 and 7.8. The
first article is SVM-based feature selection technique. We selected features that
are relevant to the certain biological activity of the molecule. The comparison of
our methods with other standard methods demonstrated its superior performance.
In the second article (Chapter 7.8) we applied Active Learning to the Virtual
Screening.
In publications from the Chapters 7.5, 7.6 and 7.7 we applied virtual
screening to the practical drug design. In publications from Chapter 7.6 we
constructed an ADME filter. This filter was applied by Aventis Pharma to the
early recognition of the potential CYP 2C9 ligands.
This thesis is an example of successful applications of virtual screening in
Drug Design using Support Vector Machine.10
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4.2 From molecules to Descriptors
In this chapter we will describe methods that are used for transformation
of the chemical structures of molecules to a form suitable for the analysis by
Machine Learning algorithms. A typical way to represent molecules for this
analysis is by descriptors. Descriptors are vectors in a high-dimensional space.
Chemical properties of the molecules are mapped to the individual components of
these vectors. We will mainly distinguish two types of descriptors, 2D and 3D-
based. Calculation of the first type of descriptors is based only on the molecular
graph. The second type required estimation of the possible 3D conformation of
the underlying molecule.
Space limitation in the articles usually did not allow us to introduce
descriptors that we used in sufficient details. This is the reason why we include
this introduction here. Calculation of almost all descriptors was done using a
standard MOE implementation. [9] Descriptors codes and complementary
information is provided in the tables below.
We will treat separately CATS descriptors [10] and fingerprints. [11] Both
of these types of molecular descriptors, in our research, were 2D based.
4.2.1 2D Molecular Descriptors
Descriptors that can be derived more or less directly from the molecular
graph are commonly used for the generation quantitative structre activity
relationaships (QSAR). In general, two-dimentional descriptors are
computationally inexpensive, which make them attractive for high throughput
applications.
2D molecular descriptors are defined to be numerical properties that can
be calculated from the connection table representation of a molecule (e.g.,
elements, formal charges and bonds, but not atomic coordinates). 2D descriptors
are, therefore, not dependent on the conformation of a molecule and are most
suitable for large database studies due to the speed of calculation.
3D-based descriptors, in contrary to 2D, are computationally more
expensive and should be used only when their application is well justified.
4.2.1.1 Atom Counts and Bond Counts
The atom count and bond count descriptors are functions of the counts of
atoms and bonds (subdivided according to various criteria). We used the MOE
implementation. [9] (see Table 1)
Table 1. Atom Counts and Bond Counts Descriptors.
MOE-Code Description
a_aro Number of aromatic atoms.11
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a_count Number of atoms (including implicit hydrogens). This is
calculated as the sum of (1+hi) over all non-trivial atoms i.
a_heavy Number of heavy atoms #{Zi|Zi>1}.
a_ICM Atom information content (mean). This is the entropy of the
element distribution in the molecule (including implicit
hydrogens but not lone pair pseudo-atoms). Let ni be the
number of occurrences of atomic number i in the molecule.
Let pi=ni/n where n is the sum of the ni. The value of a_ICM
is the negative of the sum over all i of pilog pi.
a_IC Atom information content (total). This is calculated to be
a_ICM times n.
a_nH Number of hydrogen atoms (including implicit hydrogens).
This is calculated as the sum of hi over all non-trivial atoms i
plus the number of non-trivial hydrogen atoms.
a_nB Number of boron atoms: #{Zi|Zi = 5}.
a_nC Number of carbon atoms: #{Zi|Zi=6}.
a_nN Number of nitrogen atoms: #{Zi|Zi=7}.
a_nO Number of oxygen atoms: #{Zi|Zi=8}.
a_nF Number of fluorine atoms: #{Zi|Zi=9}.
a_nP Number of phosphorus atoms: #{Zi|Zi=15}.
a_nS Number of sulfur atoms: #{Zi|Zi=16}.
a_nCl Number of chlorine atoms: #{Zi|Zi=17}.
a_nBr Number of bromine atoms: #{Zi|Zi=35}.
a_nI Number of iodine atoms: #{Zi|Zi=53}.
b_1rotN Number of rotatable single bonds. A bond is rotatable if it is
not in a ring, and neither atom of the bond is such that
(di+hi)<2.
b_1rotR Fraction of rotatable single bonds: b_1rotN divided by
b_count.
b_ar Number of aromatic bonds.
b_count Number of bonds (including implicit hydrogens). This is
calculated as the sum of (di/2 + hi) over all non-trivial atoms
i.
b_double Number of double bonds. Aromatic bonds are not considered12
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to be double bonds.
b_heavy Number of bonds between heavy atoms.
b_rotN Number of rotatable bonds. A bond is rotatable if it is not in
a ring, and neither atom of the bond is such that (di+hi)<2.
b_rotR Fraction of rotatable bonds: b_rotN divided by b_count.
b_single Number of single bonds (including implicit hydrogens).
Aromatic bonds are not considered to be single bonds.
b_triple Number of triple bonds. Aromatic bonds are not considered
to be triple bonds.
VAdjMa Vertex adjacency information (magnitude): 1 + log2m where
m is the number of heavy-heavy bonds. If m is zero, then
zero is returned.
VAdjEq Vertex adjacency information (equality): -(1-f)log2(1-f) – f
log2f where f = (n
2- m) / n
2, n is the number of heavy atoms
and m is the number of heavy-heavy bonds. If f is not in the
open interval (0,1), then 0 is returned.
4.2.1.2 Physical Properties
The physical properties descriptors capture electronic, lipophilic and steric
characteristics of a molecule. [12] Very well known examples of such properties
are molecular weight, octanol-water partitioning coefficient (LogP), the total
energy, the ionization potential, the charge, the molecular refractability and
hundreds of others. [13]
Many physical property descriptors (Table 2) can be easily measured, but
for most of them good and fast computer algorithms exist that can to a certain
extent replace the measurement. The following physical properties were used in
this research (Chapters 7.2,7.3 and 7.6). They can be calculated by MOE [9] from
the connection table (i.e without dependence on conformation) of a molecule.
Table 2. Physical Properties descriptors
MOE-Code Description
AM1_dipole The dipole moment calculated using the AM1 Hamiltonian
[14].
AM1_E The total energy (kcal/mol) calculated using the AM1
Hamiltonian [14].
AM1_Eele The electronic energy (kcal/mol) calculated using the AM1
Hamiltonian [14].
AM1_HF The heat of formation (kcal/mol) calculated using the AM113
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Hamiltonian [14].
AM1_IP The ionization potential (kcal/mol) calculated using the
AM1 Hamiltonian [14].
AM1_HF The energy(eV) of the Lowest Unoccupied Molecular
Orbital calculated using the AM1 Hamiltonian [14].
AM1_HOMO The energy (eV) of the Highest Occupied Molecular
Orbital calculated using the MOPAC AM1 Hamiltonian
[14].
apol Sum of the atomic polarizabilities (including implicit
hydrogens) with polarizabilities taken from [15].
bpol Sum of the absolute value of the difference between
atomic polarizabilities of all bonded atoms in the molecule
(including implicit hydrogens) with polarizabilities taken
from [15].
density Molecular mass density: Weight divided by vdw_vol.
FCharge Total charge of the molecule (sum of formal charges).
MNDO_dipole The dipole moment calculated using the MNDO
Hamiltonian [14].
MNDO_E The total energy (kcal/mol) calculated using the MNDO
Hamiltonian [14].
MNDO_Eele The electronic energy (kcal/mol) calculated using the
MNDO Hamiltonian [14].
MNDO_HF The heat of formation (kcal/mol) calculated using the
MNDO Hamiltonian [14].
MNDO_IP The ionization potential (kcal/mol) calculated using the
MNDO Hamiltonian [14].
mr Molecular refractivity (including implicit hydrogens). This
property is calculated from an 11 descriptor linear model
[16] with r
2= 0.997, RMSE = 0.168 on 1,947 small
molecules.
PM3_dipole The dipole moment calculated using the PM3 Hamiltonian
[14].
PM3_E The total energy (kcal/mol) calculated using the PM3
Hamiltonian [14].
PM3_Eele The electronic energy (kcal/mol) calculated using the PM3
Hamiltonian [14].14
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PM3_HF The heat of formation (kcal/mol) calculated using the PM3
Hamiltonian [14].
PM3_IP The ionization potential (kcal/mol) calculated using the
PM3 Hamiltonian [14].
PM3_HF The energy(eV) of the Lowest Unoccupied Molecular
Orbital calculated using the PM3 Hamiltonian [14].
SMR Molecular refractivity (including implicit hydrogens). This
property is an atomic contribution model [17] that assumes
the correct protonation state (washed structures). The
model was trained on ~7000 structures and results may
vary from the mr descriptor.
Weight Molecular weight (including implicit hydrogens) with
atomic weights taken from [15].
logP(o/w) Log of the octanol/water partition coefficient (including
implicit hydrogens). This property is calculated from a
linear atom type model [18] with r
2 = 0.931, RMSE=0.393
on 1,827 molecules.
Reactive Indicator of the presence of reactive groups. A non-zero
value indicates that the molecule contains a reactive group.
The table of reactive groups is based on the Oprea set [19]
and includes metals, phospho-, N/O/S-N/O/S single bonds,
thiols, acyl halides, Michael Acceptors, azides, esters, etc.
SlogP Log of the octanol/water partition coefficient (including
implicit hydrogens). This property is an atomic
contribution model [17] that calculates logP from the given
structure; i.e., the correct protonation state (washed
structures). Results may vary from the logP(o/w)
descriptor. The training set for SlogP was ~7000
structures.
TPSA Polar surface area calculated using group contributions to
approximate the polar surface area from connection table
information only. The parameterization is that of Ertl et al.
[20].
vdw_vol van der Waals volume calculated using a connection table
approximation.
vdw_area Area of van der Waals surface calculated using a
connection table approximation.15
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4.2.1.3 Adjacency and Distance Matrix Descriptors
Descriptors of this class are based on either the adjacency matrix or the
topological distance matrix. The adjacency matrix M of a molecular graph
consists of entries aij = 1 for adjacent vertices, and aij = aji = 0 otherwise. The
entries d of the topological distance matrix D hold the minimal number of edges
between vertex i and vertex j.
The adjacency matrix of CH3CH=O is displayed on the left of Figure 2
and its distance matrix is displayed on the right (Figure 2):
Petitjean [21] defines the “eccentricity” of a vertex to be the longest path
from that vertex to any other vertex in the graph. The graph “radius” is the
smallest vertex eccentricity in the graph and the graph “diameter” as the largest
vertex eccentricity. These values are calculated using the distance matrix and are
used for several descriptors described below.
The following descriptors were calculated by MOE from the distance and
adjacency matrices of the heavy atoms [9] used in the research projects described
in chapters 7.2,7.3 and 7.6. (see Table 3)
Table 3. Adjacency and Distance Matrix Descriptors.
MOE-Code Description
balabanJ Balaban's connectivity topological index [22].
Diameter Largest value in the distance matrix [21].
petitjean Value of (diameter - radius) / diameter.
petitjeanSC Petitjean graph Shape Coeffecient as defined in [21]:
(diameter - radius) / radius.
Radius If ri is the largest matrix entry in row i of the distance matrix
D, then the radius is defined as the smallest of the ri [21].
VDistEq If m is the sum of the distance matrix entries then VdistEq is
defined to be the sum of log2 m - pi log2 pi / m where pi is the
number of distance matrix entries equal to i.
VDistMa If m is the sum of the distance matrix entries then VDistMa is
C1 0 1 1 1 1 0 0 0 1 1 1 1 2 2
H2 1 0 0 0 0 0 0 1 0 2 2 2 3 3
H3 1 0 0 0 0 0 0 1 2 0 2 2 3 3
H4 1 0 0 0 0 0 0 1 2 2 0 2 3 3
C5 1 0 0 0 0 1 1 1 2 2 2 0 1 1
H6 0 0 0 0 1 0 0 2 3 3 3 1 0 2
O7 0 0 0 0 1 0 0 2 3 3 3 1 2 0
C1
C5 H2
H3
H4
H6
O7
Figure 2. Calculation of the adjacent matrix using molecular graph representation.16
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defined to be the sum of log2m - Dij log2 Dij / m over all i
and j.
weinerPath Wiener path number: half the sum of all the distance matrix
entries as defined in [23] and [24].
weinerPol Wiener polarity number: half the sum of all the distance
matrix entries with a value of 3 as defined in [23].
4.2.1.4 Connectivity (Kier&Hall) and Kappa Shape Indices
Connectivity and Kappa Shape Indices were used in our following
research projects: Chapters 7.2,7.3 and 7.6.
The introduction to this type of descriptors is included here, for their
calculation the MOE package was applied. [9] For a heavy atom i let vi = (pi - hi) /
(Zi - pi - 1) where pi is the number of  and  valence electrons of atom i. The
Kier and Hall chi connectivity indices are calculated from the di and vi
values.Here hi, Zi and di are defined as follows:
1) Z denotes the atomic number of an atom. Heavy atoms are atoms that have
an atomic number strictly greater than 1.
2) The hydrogen count, h, of an atom is the number of hydrogens to which it is
(or should be) attached. This count includes all hydrogen atoms that are
necessary to fill valence.
3) The heavy degree, d, of an atom is the number of heavy atoms to which it is
bonded. That is, d is the number of bonded neighbors of the atom in the
hydrogen suppressed graph.
The Kier and Hall kappa molecular shape indices [25] compare the
molecular graph with minimal and maximal molecular graphs, and are intended to
capture different aspects of molecular shape. In the following description (Table
4), n denotes the number of atoms in the hydrogen suppressed graph, m is the
number of bonds in the hydrogen suppressed graph and a is the sum of (ri/rc - 1)
where ri is the covalent radius of atom i, and rc is the covalent radius of a carbon
atom.
Table 4. Connectivity and Kappa Shape Indices.
MOE-Code Description
chi0 Atomic connectivity index (order 0) from [25] and [26]. This
is calculated as the sum of 1/sqrt(di) over all heavy atoms i
with di > 0.
chi0_C Carbon connectivity index (order 0). This is calculated as the
sum of 1/sqrt(di) over all carbon atoms i with di> 0.
chi1 Atomic connectivity index (order 1) from [25] and [26]. This17
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is calculated as the sum of 1/sqrt(didj) over all bonds
between heavy atoms i and j where i < j.
chi1_C Carbon connectivity index (order 1). This is calculated as the
sum of 1/sqrt(didj) over all bonds between carbon atoms i
and j where i < j.
chi0v Atomic valence connectivity index (order 0) from [25] and
[26]. This is calculated as the sum of 1/sqrt(vi) over all heavy
atoms i with vi > 0.
chi0v_C Carbon valence connectivity index (order 0). This is
calculated as the sum of 1/sqrt(vi) over all carbon atoms i
with vi > 0.
chi1v Atomic valence connectivity index (order 1) from [25] and
[26]. This is calculated as the sum of 1/sqrt(vivj) over all
bonds between heavy atoms i and j where i < j.
chi1v_C Carbon valence connectivity index (order 1). This is
calculated as the sum of 1/sqrt(vivj) over all bonds between
carbon atoms i and j where i < j.
Kier1 First kappa shape index: (n-1)
2 / m
2 [25].
Kier2 Second kappa shape index: (n-1)
2/ m
2 [25].
Kier3 Third kappa shape index: (n-1) (n-3)
2 / p3
2 for odd n, and (n-
3) (n-2)
2 / p3
2 for even n [25].
KierA1 First alpha modified shape index: s (s-1)
2 / m
2 where s = n +
a [25].
KierA2 Second alpha modified shape index: s (s-1)
2 / m
2 where s = n
+ a [25].
KierA3 Third alpha modified shape index: (n-1) (n-3)
2 / p3
2 for odd
n, and (n-3) (n-2)
2/ p3
2 for even n where s = n + a [25].
KierFlex Kier molecular flexibility index: (KierA1) (KierA2) / n [25].
Zagreb Zagreb index: the sum of di
2 over all heavy atoms i.
4.2.1.5 Descriptors of the Surface Areas
The Surface Area descriptors (Table 5) were calculated based on the
estimation of the van der Waals surface area. For each atom the van der Waals
surface area vi was calculated together with the other atomic property, pi. The vi
were calculated using a connection table approximation. Each descriptor in a
series is defined to be the sum of the vi over all atoms i such that pi is in a
specified range (a,b].18
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As pi we used contribution to the logP(o/w) and Molecular Refractivity. In
the descriptions to follow, Li denotes the contribution to logP(o/w) for atom i as
calculated in the SlogP descriptor [17]. Ri denotes the contribution to Molar
Refractivity for atom i as calculated in the SMR descriptor [17]. The ranges were
determined by percentile subdivision over a large collection of compounds as
implemented in MOE. [9]
Table 5. Surface Area Descriptors.
MOE-Code Description
SlogP_VSA0 Sum of vi such that Li <= -0.4.
SlogP_VSA1 Sum of vi such that Li is in (-0.4,-0.2].
SlogP_VSA2 Sum of vi such that Li is in (-0.2,0].
SlogP_VSA3 Sum of vi such that Li is in (0,0.1].
SlogP_VSA4 Sum of vi such that Li is in (0.1,0.15].
SlogP_VSA5 Sum of vi such that Li is in (0.15,0.20].
SlogP_VSA6 Sum of vi such that Li is in (0.20,0.25].
SlogP_VSA7 Sum of vi such that Li is in (0.25,0.30].
SlogP_VSA8 Sum of vi such that Li is in (0.30,0.40].
SlogP_VSA9 Sum of vi such that Li > 0.40.
SMR_VSA0 Sum of vi such that Ri is in [0,0.11].
SMR_VSA1 Sum of vi such that Ri is in (0.11,0.26].
SMR_VSA2 Sum of vi such that Ri is in (0.26,0.35].
SMR_VSA3 Sum of vi such that Ri is in (0.35,0.39].
SMR_VSA4 Sum of vi such that Ri is in (0.39,0.44].
SMR_VSA5 Sum of vi such that Ri is in (0.44,0.485].
SMR_VSA6 Sum of vi such that Ri is in (0.485,0.56].
SMR_VSA7 Sum of vi such that Ri > 0.56.
4.2.1.6 Pharmacophore Feature Descriptors
For our reseach we usually used chemical structures without alternation:
we assumed that it is in the correct protonated form and other structurally relevant
provided information is correct. This is true for the compounds from COBRA
database [27] (Chapter 7.3,7.7,7.8) and some commercially available libraries19
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(Chapters 7.2,7.7,7.8). During the search for the ligands for dopamine D3 receptor
we manually checked the correct protonation form of the compounds. (Chapter
7.5)
This preprocessing of compounds is particularly relevant during
calculation of the Pharmacophore Atom Types. Pharmacophore Atom Type
descriptors (Table 6) consider only the heavy atoms of a molecule and assign a
type to each atom. That is, hydrogens are suppressed during the calculation. The
atom typing mechanism is a rule-based system for assigning pharmacophore
features to atoms. The feature set was Donor, Acceptor, Polar (both Donor and
Acceptor), Positive (base), Negative (acid), Hydrophobe and Other. Assignments
may take into account implied protonation, deprotonation, keto/enol
considerations and tautomerism. [9]
Table 6. Pharmacophore Features Descriptors.
MOE-Code Description
a_acc Number of hydrogen bond acceptor atoms (not counting
acidic atoms but counting atoms that are both hydrogen bond
donors and acceptors such as -OH).
a_acid Number of acidic atoms.
a_base Number of basic atoms.
a_don Number of hydrogen bond donor atoms (not counting basic
atoms but counting atoms that are both hydrogen bond
donors and acceptors such as -OH).
a_hyd Number of hydrophobic atoms.
vsa_acc Approximation to the sum of VDW surface areas of pure
hydrogen bond acceptors (not counting acidic atoms and
atoms that are both hydrogen bond donors and acceptors
such as -OH).
vsa_acid Approximation to the sum of VDW surface areas of acidic
atoms.
vsa_base Approximation to the sum of VDW surface areas of basic
atoms.
vsa_don Approximation to the sum of VDW surface areas of pure
hydrogen bond donors (not counting basic atoms and atoms
that are both hydrogen bond donors and acceptors such as -
OH).
vsa_hyd Approximation to the sum of VDW surface areas of
hydrophobic atoms.
vsa_other Approximation to the sum of VDW surface areas of atoms20
Introduction
typed as "other".
vsa_pol Approximation to the sum of VDW surface areas of polar
atoms (atoms that are both hydrogen bond donors and
acceptors), such as -OH.
4.2.1.7 Partial Charge Descriptors
Descriptors that depend on the partial charge of each atom of a chemical
structure require calculation of those partial charges. An unfortunate complication
is the fact that there are numerous methods of calculating partial charges. The
main difference between these variants is the source of the partial charges.
We used standard MOE implementation of the partial charge descriptors.
[9] Let qi denote the partial charge of atom i as defined above. Let vi be the van
der Waals surface area of atom i (as calculated by a connection table
approximation). The following descriptors were calculated by MOE [9]. (see
Table 7)
Table 7. Partial Charge Descriptors.
MOE-Code Description
PEOE_PC+ Total positive partial charge: the sum of the positive qi.
PEOE_PC- Total negative partial charge: the sum of the negative qi.
PEOE_RPC+ Relative positive partial charge: the largest positive qi
divided by the sum of the positive qi.
PEOE_RPC- Relative negative partial charge: the smallest negative qi
divided by the sum of the negative qi.
PEOE_VSA_POS Total positive van der Waals surface area. This is the sum of
the vi such that qi is non-negative. The vi are calculated using
a connection table approximation.
PEOE_VSA_NEG Total negative van der Waals surface area. This is the sum of
the vi such that qi is negative. The vi are calculated using a
connection table approximation.
PEOE_VSA_PPOS Total positive polar van der Waals surface area. This is the
sum of the vi such that qi is greater than 0.2. The vi are
calculated using a connection table approximation.
PEOE_VSA_PNEG Total negative polar van der Waals surface area. This is the
sum of the vi such that qi is less than -0.2. The vi are
calculated using a connection table approximation.
PEOE_VSA_HYD Total hydrophobic van der Waals surface area. This is the
sum of the vi such that |qi| is less than or equal to 0.2. The vi
are calculated using a connection table approximation.21
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PEOE_VSA_POL Total polar van der Waals surface area. This is the sum of
the vi such that |qi| is greater than 0.2. The vi are calculated
using a connection table approximation.
PEOE_VSA_FPOS Fractional positive van der Waals surface area. This is the
sum of the vi such that qi is non-negative divided by the total
surface area. The vi are calculated using a connection table
approximation.
PEOE_VSA_FNEG Fractional negative van der Waals surface area. This is the
sum of the vi such that qi is negative divided by the total
surface area. The vi are calculated using a connection table
approximation.
PEOE_VSA_FPPOS Fractional positive polar van der Waals surface area. This is
the sum of the vi such that qi is greater than 0.2 divided by
the total surface area. The vi are calculated using a
connection table approximation.
PEOE_VSA_FPNEG Fractional negative polar van der Waals surface area. This is
the sum of the vi such that qi is less than -0.2 divided by the
total surface area. The vi are calculated using a connection
table approximation.
PEOE_VSA_FHYD Fractional hydrophobic van der Waals surface area. This is
the sum of the vi such that |qi| is less than or equal to 0.2
divided by the total surface area. The vi are calculated using
a connection table approximation.
PEOE_VSA_FPOL Fractional polar van der Waals surface area. This is the sum
of the vi such that |qi| is greater than 0.2 divided by the total
surface area. The vi are calculated using a connection table
approximation.
PEOE_VSA+6 Sum of vi where qi is greater than 0.3.
PEOE_VSA+5 Sum of vi where qi is in the range [0.25,0.30).
PEOE_VSA+4 Sum of vi where qi is in the range [0.20,0.25).
PEOE_VSA+3 Sum of vi where qi is in the range [0.15,0.20).
PEOE_VSA+2 Sum of vi where qi is in the range [0.10,0.15).
PEOE_VSA+1 Sum of vi where qi is in the range [0.05,0.10).
PEOE_VSA+0 Sum of vi where qi is in the range [0.00,0.05).
PEOE_VSA-0 Sum of vi where qi is in the range [-0.05,0.00).
PEOE_VSA-1 Sum of vi where qi is in the range [-0.10,-0.05).22
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PEOE_VSA-2 Sum of vi where qi is in the range [-0.15,-0.10).
PEOE_VSA-3 Sum of vi where qi is in the range [-0.20,-0.15).
PEOE_VSA-4 Sum of vi where qi is in the range [-0.25,-0.20).
PEOE_VSA-5 Sum of vi where qi is in the range [-0.30,-0.25).
PEOE_VSA-6 Sum of vi where qi is less than -0.30.
4.2.2 Topological Cross-correlation Pharmacophores
Topological cross-correlation of generalized atom types is a simple
molecular descriptor that leads to a molecular size independent description of
potential pharmacophores. [10] The general idea of this representation scheme is
to count the distances between atom pairs and then to regard the histogram of
counts as a simplifying but exhaustive pharmacophore fingerprint of the
molecule. Distances are expressed as the number of bonds along the shortest path
connecting two nodes (non-hydrogen atoms) in the molecular graph. Each node is
checked as to whether it can be assigned one of the following generalized atom
types: hydrogen- bond donor (D), hydrogen-bond acceptor (A), positively charged
(P), negatively charged (N), or lipophilic (L). Atom types were defined using
SMILES [28] as follows: lipophilic (C(C)(C)(C)(C), Cl); positive ([+], NH2);
negative ([-], COOH, SOOH, POOH); hydrogen-bond donor (OH, NH, NH2);
hydrogen-bond acceptor: (O, N[!H]).
All possible node pairs are then checked: the numbers of all 15 possible
pairs of generalized atom types (DD, DA, DP, DN, DL, AA, AP, AN, AL, PP,
PN, PL, NN, NL, LL) are determined, and the resulting histogram counts are
divided by the total number of non-hydrogen atoms to obtain scaled vectors.
Distances of up to ten bonds were considered in the present studies, which led to a
150 (15x10) dimensional vector representation of a molecular compound.
4.2.3 3D Molecular Descriptors
Three-dimensional descriptors require the generation of molecular
conformers prior to any computation that is related directly to the descriptor. This
makes the handling of three-dimensional descriptors more complicated since the
output is always dependent on the conformers.
Despite this fact we have used 3D molecular descriptors in our research.
Sometimes information required for the correct prediction of the ligand activity
may be extracted only from the 3D structure of the molecule, for instance, when
biological activity of a molecule depends on the exact locations of the certain
functional groups.23
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4.2.3.1 Potential Energy Descriptors
The energy descriptors use a potential energy model to calculate energetic
quantities from stored 3D conformations.(Table 8) Most of the energy descriptors
belong to the orientation independent class; that is, they depend on internal
coordinates alone and not on an external reference frame. Descriptors that rely on
an external reference frame are clearly indicated in the Table 8.
Table 8. Potential Energy Descriptors.
MOE-Code Description
E Value of the potential energy.
E_ang Angle bend potential energy.
E_ele Electrostatic component of the potential energy.
E_nb Value of the potential energy with all bonded terms disabled.
E_oop Out-of-plane potential energy.
E_sol Solvation energy.
E_stb Bond stretch-bend cross-term potential energy.
E_str Bond stretch potential energy.
E_strain Local strain energy: the current energy minus the value of
the energy at a near local minimum. The current energy is
calculated as for the E descriptor. The local minimum energy
is the value of the E descriptor after first performing an
energy minimization. Current chirality is preserved and
charges are left undisturbed during minimization.
E_tor Torsion (proper and improper) potential energy.
E_vdw van der Waals component of the potential energy.
E_rele Electrostatic interaction energy between the ligand and
“receptor”
E_rnb Non-bonded interaction energy between the molecule and a
"receptor". It is similar to the other E_r* calls in that it is an
interaction energy term.
E_rsol Solvation free energy difference. Let L be the free energy of
solvation of the molecule (ligand), R be the free energy of
solvation of the atoms current (receptor), and G be the free
energy of solvation of the RL complex. Consequently, the
returned value is G – L - R.24
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E_rvdw van der Waals interaction energy between the molecule and
the atoms currently loaded.
4.2.3.2 Conformation Dependent Charge Descriptors
The following descriptors (Table 9) depend upon the partial charges of the
molecules and their conformations. Accessible surface area (ASA) refers to the
water accessible surface area using a probe radius of 1.4 . Let qi denote the
partial charge of atom i.
Table 9. Conformation Dependent Charge Descriptors.
MOE-Code Description
ASA+ Water accessible surface area of all atoms with positive
partial charge (strictly greater than 0).
ASA- Water accessible surface area of all atoms with negative
partial charge (strictly less than 0).
ASA_H Water accessible surface area of all hydrophobic (|qi|<0.2)
atoms.
ASA_P Water accessible surface area of all polar (|qi|>=0.2) atoms.
DASA Absolute value of the difference between ASA+ and ASA-.
CASA+ Positive charge weighted surface area, ASA+ times max { qi >
0 } [29].
CASA- Negative charge weighted surface area, ASA- times max { qi
< 0 } [29].
DCASA Absolute value of the difference between CASA+ and CASA-
[29].
dipole Dipole moment calculated from the partial charges of the
molecule.
dipoleX The x component of the dipole moment (external
coordinates).
dipoleY The y component of the dipole moment (external
coordinates).
dipoleZ The z component of the dipole moment (external
coordinates).
FASA+ Fractional ASA+ calculated as ASA+ / ASA.
FASA- Fractional ASA- calculated as ASA- / ASA.25
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FCASA+ Fractional CASA+ calculated as CASA+ / ASA.
FCASA- Fractional CASA- calculated as CASA- / ASA.
FASA_H Fractional ASA_H calculated as ASA_H / ASA.
FASA_P Fractional ASA_P calculated as ASA_P / ASA.
4.2.3.3 Surface Area, Volume and Shape Descriptors
The following descriptors depend on the structure connectivity and
conformation. (Table 10)
Table 10. Surface Area, Volume and Shape Descriptors.
MOE-Code Description
ASA Water accessible surface area calculated using a radius of 1.4
A for the water molecule. A polyhedral representation is
used for each atom in calculating the surface area.
dens Mass density: molecular weight divided by van der Waals
volume as calculated in the vol descriptor.
glob Globularity, or inverse condition number (smallest
eigenvalue divided by the largest eigenvalue) of the
covariance matrix of atomic coordinates. A value of 1
indicates a perfect sphere while a value of 0 indicates a two-
or one-dimensional object.
pmi Principal moment of inertia.
pmiX x component of the principal moment of inertia (external
coordinates).
pmiY y component of the principal moment of inertia (external
coordinates).
pmiZ z component of the principal moment of inertia (external
coordinates).
rgyr Radius of gyration.
std_dim1 Standard dimension 1: the square root of the largest
eigenvalue of the covariance matrix of the atomic
coordinates. A standard dimension is equivalent to the
standard deviation along a principal component axis.
std_dim2 Standard dimension 2: the square root of the second largest
eigenvalue of the covariance matrix of the atomic
coordinates. A standard dimension is equivalent to the26
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standard deviation along a principal component axis.
std_dim3 Standard dimension 3: the square root of the third largest
eigenvalue of the covariance matrix of the atomic
coordinates. A standard dimension is equivalent to the
standard deviation along a principal component axis.
vol van der Waals volume calculated using a grid approximation
(spacing 0.75 A).
VSA van der Waals surface area. A polyhedral representation is
used for each atom in calculating the surface area.
4.2.4 Three Point Pharmacophore
The concept of a pharmacophore key was introduced by Sheridan and co-
workers [30] as a means to account for the potential for intermolecular
interactions in a 3D database search. Pharmacophore keys are 3D structural keys
whose features include perspective macromolecular recognition sites. These sites
include hydrogen bond donors, hydrogen bond acceptors, positively charged
centers, aromatic ring centers, and hydrophobic centers. The pharmacophore itself
is defined as a set of three centers forming a triangle. To generate the key, the
pharmacophores exhibited by a particular conformation or ensemble of
conformations are mapped onto appropriate bits in the binary set. This process is
illustrated in Figure 3.
Acceptor
Ring
Acceptor Ring
Ring Donor
Donor
Donor
Donor
Figure 3. Three-point pharmacophore key generation. Each pharmacophore pattern present
in the reference molecule is ‘projected’ onto a particular bit position, determined by the three
‘atom’ types and their mutual distances.27
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4.3 From Descriptors to the Predictive Model.
Support Vector Machine
This section will describe Machine Learning technique that we used for
constructing models for prediction of the biological activity of potential
compound. As we have shown in the previous section chemical formula of the
molecule is first transformed to the descriptor vector. Using this description we
will then train the classifier with the compounds with measured biological
activity. Typically we will mark compounds as active (class) or inactive (non-
class). In this case we have a binary classifier. For the classification we used
Support Vector Machine, which is described below.
More than 60 years ago R.A. Fisher [31] suggested the first algorithm for
pattern recognition. He considered a model of two normal distributed populations,
N(m1,1) and N(m2,2) of n-dimensional vectors x with mean vectors m1 and m2
and co-variance matrices 1 and 2, and showed that the optimal (Bayesian)
solution is a quadratic decision function:
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In the case where 1 = 2 =  the quadratic decision function (1)
degenerates to a linear function:
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To estimate the quadratic decision function one has to determine
(n(n+3))/2 free parameters. To estimate the linear function only n free parameters
have to be determined. In the case where the number of observations is small (say
less than 10n
2) estimating o(n
2) parameters is not reliable. Fisher therefore
recommended, even in the case of 1  2, to use the linear discriminator function
(2) with  of the form:
2 1 ) 1 (    τ τ − + = (3)
where  is some constant. The optimal coefficient for  was found in [32]. Fisher
also recommended a linear decision function for the case where the two
distributions are not normal. Algorithms for pattern recognition were therefore
from the very beginning associated with the construction of linear decision
surfaces.28
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In 1962 Rosenblatt [33] explored a different kind of learning machines:
perceptrons or neural networks. The perceptron consists of connected neurons,
where each neuron implements a separating hyperplane, so the perceptron as a
whole implements a piecewise linear separating surface.
No algorithm that minimizes the error on a set of vectors by adjusting all
the weights of the network was found in Rosenblatt's time, and Rosenblatt
suggested a scheme where only the weights of the output unit were adaptive.
According to the fixed setting of the other weights the input vectors are non-
linearly transformed into the feature space, Z, of the last layer of units. In this
space a linear decision function is constructed:
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by adjusting the weights i from the ith hidden unit to the output unit so as to
minimize some error measure over the training data. As a result of Rosenblatt's
approach, construction of decision rules was again associated with the
construction of linear hyperplanes in some space.
An algorithm that allows for all weights of the neural network to adapt in
order locally to minimize the error on a set of vectors belonging to a pattern
recognition problem was found in 1986 [34-36] when the back-propagation
algorithm was discovered. The solution involves a slight modification of the
mathematical model of neurons. Therefore, neural networks implement "piece-
wise linear-type" decision functions.
This was the invention of the artificial neural networks (ANN). ANN
means three-layered, fully connected, feed-forward networks that can be trained
to approximate any continious, non-linear function. Figure 4 shows example of a
simple ANN with four input neurons, two hidden neurons and one output neurons.
The input neuron simply represents the input vector x, i.e. the descriptor
variable of the compound that is to be predicted. All input neurons are connected
to all hidden neurons of the second layer. Each connection has an assigned weight
x
w

whid
hid
input layer
hidden layer
output layer
Figure 4. Three-layered Neural Network.29
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w, and each neuron of the hidden layer has an assigned ‘threshold’ .
Analogously, the third layer is connected to the hidden layer vie the weigths
hid
h w
and the output threshold
hid θ . The output y of an ANN can be expressed by
hid
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where H is the number of hidden neurons and N is the number of input
neurons, T is so-called ‘transfer function’. Diffeent transfer functions can be
applied. [37] The typical training algorithm is usually variations of the back
propagation methodology.
In contrast to ANN the Support Vector Machine (SVM) implements the
following idea: it maps the input vectors into some high dimensional feature space
Z through some non-linear mapping chosen a priori. In this space a linear decision
surface is constructed with special properties that ensure high generalization
ability of the machine.
The conceptual part of this problem was solved in 1965 [38] for the case
of optimal hyperplanes for separable classes. An optimal hyperplane is here
defined as the linear decision function with maximal margin between the vectors
of the two classes. It was observed that to construct such optimal hyperplanes one
only has to take into account a small amount of the training data, the so called
“support vectors”, which determine this margin. It was shown that if the training
vectors are separated without errors by an optimal hyperplane the expectation
value of the probability of committing an error on a test example, E[Pr(error)] is
bounded by the ratio between the expectation value of the number of support
vectors and the number of training vectors [39]:
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] vectors training of number [
] vectors support of number [
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error E ≤ (5)
Note that this bound does not explicitly contain the dimensionality of the
space of separation. It follows from this bound, that if the optimal hyperplane can
be constructed from a small number of support vectors relative to the training set
size the generalization ability will be high—even in an infinite dimensional space.
In Section 5 we will demonstrate that the ratio (5) for a real life problems can be
as low as 0.03 and the optimal hyperplane generalizes well in a billion
dimensional feature space.
Let 0 = + • b z w be the optimal hyperplane in feature space. We will
show, that the weights W0 for the optimal hyperplane in the feature space can be
written as some linear combination of support vectors
 =
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The linear decision function I (z) in the feature space will accordingly be
of the form:
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where (zi • z) is the dot-product between support vectors zi and vector z in feature
space. The decision function can therefore be described as a two-layer network.
However, even if the optimal hyperplane generalizes well the technical problem
of how to treat the high-dimensional feature space remains. In 1992 it was shown
[39], that the order of operations for constructing a decision function can be
interchanged: instead of making a non-linear transformation of the input vectors
followed by dot-products with support vectors in feature space, one can first
compare two vectors in input space (by e.g. taking their dot-product or some
distance measure), and then make a non-linear transformation of the value of the
result (see Figure 5). This enables the construction of rich classes of decision
surfaces, for example polynomial decision surfaces of arbitrary degree. This type
of learning machine is called a support-vector machine.
The technique of Support Vector Machine was first developed for the
restricted case of separating training data without errors.[40] Here we will
describe two cases: separation without error is possible and separation without
error is not possible.
4.3.1 Optimal hyperplane
In this section a review of the method of optimal hyperplanes [41] for
separation of training data without errors will be given. In the next section the
introduction of a notion of soft margins is described, that will allow for an
analytic treatment of learning with errors on the training set.
g(X) Z W • Z Y X
Figure 5. Illustration of the principles of SVM. First data x is mapped to a very high-
dimentional space via g(x): z = g(x). Then the decision surface is y = w • z constructed in this
very high-dimentional space.31
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4.3.1.1 The optimal hyperplane algorithm
The set of labeled training patterns
(y1,x1), . . . . . . ,(yl,xl)
is said to be linearly separable if there exists a vector w and a scalar b such that
the inequalities
1 ) ( 0 + ≥ + • w w i x if yi = +1,
1 ) ( 0 − ≤ + • w w i x if yi = -1 (9)
are valid for all elements of the training set (8). Below we write the inequalities
(9) in the form []:
1 ] ) [( 0 ≥ + • w x w y i i i = 1, …, l (10)
The optimal hyperplane
0 ) ( 0 = + • w x w i (11)
is the unique one which separates the training data with a maximal margin: it
determines the direction w/|w| where the distance between the projections of the
training vectors of two different classes is maximal. This distance  (w , b) is
given by
w
w x
w
w x
w
•
=
•
=
− = = 1 : 1 : max min ) , (
y x y x b ρ
.
(12)
The optimal hyperplane is the hyperplane with parameters (w0, b0) that
maximize the distance (12). It follows from (12) and (10) that
0 0 0
0 w w w
w
•
= =
2 2
) , ( 0 b ρ (13)
This means that the optimal hyperplane is the unique one that minimizes
|w0| under the constraints (10). Constructing an optimal hyperplane is therefore a
quadratic programming problem.
Vectors xi for which yi(w • xi + b) = 1 will be termed support vectors. In
section 4.3.5 we show that the vector w0 that determines the optimal hyperplane
can be written as a linear combination of training vectors:
i i
l
i
i y x w0
0
1
α 
=
= (14)32
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where
0
i α > 0. Since  > 0 only for support vectors (see Section 2.3.5), the
expression (14) represents a compact form of writing w0. We also show that to
find the vector of parameters i:
) (
0 0
1 0 l
T α α  = Λ
one has to solve the following quadratic programming problem:
Λ Λ − Λ = Λ D
T T W
2
1
1 ) ( (15)
with respect to ) ( 1 l
T α α  = Λ , subject to the constraints:
0 ≥ Λ (16)
0 = Λ Y
T (17)
where ) 1 , , 1 ( 1  =
T is a l-dimentional unit vector, ) ( 1 l
T y y  = Y is the l-
dimentional vector of labels, and D is a symmetric l l× matrix with elements
j i x x • = j i ij y y D , i,j = 1,…..,l. (18)
The inequality (16) describes the nonnegative quadrant. We therefore have
to maximize the quadratic form (15) in the nonnegative quadrant, subject to the
constraints (17).
When the training data (8) can be separated without errors we also show in
Section 2.3.5. the following relationship between the maximum of the functional
(15), the pair ( 0 Λ , b0), and the maximal margin 0 from (13):
2
0
0
2
) (
ρ
= Λ W (19)
If some 0 Λ and large constant W the inequality
0 *) ( W W > Λ (20)
is valid, one can accordingly assert that all hyperplanes that separate the training
data have a margin
0
2
W
< ρ
.33
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If the training set (8) cannot be separated by a hyperplane, the margin
between patterns of the two classes becomes arbitrary small, resulting in the value
of the functional W() turning arbitrary large. Maximizing the functional (15)
under constraints (16) and (17) one therefore either reaches a maximum (in this
case one has constructed the hyperplane with the maximal margin po), or one
finds that the maximum exceeds some given (large) constant W0 (in which case a
separation of the training data with a margin larger then 0 / 1 W is impossible).
The problem of maximizing functional (15) under constraints (16) and
(17) can be solved very efficiently using the following scheme. Divide the
training data into a number of portions with a reasonable small number of training
vectors in each portion. Start out by solving the quadratic programming problem
determined by the first portion of training data. For this problem there are two
possible outcomes: either this portion of the data cannot be separated by a
hyperplane (in which case the full set of data as well cannot be separated), or the
optimal hyperplane for separating the first portion of the training data is found.
Let the vector that maximizes functional (15) in the case of separation of
the first portion be 1 Λ . Among the coordinates of vector 1 Λ some are equal to
zero. They correspond to non-support training vectors of this portion. Make a new
set of training data containing the support vectors from the first portion of training
data and the vectors of the second portion that do not satisfy constraint (10),
where w is determined by 1 Λ . For this set a new functional W2(Λ) is constructed
and maximized at 2 Λ . Continuing this process of incrementally constructing a
solution vector * Λ covering all the portions of the training data one either finds
that it is impossible to separate the training set without error, or one constructs the
optimal separating hyperplane for the full data set, 0 * Λ = Λ . Note, that during this
process the value of the functional W(Λ) is monotonically increasing, since more
and more training vectors are considered in the optimization, leading to a smaller
and smaller separation between the two classes.
4.3.2 The Soft Margin hyperplane
Consider the case where the training data cannot be separated without
error. In this case one may want to separate the training set with a minimal
number of errors. To express this formally let us introduce some non-negative
variables 0 ≥ i ξ , i = 1,...,l. (Figure 6)
We can now minimize the functional

=
= Φ
l
i
i
1
) (
σ ξ ξ (21)
for small , subject to constrains
i i i b x w y ξ − ≥ + • 1 ) ( (22)
0 ≥ i ξ (23)34
Introduction
For sufficiently small  the functional (21) describes the number of the
training errors. [41]
Minimizing (21) one finds some minimal subset of training errors:
(yi1,xi1),…..,(yik,xik)
If these data are excluded from the training set one can separate the
remaining part of the training set without errors. To separate the remaining part of
the training data one can construct an optimal separating hyperplane.
This idea can be expressed formally as: minimize the functional






+ 
=
l
i
i CF w
1
2
2
1 σ ξ (24)
subject to constraints (22) and (23), where F(u) is a monotonic convex function
and C is a constant.
For sufficiently large C and sufficiently small a, the vector wo and
constant b0, that minimize the functional (24) under constraints (22) and (23),
determine the hyperplane that minimizes the number of errors on the training set
and separate the rest of the elements with maximal margin.


  


  
 
Active molecule
N-dimensional descriptor space (reduced to 2D)
Inactive molecule
Figure 6. Construction of the optimal SVM plane. SVM identifies most optimal (linear or
non-linear) hyperplane in n-dimensional descriptor space separating actives from inactives35
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Note, however, that the problem of constructing a hyperplane which
minimizes the number of errors on the training set is in general NP-complete. To
avoid NP-completeness of our problem we will consider the case of  = 1 (the
smallest value of  for which the optimization problem (15) has a unique
solution). In this case the functional (24) describes (for sufficiently large C) the
problem of constructing a separating hyperplane which minimizes the sum of
deviations, £, of training errors and maximizes the margin for the correctly
classified vectors. If the training data can be separated without errors the
constructed hyperplane coincides with the optimal margin hyperplane.
In contrast to the case with  < 1 there exists an efficient method for
finding the solution of (24) in the case of  = 1. Let us call this solution the soft
margin hyperplane. In Section 2.3.5 we consider the problem of minimizing the
functional






+ 
=
l
i
i CF w
1
2
2
1
ξ (25)
subject to the constraints (22) and (23), where F(u) is a monotonic convex
function with F(0) = 0. To simplify the formulas we only describe the case of F(u)
= u2 in this section. For this function the optimization problem remains a
quadratic programming problem. In Section 2.3.5 we show that the vector w, as
for the optimal hyperplane algorithm, can be written as a linear combination of
support vectors xi:
i i
l
i
i y x w0
0
1
α 
=
=
To find vector ) ,......, ( 1 l
T α α =  one has to solve the dual quadratic
programming problem of maximizing
 


 


+ Λ Λ − Λ = Λ
2 2
1
1 ) , (
2 δ
δ D
T T W (26)
subject to constraints
0 = Λ Y
T (27)
0 ≥ δ (28)
1 0 δ ≤ Λ ≤ (29)
where are the same elements as used in the optimization problem for constructing
an optimal hyperplane, δ is a scalar, and (29) describes coordinate-wise
inequalities.
Note that (29) implies that the smallest admissible value δ in functional
(26) is36
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) ,......, max( 1 max l α α α δ = =
Therefore to find a soft margin classifier one has to find a vector Λ that
maximize
 


 


+ Λ Λ − Λ = Λ
2 2
1
1 ) (
2
max α
D
T T W (30)
under the constraints Λ > 0 and (27). This problem differs from the problem of
constructing an optimal margin classifier only by the additional term with amax in
the functional (30). Due to this term the solution to the problem of constructing
the soft margin classifier is unique and exists for any data set.
The functional (30) is not quadratic because of the term with amax.
Maximizing (30) subject to the constraints Λ > 0 and (27) belongs to the group of
so-called convex programming problems. Therefore, to construct a soft margin
classifier one can either solve the convex programming problem in the l-
dimensional space of the parameters Λ, or one can solve the quadratic
programming problem in the dual l + 1 space of the parameters Λ and δ . In our
experiments we construct the soft margin hyperplanes by solving the dual
quadratic programming problem.
4.3.3 The Method of Convolution of the Dot-Product in Feature
Space
The algorithms described in the previous sections construct hyperplanes in
the input space.To construct a hyperplane in a feature space one first has to
transform the n-dimensional input vector x into an N-dimensional feature vector
through a choice of an N-dimensional vector function:
N n ℜ → ℜ : φ
An N-dimentional linear separator w and a bias b is then constructed for
the set of transformed vectors:
) ( , ), ( ), ( ) ( 2 1 i i i i x x x x N φ φ φ φ  = i = 1,……,l
Classification of an unknown vector x is done by first transforming the
vector to the separating space ) ( : x x x φ → and then taking the sign of the function
b w f + • = ) ( ) ( x x φ (31)
According to the properties of the soft margin classifier method the vector
w can be written as a linear combination of support vectors (in the feature space).
That means37
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i i
l
i
i y x w α 
=
=
1
(32)
The linearity of the dot-product implies, that the classification function f in
(31) for an unknown vector x only depends on the dot-products:
b y b f i i
l
i
i + • = + • = 
=
x x w x x α φ φ
1
) ( ) ( ) ( (33)
The idea of constructing support-vector macine comes from considering
general forms of the dot-product in a Hilbert space [32]:
) , ( ) ( ) ( v u v u K ≡ •φ φ (34)
According to the Hilbert-Schmidt Theory [42] any symmetric function
K(u, v), with K(u, v) 2 L ∈ , can be expanded in the form
) ( ) ( ) , (
1
v u v u i i
i
i K φ φ λ • =
∞
=
(35)
where 2 L i ∈ λ and i φ are eigenvalues and eigenfunctions
) ( ) ( ) , ( v u u v u i i i d K φ λ φ = 
of the integral operator defined by the kernel K(u, v). A sufficient condition to
ensure that (34) defines a dot-product in a feature space is that all the eigenvalues
in the expansion (35) are positive. To guarantee that these coefficients are
positive, it is necessary and sufficient (Mercer's Theorem) that the condition
0 ) ( ) ( ) , ( >  v u v u v u d d g g K
is satisfied for all g such that
∞ <  u u d g ) (
2
Functions that satisfy Mercer's theorem can therefore be used as dot-
products. Aizerman, Braverman and Rozonoer [43] consider a convolution of the
dot-product in the feature space given by function of the form
 


 

 −
− =
σ
v u
v u exp ) , ( K (36)38
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which they call Potential Functions.
However, the convolution of the dot-product in feature space can be given
by any function satisfying Mercer's condition; in particular, to construct a
polynomial classifier of degree d in n-dimensional input space one can use the
following function
d K ) 1 ( ) , ( + • = v u v u (37)
Using different dot-products ) , ( v u K one can construct different learning
machines with arbitrary types of decision surfaces [39]. The decision surface of
these machines has a form

=
=
l
i
i i K y f
1
) , ( ) ( i x x x α
where xi is the image of a support vector in input space and i is the weight of a
support vector in the feature space.
To find the vectors xi and weights i one follows the same solution scheme
as for the original optimal margin classifier or soft margin classifier. The only
difference is that instead of matrix D (determined by (18)) one uses the matrix
) , ( , j i x x K y y D j i j i = i,j =1,…..,l
4.3.4 General Features of Support Vector Machine
4.3.4.1 Decision Rules by SVM
To construct a support-vector machine decision rule one has to solve a
quadratic optimization problem:
 


 


+ Λ Λ − Λ = Λ
2 2
1
1 ) (
2 δ
D
T T W ,
under the simple constraints:
1 0 δ ≤ Λ ≤
0 = Λ Y
T
where matrix
) , ( , j i x x K y y D j i j i = i,j =1,…..,l39
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is determined by the elements of the training set, and ) , ( v u K is the function
determining the convolution of the dot-products.
The solution to the optimization problem can be found efficiently by
solving intermediate optimization problems determined by the training data that
currently constitute the support vectors. This technique is described in Section
4.3.2. The obtained optimal decision function is unique.
Each optimization problem can be solved using any standard techniques.
4.3.4.2 The Support Vector Machine is a universal machine
By changing the function ) , ( v u K for the convolution of the dot-product
one can implement different learning machines.
In the next section we will consider support-vector machines that use
polynomial decision surfaces. To specify polynomials of different order d one can
use the following functions for convolution of the dot-product
d K ) 1 ( ) , ( + • = v u v u
Radial Basis Function machines with decision functions of the form















 −
− = 
=
n
i
i
i sign f
1
2
2
exp ) (
σ
α
x x
x
can be implemented by using convolutions of the type







 −
− = 2
2
exp ) , (
σ
v u
v u K
In this case the support-vector machine will construct both the centers xi of
the approximating function and the weights i.
One can also incorporate a priori knowledge of the problem at hand by
constructing special convolution functions. Support-vector machines are therefore
a rather general class of learning machines which changes its set of decision
functions simply by changing the form of the dot-product.
4.3.4.3 Generalization Ability
To control the generalization ability of a learning machine one has to
control two different factors: the error-rate on the training data and the capacity of
the learning machine as measured by its VC-dimension (Vapnik, 1982). There
exists a bound for the probability of errors on the test set of the following form:
with probability 1 - ;
Pr (test error) < Frequency (training error) + Confidence interval (38)40
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the inequality is valid. In the bound (38) the confidence interval depends on the
VC-dimension of the learning machine, the number of elements in the training set,
and the value of .
The two factors in (38) form a trade-off: the smaller the VC-dimension of
the set of functions of the learning machine, the smaller the confidence interval,
but the larger the value of the error frequency.
A general way for resolving this trade-off was proposed as the principle of
structural risk minimization: for the given data set one has to find a solution that
minimizes their sum. A particular case of structural risk minimization principle is
the Occam-Razor principle: keep the first term equal to zero and minimize the
second one.
It is known that the VC-dimension of the set of linear indicator functions
) ) (( ) ( b sign I + • = x w x , x C ≤ x
with fixed threshold b is equal to the dimensionality of the input space. However,
the VC-dimension of the subset
) ) (( ) ( b sign I + • = x w x x C ≤ x w C ≤ w
(the set of functions with bounded norm of the weights) can be less than the
dimensionality of the input space and will depend on Cw.
From this point of view the optimal margin classifier method executes an
Occam-Razor principle. It keeps the first term of (38) equal to zero (by satisfying
the inequality (9)) and it minimizes the second term (by minimizing the functional
w • w). This minimization prevents an over-fitting problem.
However, even in the case where the training data are separable one may
obtain better generalization by minimizing the confidence term in (38) even
further at the expense of errors on the training set. In the soft margin classifier
method this can be done by choosing appropriate values of the parameter C. In the
support-vector machine algorithm one can control the trade-off between
complexity of decision rule and frequency of error by changing the parameter C,
even in the more general case where there exists no solution with zero error on the
training set. Therefore the support-vector machine can control both factors for
generalization ability of the learning machine.
4.3.5 Constructing Separating Hyperplanes
In this section we derive both the method for constructing optimal
hyperplanes and soft margin hyperplanes.
4.3.5.1 Optimal hyperplane algorithm
It was shown in Section 4.3.1.1, that to construct the optimal hyperplane
0 0 0 = + • b x w (40)41
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which separates a set of training data
(y1,x1),…, (yl,xl)
one has to minimize a functional
w w• = Φ
subject to the constraints
1 ) ( ≥ + • b x w y i i , i=1,. . . . .l (41)
To do this we use a standard optimization technique. We construct a
Lagrangian

=
− + • − • =
l
i
i i i b x w y b L
1
] 1 ) ( [
2
1
) , ( α w w  w, (42)
where ) ,......, ( 1 l
T α α =  is the vector of non-negative Lagrange multipliers
corresponding to the constraints (41).
It is known that the solution to the optimization problem is determined by
the saddle point of this Lagrangian in the 2l + 1-dimensional space of w, , and
b, where the minimum should be taken with respect to the parameters w and b,
and the maximum should be taken with respect to the Lagrange multipliers .
At the point of the minimum (with respect to w and b) one obtains:
0
) , (
1
0
0
= 





− =
∂
∂ 
= =
l
i
i iy
b L
i
w w
x w
w
 w,
α (43)
0
) , (
0
= =
∂
∂ 
= i
i
b b
y
b
b L
α
i x
 w,
(44)
From equality (43) we derive

=
=
l
i
i iy
1
i x w α (45)
which expresses, that the optimal hyperplane solution can be written as a linear
combination of training vectors. Note, that only training vectors x, with ai > 0
have an effective contribution to the sum (45).
Substituting (45) and (44) into (42) we obtain42
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0 0
1 2
1
) ( w w  • − =
=
l
i
i W α (46)
j i j i
l
i
l
j
j i
l
i
i y y x x • − =  
= = = 1 1 1 2
1
α α α (47)
In vector notation this can be rewritten as
D   
T T W
2
1
1 ) ( − = (48)
where 1 is an l-dimensional unit vector, and D is a symmetric t x ^-matrix with
elements
j i x x D • = j i ij y y
To find the desired saddle point it remains to locate the maximum of (48)
under the constraints (43)
0 = Y 
T
where ) ,......, ( 1 l
T y y = Y , and
0 ≥ 
The Kuhn-Tucker theorem plays an important part in the theory of
optimization. According to this theorem, at our saddle point in w0, b0, 0  , any
Lagrange multiplier
0
i α and its corresponding constraint are connected by an
equality
0 ] 1 ) ( [ 0 0 = − + • b w yi i i x α , i =1, . . . ,l
From this equality comes that non-zero values ai are only achieved in the
cases where
0 1 ) ( 0 0 = − + • b w yi i x
In other words: 0 ≠ i α only for cases were the inequality is met as an
equality. We call vectors xi for which
1 ) ( 0 0 = + • b w yi i x
for support-vectors. Note, that in this terminology the Eq. (45) states that the
solution vector w0 can be expanded on support vectors.43
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Another observation, based on the Kuhn-Tucker Eqs. (44) and (45) for the
optimal solution, is the relationship between the maximal value W( 0  ) and the
separation distance 0:
  
= = =
= − = • = •
l
i
i
l
i
i i
l
i
i i b y y
1
0
1
0
0
1
0
0 0 ) 1 ( α α α 0 i w x w w
Substituting this equality into the expression (46) for W( 0  ) we obtain
2 2
1
) (
0
1
0
0
0
0
0
w w
w w
•
= • − = Λ 
=
l
i
i W α
Taking into account the expression (13) from Section 2 we obtain
2
0
0
2
) (
ρ
= Λ W
where 0 is the margin for the optimal hyperplane.
4.3.5.2 Soft margin hyperplane Algorithm
Below we first consider the case of F(u) = u
k. Then we describe the
general result for a monotonic convex function F(u).
To construct a soft margin separating hyperplane we maximize the
functional
k l
i
i C 





+ • = Φ 
=1 2
1
ξ w w , k > 1
under the constraints
i i i b x w y ξ − ≥ + • 1 ) ( , i =1, . . . ,l (49)
0 ≥ i ξ i =1, . . . ,l (50)
The Lagrange functional for this problem is
  
= = =
− + − + • − 





+ • =
l
i
i i
l
i
i i i i
k l
i
i r b x w y C b L
1 1 1
] 1 ) ( [
2
1
) , , , , ( ξ ξ α ξ ξ w w R  w
(51)
where the non-negative multipliers ) ,......, ( 1 l
T α α =  arise from the constraint
(49), and the multipliers ) ,......, ( 1 l
T r r = R enforce the constraint (50).44
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We have to find the saddle point of this functional (the minimum with
respect to the variables wi, b, and i-, and the maximum with respect to the
variables i, and ri).
Let us use the conditions for the minimum of this functional at the
extremum point:
0
1
0
0
= − =
∂
∂ 
= =
l
i
i iy
L
i
w w
x w
w
α (52)
0
0
= =
∂
∂ 
= i
i i
b b
y
b
L
α
α (53)
i i
k l
i
i
i
r kC
L
i i
− − 





=
∂
∂
−
= =
 α ξ
ξ
ξ ξ
1
1
0
0
(54)
If we denote
1
1
1
0 −
=





 = 
k l
i
i Ck
δ
ξ (55)
we can rewrite Eq. (54) as
0 = − − i i r α δ (56)
From the equalities (52)-(55) we find
i
l
i
i iy x w 
=
=
1
0 α
0
1
= 
=
l
i
i iy α (57)
i i r + =α δ (58)
Substituting the expressions for w0, b0, and  into the Lagrange functional
(51) we obtain





 − − • − = −
−
= = =   k kC
y y W k
k k
j i j i
l
i
l
j
j i
l
i
i
1
1
) ( 2
1
) ( 1 1
1
1 1 1
δ
α α α δ x x , (59)
To find the soft margin hyperplane solution one has to maximize the form
functional (59) under the constraints (57)-(58) with respect to the non-negative
variables i α , ri with i = 1,...,l. In vector notation (59) can be rewritten as45
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










 − + − = −
−
k kC
W k
k k
T T 1
1
) ( 2
1
( 1 1
1 δ
D  1  ) (60)
where  and D are as defined above. To find the desired saddle point one
therefore has to find the maximum of (60) under the constraints
0 = Y 
T (61)
1 R  δ = + (62)
0 ≥  (63)
and
0 ≥ R (64)
From (62) and (64) one obtains that the vector  should satisfy the
conditions
1  δ ≤ ≤ 0 (65)
From conditions (62) and (64) one can also conclude that to maximize (60)
) ,......, max( 1 max l α α α δ = =
Substituting this value of S into (60) we obtain











 − + − = −
−
k kC
W k
k k
T T 1
1
) ( 2
1
) ( 1 1
1
max α
D  1   (66)
To find the soft margin hyperplane one can therefore either find the
maximum of the quadratic form (51) under the constraints (61) and (65), or one
has to find the maximum of the convex function (60) under the constraints (61)
and (56). For the experiments reported in this paper we used k = 2 and solved the
quadratic programming problem (51).
For the case of F(u) = u the same technique brings us to the problem of
solving the following quadratic optimization problem: minimize the functional
D  1  
T T W
2
1
) ( − =
under the constraints
1  C ≤ ≤ 0
and46
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0 = Y 
T
The general solution for the case of a monotone convex function F(u) can
also be obtained from this technique. The soft margin hyperplane has a form
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For convex monotone functions F(u) with F(0) = 0 the following
inequality is valid:
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Therefore the second term in square brackets is positive and goes to
infinity when max α goes to infinity.
Finally, we can consider the hyperplane that minimizes the form
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subject to the constraints (49)-(50), where the second term minimizes the least
square value for the errors. This lead to the following quadratic programming
problem: maximize the functional
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in the non-negative quadrant 0 ≥  subject to the constraint 0 = Y 
T .47
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4.4 Selecting relevant descriptors
Descriptor selection or Feature selection plays an important role in Virtual
Screening. Calculation of the irrelevant descriptors that are unimportant for the
correct classification of the compound is time consuming. It limits chemical space
that can be analysed by virtual screening by overloading available computational
resources. Feature Selection can also simplify interpretability of the model. It is
significantly easier to analyse model with lower number of parameters.
In this section we will first review the methods of Feature Selection and
then describe in more details concept and techniques used in our research.
4.4.1 Feature selection methods
Feature selection or attribute selection has been a traditional research topic
dating back to at least as early as the 70’s (e.g. [44]). It is a broad subject that
spans to research disciplines such as statistics [45], [63], [46], pattern recognition
[47], [48], [49], data mining [50], machine learning [51], neural networks [52],
fractals [53], rough sets theory [54], mathematical programming [55] [56] and
many others.
The advantages of feature selection are that it reduces the dimensionality
of the feature space and removes the redundant, irrelevant or noisy data. The
immediate effects for data analysis tasks are speeding up the running time of the
learning algorithms, improving the data quality, increasing the accuracy of the
resulting model.
What is a feature selection? Suppose X is the original feature space with a
cardinality of q, and Xs is the selected feature space with a cardinality of qs,
X X ⊆ s , J(Xs) is the selection criterion for selected feature space Xs. Without
loss of generality, we assume that a higher value of J indicates a better feature
space. The goal is to maximize J(Xs). Formally, the problem of feature selection is
to find a sub-space X X ⊆ s such that
) ( max ) (
, Z X
Z X Z J J
s q s = ⊂ =
If an exhaustive approach is performed, then we need to consider all  


 


s q
q
possible combinations. The number of combinations grows exponentially, making
the exhaustive search unfeasible for larger values of q. Even for moderate values
of q, performing the exhaustive search is impractical. Finding the best feature
subset is usually intractable [57], and many problems related to feature selection
have been shown to be NP-hard [58]. There are three kinds of feature selection
strategies: (i) The number of features, say qs is already given, and the task of the
search algorithms is to decide which qs features constitute a (sub)optimal feature
subset. (ii) The second strategy is to search the smallest feature dimensionality for
which the discrimination performance exceeds a specified value. (iii) The third48
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search strategy selects a (sub)optimal feature subset which has a trade-off
between the class discriminability (e.g. classification error rate) and the subset
size (e.g. the number of selected features).
4.4.2 Relevance to the Concept: Weak and Strong Relevance
Determining which of the features are relevant to the learning task is a
central issue in machine learning, as the inclusion of irrelevant or redundant
features can reduce the performance of different learning algorithms. In order to
determine which of the features are relevant or not, we need to first know the
concepts of weak relevance and strong relevance. There are a number of different
definitions in the machine learning literature for what it means for features to be
”relevant”. John, Kohavi and Pfleger [59] [60] define two notations of relevance
[61]:
Strong Relevance: An attribute xi is strongly relevant if its removal yields
a deterioration of the performance of the Bayes Optimum Classifier.
Weak Relevance: An attribute xi is weakly relevant if not strongly
relevant and there exists a subset of variables V such that the performance on
{ } i x V ∪ is better than the performance on V.
Therefore features that are neither strongly relevant nor weakly relevant
are irrelevant. Irrelevant features should be left out.
4.4.3 General Characteristics of Feature Selection methods
Feature selection aims to search the relevant features in the feature space.
Researchers have studied various aspects of feature selection. From the point of
view of heuristic search, Blum and Langley [62] argue that the following four
issues, which affect the nature of the search, can characterize any feature selection
method.
1. The starting point in the feature space. Depending on which point to start
with, the search direction will vary. Search from no features and
successively add others is called forward selection. In contrast, search
from all features and successively remove features is called backward
selection. A third method could be to combine forward and backward
search.
2. The organization of the search procedure. Obviously, if the number of
features is too large, the exhaustive search of all the feature subspace is
prohibitive, as there are 2
N possible combinations for N features. For
example, heuristic search is more realistic than exhaustive search, but it
does not guarantee finding the optimal solutions.
3. The evaluation strategy. How feature subsets are evaluated is an important
problem. As for classification, the ideal feature subset should have the best
separation of the data. Data separation is usually computed by an inter-
class distance measure [63]. We usually used classification accuracy for
the evaluation of the feature subset. Classification accuracy is defined as
the percentage of test examples correctly classified by some algorithm.49
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Many induction algorithms incorporate a criterion based on information
theory, others directly measure accuracy on the training set.
4. The criterion for stopping the search. During the process of evaluation, we
might want to stop the search, when observing that there is no
improvement of the classification accuracy.
4.4.4 Categorization Scheme of Feature Selection Methods
There is plenty of effort to compare and evaluate different feature
selection methods [44] [64], but there are very few attempts to categorize the
feature selection methods in the literature. Siedlecki and Sklansky [65] discussed
the evolution of feature selection methods and grouped the methods into past,
present and future categories. Their main focus was the branch and bound method
and its variants. Dash and Liu [66] divided 32 existing feature selection methods
into different groups based on the major two characteristics of feature selection:
generation procedure (complete, heuristic and random) and evaluation function
(distance, information, consistency, classification error rate). A taxonomy of
feature selection algorithms into broad categories was given by Jain and Zongker
[67], where the methods were first divided into those based on statistical pattern
recognition (SPR) classification techniques, and those using artificial neural
networks. The SPR category was then further divided into sub-categories. The
categorization can also be simply done according to the monotonicity of the
selection evaluation criteria, that is, monotonic versus non-monotonic. Another
categorization could be according to the time complexity of the feature selection
algorithm, e.g. the time complexity of floating search methods [68] is O(2
n), while
that of the sequential backward and sequential forward selection methods is (n
2),
where  denotes a tight estimate of complexity, while O denotes an estimate of
complexity for which only an upper bound is known. Moreover, the feature
selection methods can be categorized into two general groups [69], that is, the
classifier-specific selection methods where the goodness is evaluated by a given
criterion (e.g. the error rate of a certain classifier, this is useful for cases where we
know which classification will be performed after selection) and the
classifierindependent selection methods where the goodness is evaluated by the
methods’ own criterion (e.g. measures based on the approximation of class-
conditional probability density functions, this is useful for cases where we don’t
know which classification will be used). Other categorization schemes include
simply dividing the feature selection methods into: optimal (e.g. exhaustive
search) vs. non-optimal (suboptimal), from the point of view of the optimality of
the resulting subset; backward elimination vs. forward selection, from the point of
view of starting point in the feature search space; and many others.
On the other hand, feature selection can be generally regarded as an
optimization problem. For a general optimization problem, one may use the
optimization tree category [70], that divides optimization techniques into discrete
optimization and continuous optimization, both of which are then further divided
into other subcategories. For more references on optimization, the reader is
referred to Optimization Online [71].50
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We describe three typical model approaches in the following, i.e. the Filter
Selection Model, the Wrapper Selection Model, and the Embedded Selection
Model.
4.4.5 Filter Selection Method
The filter selection model is the earliest approach to feature selection. It
utilizes an independent search criterion to find the appropriate feature subset
before a machine learning algorithm is performed, thus it was termed as filter
method by John, Kohavi and Pfleger [59]: it filters out irrelevant attributes before
induction occurs, that is, the search is done independently of an induction
algorithm. The procedure of the filter model is shown in Figure 7. The advantage
of the filter model is that it does not need to re-run the algorithm for every
induction algorithm when choosing to run on a reduced feature dataset, as a
consequence, the filter approach is generally computational efficient, and it is
practical for data sets with very high dimensionality.
There are a number of different representative filter algorithms in the
literature. FOCUS, an algorithm designed by Almuallim and Dietterich [72]
originally for 7the boolean domain, searches the feature space by looking at each
feature in isolation, then turn to pairs of features, triples, and so on, and stops until
it finds the minimal combination of features. The minimal feature subset divides
the training data into pure classes, i.e. no instances have more than one class. The
original training samples which are characterized by the resulting feature subset,
are then passed to the decision tree induction algorithm ID3 [73].
Another representative work of the filter approach is the RELIEF
algorithm due to Kira and Rendell [74]. The RELIEF algorithm follows the
general and simple filter scheme, that is, it first evaluates the individual feature
according to the evaluation criterion, and thereafter, the best n features are
selected. However it uses a more complex evaluation function. The training
samples, characterized by the selected features, are then passed to ID3. Two
extensions were made to this algorithm by Kononenko [75], where more general
data types can be treated. Although both FOCUS and RELIEF use the decision
tree induction algorithm after feature selection, they are naturally not confined to
decision tree algorithms, i.e. other induction algorithms can be used instead.
Since the filter approach does not take into account the learning bias
introduced by the final induction algorithm, it may not be able to select the most
suitable subset for the final induction algorithm. For this reason, the wrapper
model was proposed.
4.4.5.1 Kolmogorov-Smirnov Statistics.
KS-based statistics represent a model-independent method for feature
selection. It is routinely used for feature selection from different data sets and
Descriptor Vector Feature Selection Learning Machine Model
Figure 7. Filter-based feature selection.51
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features. Its main advantage over other methods is the independence from the
particular statistical model that generates the data, in contrast to other methods,
that performwell only if the data adopts certain statistics. For instance,
“correlation coefficient” [76] [77] based feature selection performs best if the data
can be modeled by Gaussian mixtures,1 and its accuracy drops otherwise. Very
often it is impossible to correctly guess statistical models of the data a priori,
which results in only approximately correct models. If the underlying statistics is
not known or a Gaussian mixture [78] model is not appropriate, KS statistics can
be a method of choice.
In KS statistics each feature is first tested to have different statistics for
class and nonclass samples. This is done by merging feature values for class and
nonclass and building two separate cumulative fraction functions, one for class
and one for nonclass. The cumulative fraction function represents the dependency
of the percentage of samples whose feature values are below a certain threshold,
on the position of the threshold value in the sorted list of feature values. An
example of the cumulative function for the data set {0.08, 0.10, 0.15, 0.17, 0.24,
0.34, 0.38, 0.42, 0.49, 0.50, 0.70, 0.94, 0.95, 1.26, 1.37, 1.55, 1.75, 3.20, 6.98,
50.57} is given in Figure 8. The maximum difference D of two cumulative
functions for class and nonclass is then used as a measure for the significance of a
distinguishing feature. An example of this measure is given in Figure 8.
A KS statistics test is performed for all available features, which are then
sorted with respect to the KS test results, and only the most relevant features are
considered for further training.
4.4.6 Wrapper Selection Model
The strategy of the wrapper model is to use an induction algorithm to
estimate the merit of the searched feature subset on the training data and using the
estimated accuracy of the resulting classifier as its metric . The wrapper
approaches often have better results than the filter approaches because they are
tuned to the specific interaction between an induction algorithm and its training
data. In this way, feature selection takes into account the biases from the final
Figure 8. a) Example of the cumulative function b) illustration of the Kolmogorov-Smirnov
Statistics.52
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learning algorithm. The use of wrapper approaches was supported by the study of
Aha and Banket [79], Doak [80] and John et al. [59].
The wrapper selection procedure is illustrated in Figure 9.
The disadvantage of the wrapper model is that it is less tractable because
of the prohibitive cost of running the classification algorithm many times when
the dimensionality is considerably high.
4.4.6.1 SVM-Based wrapper for feature Selection
Usually feature selection algorithms are applied prior to the classifier
training: A feature selection algorithm first selects a set of features and then a
classifier is trained based on the features of this subset. Recently it was
demonstrated that feature selection schemes, where the feature selection algorithm
relies on the model that is created during training, produce better results. [57]
Accordingly an alternative scheme for feature selection was suggested: The
classifier is first trained using all available features. Then, the least important
features are deleted. The drawback of this approach is that the trained classifier
usually assumes a certain statistical model for the data, which might be only
approximately correct. Current algorithms for nonlinear classifier training like
artificial neural networks or SVM estimate a statistical model for the data
sufficiently well to make this approach an alternative to modelindependent feature
selection.
The separating surface generated by SVM is given by
b K f
i
sv
i i + = ) , ( ) ( x x x α
Here i, b, and xi are parameters of the SVM, determined during training.
sv
i x are support vectors, which represent a subset of the training samples that
determine the separating surface. This surface corresponds to the linear separation
in a very high-dimensional space, where data points are mapped during SVM
training. [81] This mapping is determined solely by the kernel function
) ' , ( x x K .[41] In this high-dimensional space the separating surface is given by
b f + • = ) ( ) ( x w x
where
Descriptor Vector Feature Selection Learning Machine Model
Figure 9. Wrapper-based approach to feature selection.53
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 =
i
sv
i i a w x
is a normal vector of the separating hyperplane. To estimate the importance Rf of
a feature to the accuracy of the SVM prediction we calculated a projection of the
feature change in the mapped space to the normal of the SVM plane:
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For estimating the relevance of a feature to classification we should
calculate Rf only in the vicinity of the separating hyperplane. To achieve it we will
sum Rf only over support vectors, extending the principle of SVM that the
position of the classifying hyperplane depends only on support vectors:
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Empirically we observed that data normalization improved the performance in
some cases; therefore, the final formula that we used to perform feature selection
is
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Summarizing, Rf was calculated for all features, and those features with
low Rf value were excluded from the features used for training. It is important to
note that Rf depends only on the support vectors.
For constructing SVM models we used the SVM-light package. [82] A
fifth-order polynomial kernel was used in SVM training:
5 ) 1 ) ' ( ( ) ' , ( + • = x x x x s K . Training parameters s and C were optimized using a
gradient decent-like algorithm to achieve maximum accuracy of prediction for the
validation set. Parameter C is an internal parameter that is set prior to SVM
training. It defines the tradeoff between the separating margin and the penalty for
incorrect predictions. [81]54
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4.4.7 Embedded Selection Model
In contrast to the wrapper approach, which treats feature selection as a
wrapper around the induction process, the embedded approach embeds the
selection within the basic induction algorithm. Examples of this model are the
decision tree algorithms ID3 and C4.56 7 by Quinlan [73] [83] and CART 8 by
Breiman [84]. These decision tree algorithms use recursive partitioning methods
for induction, and carry out a greedy search through the space of decision trees.
At each stage they use an evaluation function to select the attribute that has the
best ability to discriminate among the classes. They partition the training data
based on this attribute and repeat the process on each subset, extending the tree
downwards until no further discrimination is possible.
Besides these three approaches, another model called weighted model was
also introduced [85], where feature weighting is considered.55
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5 Zusammenfassung
Die vorliegende Dissertation stellt eine kumulative Arbeit dar, die in
insgesamt acht wissenschaftlichen Publikationen (fünf publiziert, zwei
eingerichtet und eine in Vorbereitung) dargelegt ist. In diesem Forschungsprojekt
wurden Anwendungen von maschinellem Lernen für das virtuelle Screening von
Moleküldatenbanken durchgeführt. Das Ziel war primär die Einführung und
Überprüfung des Support-Vector-Machine (SVM) Ansatzes für das virtuelle
Screening nach potentiellen Wirkstoffkandidaten.
In der Einleitung der Arbeit ist die Rolle des virtuellen Screenings im
Wirkstoffdesign beschrieben. Methoden des virtuellen Screenings können fast in
jedem Bereich der gesamten pharmazeutischen Forschung angewendet werden.
Maschinelles Lernen kann einen Einsatz finden von der Auswahl der ersten
Moleküle, der Optimierung der Leitstrukturen bis hin zur Vorhersage von
ADMET (Absorption, Distribution, Metabolism, Toxicity) Eigenschaften.
In Abschnitt 4.2 werden möglichen Verfahren dargestellt, die zur
Beschreibung von chemischen Strukturen eingesetzt werden können, um diese
Strukturen in ein Format zu bringen (Deskriptoren), das man als Eingabe für
maschinelle Lernverfahren wie Neuronale Netze oder SVM nutzen kann. Der
Fokus ist dabei auf diejenigen Verfahren gerichtet, die in der vorliegenden Arbeit
verwendet wurden. Die meisten Methoden berechnen Deskriptoren, die nur auf
der zweidimensionalen (2D) Struktur basieren. Standard-Beispiele hierfür sind
physikochemische Eigenschaften, Atom- und Bindungsanzahl etc. (Abschnitt
4.2.1). CATS Deskriptoren, ein topologisches Pharmakophorkonzept, sind
ebenfalls 2D-basiert (Abschnitt 4.2.2). Ein anderer Typ von Deskriptoren
beschreibt Eigenschaften, die aus einem dreidimensionalen (3D) Molekülmodell
abgeleitet werden. Der Erfolg dieser Beschreibung hangt sehr stark davon ab, wie
repräsentativ die 3D-Konformation ist, die für die Berechnung des Deskriptors
angewendet wurde.
Eine weitere Beschreibung, die wir in unserer Arbeit eingesetzt haben,
waren Fingerprints. In unserem Fall waren die verwendeten Fingerprints
ungeeignet zum Trainieren von Neuronale Netzen, da der Fingerprintvektor zu
viele Dimensionen (~ 10
5) hatte. Im Gegensatz dazu hat das Training von SVM
mit Fingerprints funktioniert. SVM hat den Vorteil im Vergleich zu anderen
Methoden, dass sie in sehr hochdimensionalen Räumen gut klassifizieren kann.
Dieser Zusammenhang zwischen SVM und Fingerprints war eine Neuheit, und
wurde von uns erstmalig in die Chemieinformatik eingeführt.
In Abschnitt 4.3 fokussiere ich mich auf die SVM-Methode. Für fast alle
Klassifikationsaufgaben in dieser Arbeit wurde der SVM-Ansatz verwendet. Ein
Schwerpunkt der Dissertation lag auf der SVM-Methode. Wegen
Platzbeschränkungen wurde in den beigefügten Veröffentlichungen auf eine
detaillierte Beschreibung der SVM verzichtet. Aus diesem Grund wird in
Abschnitt 4.3 eine vollständige Einführung in SVM gegeben. Darin enthalten ist
eine vollständige Diskussion der SVM Theorie: optimale Hyperfläche, Soft-
Margin-Hyperfläche, quadratische Programmierung als Technik, um diese56
Zusammenfassung
optimale Hyperfläche zu finden. Abschnitt 4.3 enthält auch eine Diskussion von
Kernel-Funktionen, welche die genaue Form der optimalen Hyperfläche
bestimmen.
In Abschnitt 4.4 ist eine Einleitung in verschiede Methoden gegeben, die
wir für die Auswahl von Deskriptoren genutzt haben. In diesem Abschnitt wird
der Unterschied zwischen einer „Filter“- und der „Wrapper“-basierten Auswahl
von Deskriptoren herausgearbeitet. In Veröffentlichung 3 (Abschnitt 7.3) haben
wir die Vorteile und Nachteile von Filter- und Wrapper-basierten Methoden im
virtuellen Screening vergleichend dargestellt.
Abschnitt 7 besteht aus den Publikationen, die unsere
Forschungsergebnisse enthalten.
Unsere erste Publikation (Veröffentlichung 1) war ein Übersichtsartikel
(Abschnitt 7.1). In diesem Artikel haben wir einen Gesamtüberblick der
Anwendungen von SVM in der Bio- und Chemieinformatik gegeben. Wir
diskutieren Anwendungen von SVM für die Gen-Chip-Analyse, die DNA-
Sequenzanalyse und die Vorhersage von Proteinstrukturen und
Proteininteraktionen. Wir haben auch Beispiele beschrieben, wo SVM für die
Vorhersage der Lokalisation von Proteinen in der Zelle genutzt wurden. Es wird
dabei deutlich, dass SVM im Bereich des virtuellen Screenings noch nicht
verbreitet war.
Um den Einsatz von SVM als Hauptmethode unserer Forschung zu
begründen, haben wir in unserer nächsten Publikation (Veröffentlichung 2)
(Abschnitt 7.2) einen detaillierten Vergleich zwischen SVM und verschiedenen
neuronalen Netzen, die sich als eine Standardmethode im virtuellen Screening
etabliert haben, durchgeführt. Verglichen wurde die Trennung von wirstoffartigen
und nicht-wirkstoffartigen Molekülen („Druglikeness“-Vorhersage). Die SVM
konnte 82% aller Moleküle richtig klassifizieren. Die Klassifizierung war zudem
robuster als mit dreilagigen feedforward-ANN bei der Verwendung verschiedener
Anzahlen an Hidden-Neuronen. In diesem Projekt haben wir verschiedene
Deskriptoren zur Beschreibung der Moleküle berechnet: Ghose-Crippen
Fragmentdeskriptoren [86], physikochemische Eigenschaften [9] und
topologische Pharmacophore (CATS) [10].
Die Entwicklung von weiteren Verfahren, die auf dem SVM-Konzept
aufbauen, haben wir in den Publikationen in den Abschnitten 7.3 und 7.8
beschrieben. Veröffentlichung 3 stellt die Entwicklung einer neuen SVM-
basierten Methode zur Auswahl von relevanten Deskriptoren für eine bestimmte
Aktivität dar. Eingesetzt wurden die gleichen Deskriptoren wie in dem oben
beschriebenen Projekt. Als charakteristische Molekülgruppen haben wir
verschiedene Untermengen der COBRA Datenbank ausgewählt: 195 Thrombin
Inhibitoren, 226 Kinase Inhibitoren und 227 Faktor Xa Inhibitoren. Es ist uns
gelungen, die Anzahl der Deskriptoren von ursprünglich 407 auf ungefähr 50 zu
verringern ohne signifikant an Klassifizierungsgenauigkeit zu verlieren. Unsere
Methode haben wir mit einer Standardmethode für diese Anwendung verglichen,
der Kolmogorov-Smirnov Statistik. Die SVM-basierte Methode erwies sich
hierbei in jedem betrachteten Fall als besser als die Vergleichsmethoden
hinsichtlich der Vorhersagegenauigkeit bei der gleichen Anzahl an Deskriptoren.57
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Eine ausführliche Beschreibung ist in Abschnitt 4.4 gegeben. Dort sind auch
verschiedene „Wrapper“ für die Deskriptoren-Auswahl beschrieben.
Veröffentlichung 8 beschreibt die Anwendung von aktivem Lernen mit
SVM. Die Idee des aktiven Lernens liegt in der Auswahl von Molekülen für das
Lernverfahren aus dem Bereich an der Grenze der verschiedenen zu
unterscheidenden Molekülklassen. Auf diese Weise kann die lokale Klassifikation
verbessert werden. Die folgenden Gruppen von Moleküle wurden genutzt: ACE
(Angiotensin converting enzyme), COX2 (Cyclooxygenase 2), CRF
(Corticotropin releasing factor) Antagonisten, DPP (Dipeptidylpeptidase) IV, HIV
(Human immunodeficiency virus) protease, Nuclear Receptors, NK (Neurokinin
receptors), PPAR (peroxisome proliferator-activated receptor), Thrombin, GPCR
und Matrix Metalloproteinasen. Aktives Lernen konnte die Leistungsfähigkeit des
virtuellen Screenings verbessern, wie sich in dieser retrospektiven Studie zeigte.
Es bleibt abzuwarten, ob sich das Verfahren durchsetzen wird, denn trotzt des
Gewinns an Vorhersagegenauigkeit ist es aufgrund des mehrfachen SVM-
Trainings aufwändig.
Die Publikationen aus den Abschnitten 7.5, 7.6 und 7.7
(Veröffentlichungen 5-7) zeigen praktische Anwendungen unserer SVM-
Methoden im Wirkstoffdesign in Kombination mit anderen Verfahren, wie der
Ähnlichkeitssuche und neuronalen Netzen zur Eigenschaftsvorhersage. In zwei
Fällen haben wir mit dem Verfahren neuartige Liganden für COX-2
(cyclooxygenase 2) und dopamine D3/D2 Rezeptoren gefunden. Wir konnten
somit klar zeigen, dass SVM-Methoden für das virtuelle Screening von
Substanzdatensammlungen sinnvoll eingesetzt werden können.
Es wurde im Rahmen der Arbeit auch ein schnelles Verfahren zur
Erzeugung großer kombinatorischer Molekülbibliotheken entwickelt, welches auf
der SMILES Notation aufbaut. Im frühen Stadium des Wirstoffdesigns ist es
wichtig, eine möglichst „diverse“ Gruppe von Molekülen zu testen. Es gibt
verschiedene etablierte Methoden, die eine solche Untermenge auswählen
können. Wir haben eine neue Methode entwickelt, die genauer als die bekannte
MaxMin-Methode sein sollte. Als erster Schritt wurde die „Probability Density
Estimation“ (PDE) für die verfügbaren Moleküle berechnet. [78] Dafür haben wir
jedes Molekül mit Deskriptoren beschrieben und die PDE im N-dimensionalen
Deskriptorraum berechnet. Die Moleküle wurde mit dem Metropolis Algorithmus
ausgewählt. [87] Die Idee liegt darin, wenige Moleküle aus den Bereichen mit
hoher Dichte auszuwählen und mehr Moleküle aus den Bereichen mit niedriger
Dichte. Die erhaltenen Ergebnisse wiesen jedoch auf zwei Nachteile hin. Erstens
wurden Moleküle mit unrealistischen Deskriptorwerten ausgewählt und zweitens
war unser Algorithmus zu langsam. Dieser Aspekt der Arbeit wurde daher nicht
weiter verfolgt.
In Veröffentlichung 6 (Abschnitt 7.6) haben wir in Zusammenarbeit mit
der Molecular-Modeling Gruppe von Aventis-Pharma Deutschland (Frankfurt)
einen SVM-basierten ADME Filter zur Früherkennung von CYP 2C9 Liganden
entwickelt. Dieser nichtlineare SVM-Filter erreichte eine signifikant höhere
Vorhersagegenauigkeit (q
2 = 0.48) als ein auf den gleichen Daten entwickelten
PLS-Modell (q
2 = 0.34). Es wurden hierbei Dreipunkt-Pharmakophordeskriptoren
eingesetzt, die auf einem dreidimensionalen Molekülmodell aufbauen. Eines der58
Zusammenfassung
wichtigen Probleme im computerbasierten Wirkstoffdesign ist die Auswahl einer
geeigneten Konformation für ein Molekül. Wir haben versucht, SVM auf dieses
Problem anzuwenden. Der Trainingdatensatz wurde dazu mit jeweils mehreren
Konformationen pro Molekül angereichert und ein SVM Modell gerechnet. Es
wurden anschließend die Konformationen mit den am schlechtesten
vorhergesagten IC50 Wert aussortiert. Die verbliebenen gemäß dem SVM-Modell
bevorzugten Konformationen waren jedoch unrealistisch. Dieses Ergebnis zeigt
Grenzen des SVM-Ansatzes auf. Wir glauben jedoch, dass weitere Forschung auf
diesem Gebiet zu besseren Ergebnissen führen kann.59
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Abstract 
The support vector machine (SVM) approach represents a data-driven method for solving 
classification tasks. It has been shown to produce lower prediction error compared to 
classifiers based on other methods like artificial neural networks, especially when large 
numbers of features are considered for sample description. In this review the theory and 
main principles of SVM are outlined, and successful applications in traditional areas of 
bioinformatics research are described. Current developments in SVM-related techniques 
are  reviewed  which  might  become  relevant  for  future  functional  genomics  and 
chemogenomics projects. In a comparative study, neural network and SVM models were 
developed  for  identification  of  small  organic  molecules  potentially  modulating  the 
function of G-protein coupled receptors. The SVM system was able to correctly classify 
approximately 90% of the compounds in a cross-validation study yielding a Matthews 
correlation coefficient of 0.78. This classifier can be used for fast filtering of compound 
libraries in virtual screening applications.  
Key words 
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Introduction to the theory of the Support Vector Machine 
The  support  vector  machine  (SVM)  approach  for  solving  classification  tasks  was 
introduced by Vapnik (Cortes and Vapnik, 1995; Vapnik 1995). It has been successfully 
applied  in  various  areas  of  research  ever  since.  Currently  we  witness  its  growing 
popularity  in  the bioinformatics field. In this  review,  we describe basic principles of 
SVM and then give examples of successful applications, together with a new application, 
namely the prediction of G-protein coupled receptor (GPCR) ligands. 
Several standard learning techniques are routinely used in bioinformatics. A basic 
task is binary classification. Typically, data are represented as labeled vectors in a high-
dimensional space. This representation is often chosen to preserve as much information 
as possible about features that are responsible for correct classification of samples. The 
choice of a particular type of label depends on the classification task. For example, if the 
task is to separate membrane proteins from cytoplasmic proteins, labels might be chosen 
to be +1 for membrane proteins (“class”) and -1 for cytoplasmic proteins (“nonclass”). In 
this case, the features might be various descriptors that map properties of the molecules 
to  real  numbers.  The  classifier  separating  “class”  from  “nonclass”  members  may  be 
conceptualized as a surface in this high-dimensional data space, structuring it into two 
parts, one for “class” and one for “nonclass”. Contrary to other approaches like, e.g., 
standard feed-forward neural networks, SVM does not construct a classifying surface 
directly in the given data space; instead, the sample points are projected to a significantly 
higher-dimensional  space,  where  the  separating  surface  can  be  found  as  a  linear 
hyperplane. The corresponding surface in the original space is then presented as a result 
of  SVM  training.  Generally  speaking,  SVM  classifiers  are  generated  by  a  two-step 
procedure: First, the data vectors are mapped (“projected”) to a high-dimensional space. 
The dimension of this space is significantly larger than dimension of the original data 
space. The algorithm finds a class-separating linear hyperplane in this high-dimensional 
space (Figure 1), and then this hyperplane is mapped back to the original data space. 
We first start with the description of the algorithm for constructing the separating 
hyperplane in a very high-dimensional “mapped” space and then review the procedure for 
identifying the corresponding classifying surface in the original space. 
[Figure 1] 
The separating hyperplane is defined as  
0 ) ( ) ( w D � � � x w x  , 
where x is a sample vector mapped to a high-dimensional space and w and w0 are 
parameters of the hyperplane that SVM will estimate. The width of the margin can be 
expressed as a minimal � for which for all vectors holds: 64
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� �
w
xk) ( D yk  . 
Here k y  are the class labels (+1 for class and -1 for nonclass membership of the 
sample xk). Without loss of generality we can apply a constraint  1 � w �  to w. In this 
case, maximizing � is equivalent to minimizing  w  and SVM training is becoming the 
problem of finding the minimum of a function with the following constraints: 
minimize ) (
2
1
) ( w w w � � �             (1) 
subject to constraints    1 ] ) [( 0 � � � w yi i x w
This problem is solved by introducing Lagrange multipliers and minimizing the 
following function:  
�
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Here ai are Lagrange multipliers. Differentiating over w and wi and substituting 
we obtain: 
� �
� �
� � �
n
j i
j i j i
n
i
i y y a a a a Q
1 , 1
) (
2
1
) ( max j i x x
subject to constraints      0
1
� �
�
n
i
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When perfect separation is not possible slack variables are introduced for sample 
vectors  violating  the  edges  of  the  margin,  and  the  optimization  problem  can  be 
reformulated:  
minimize � � � �
i
i C w � � ) (
2
1
) ( w w  .          (2) 
subject to constraints   i 0 � 1 ] ) [( � � � � w yi i x w  . 
Here i �  are slack variables. C is a tradeoff between maximizing the width of the 
margin and minimizing slack variables. These variables are not equal to zero only for 
those vectors which are within the margin. Introducing Lagrange multipliers again we 
finally obtain:  
� �
� �
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subject to constraints      0
1
� �
�
n
i
i i y� ,    n i C i ,..., 1 , 0 � � �� .
This  is  a  quadratic  programming  (QP)  problem  and  several  efficient  standard 
methods  are  known  to  solve  it  (Coleman  and  Li  1996).  Due  to  the  very  high 
dimensionality  of  the  QP  problem,  which  typically  arises  during  SVM  training,  an 
extension of the algorithm for solving QP is used in SVM applications (Joachims 1999). 
A  geometric  illustration  of  the  meaning  of  slack  variables  and  Lagrange 
multipliers  is  given  in  Figure  1.  The  main  goal  of  any  classifier  is  to  construct  a 
hyperplane that correctly predict the class membership of a data vector. It is reasonable to 
assume that vectors which are lying close to the border separating two classes should play 
a more important role in determining the exact position of the separating hyperplane. The 
main advantage of the SVM-classifier versus others is that only vectors that are lying 
sufficiently  close  to  the  class  border  determine  the  exact  position  of  the  classifying 
hyperplane. These vectors are called support vectors. Their name assumes that only they 
“support” the constructed hyperplane. The exact distance to the separating hyperplane, 
which is used as a criterion to find the support vectors, is a parameter to maximize during 
SVM training. The larger this distance is, the more pronounced is the class separation by 
the hyperplane. 
All other vectors are non-support vectors, where  1 ) ( � � i x D yi . These samples are 
correctly  classified  by  the  hyperplane  and  are  located  outside  the  separating  margin 
(Figure 1). Slack variables and Lagrange multipliers for them are equal to zero, which 
reflects the fact that their positions do not influence location of the separating hyperplane. 
Parameters of the hyperplane do not depend on them, and even if their positions are 
changed  the  separating  hyperplane  and  margin  will  remain  unchanged,  provided  that 
these points will stay outside the margin. 
Support vectors can be tentatively divided into two groups: vectors lying on the 
border of separating hyperplane, and vectors lying within the separating hyperplane. The 
origin of this tentative division is historical. Two types of SVM exist, “hard-margin” 
(Equation 1) and “soft-margin” (Equation 2) systems. In hard-margin SVM classifiers no 
support  vectors  are  allowed  within  the  separating  margin  and  the  SVM  is  trained  to 
maximize the separating margin. In soft-margin SVM classifier, which is our main focus 
here, a trade-off is introduced between having a large separating margin and a minimal 
number of misclassifications. This means that some of the vectors are tolerated within the 
separating margin for the benefit of having a larger margin. This trade-off is introduced 
by parameter C, which should be optimized to achieve maximum classification accuracy. 
Sometimes  it  is  not  possible  to  find  a  separating  hyperplane  even  in  a  very  high-
dimensional space. In this case a tradeoff is introduced between the size of the separating 
margin and penalties for every vector which is within the margin (Cortes and Vapnik 
1995). 
As illustrated in Figure 1, for all support vectors the absolute values of the slack 
variables are equal to the distances from these points to the edge of the separating margin. 
For support vectors lying on the border of separating hyperplane slack variables are equal 
to zero. For other support vectors these distances determine to which extent they violate 
the margin. They are defined in units of half of the width of the separating margin. For 
correctly  classified  vectors  within  the  separating  margin,  slack  variable  values  are 66
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between zero and one. For misclassified vectors within the margin the values of the slack 
variables are between one and two. For other misclassified points they are greater than 
two. 
For vectors lying on the edge of margin, Lagrange multipliers are between zero 
and C, slack variables for them are still equal to zero. For all support vectors, for which 
the values of slack variables are larger than zero, Lagrange multipliers are equal to C.
An important feature of SVM is the usage of Kernel functions rendering explicit 
mapping of the data to a very high-dimensional space unnecessary. In other words, scalar 
products of each vector pair are calculated in the original data space by introducing a 
kernel function  ) , ( ) ( j i j i x x x x K � � . The kernel function defines the scalar product in a 
certain high-dimensional space if it satisfies the following conditions (Cristianini and 
Shawe-Taylor 2000): 
1. K(x,x’) takes its maximum value when x’ = x.
2. |K(x,x’)| decreases with |x-x’|.
Here x and x’ are vectors in the original space for which a kernel function is 
defined that corresponds to a scalar product in the mapped high-dimensional space. 
Various  kernels  may  be  applied  (Burges  1998).  For  many  applications  a 
polynomial  kernel  functions  has  been  shown  to  be  sufficient,  e.g.  a  fifth-order 
polynomial-based kernel: 
5 ) * ) (( ) , ( r s K � � � x' x x' x
where  s  and  r  are  kernel  parameters.  This  kernel  corresponds  to  the  decision 
function:  
�
�
�
�
�
�
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i
i b K a sign f ) , ( * ) ( x x x
sv
i ,
Here ai are Lagrange multipliers determined during SVM training. The sum is 
only over support vectors x
sv. Lagrange multipliers for all other points are equal to zero. 
Parameter b determines the shift of the hyperplane, which is also found during SVM 
training. 
Kernel parameter and the error trade-off C (vide supra) should be tuned, e.g. by 
multiple cross-validation of training data. Basically, the following procedure is applied. 
The data set is divided into two parts, training and test set. The test subset is put aside and 
is used only for estimation of the performance of the trained classifier. Training data are 
divided into k non-overlapping subsets. First, the parameters to be determined are set to 
initial reasonable values. Then, the SVM is trained on the whole training data excluding 
the k subset and the performance of the obtained SVM classifier is estimated with the 
excluded  k  subset.  This  procedure  is  repeated  for  each  subset,  and  so  an  average 
performance of the SVM classifier will be obtained. This optimization can be performed, 
e.g.  by  simple  heuristics  based  on  gradient  descent  methods  (Bishop  1995).  The 67
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optimized values are employed for final training with the complete training data. The 
kernel parameters as well as the trade-off between the size of the separating margin and 
errors in predictions, C, are usually predefined prior to final training. A recommended 
starting value for C is
� �
2
1
x
   (Vapnik 1995). 
Currently  available  software  packages  allow  to  use  SVM  as  a  “black  box”, 
although some basic knowledge of SVM theory will help to obtain optimal results. 
If  more  than  a  binary  classification  is  required,  i.e.  a  multi-class  problem,  N
different subclasses will be predicted by SVM, and a multi-step binary classification is 
conducted: the data are divided into class one versus all other classes, class two versus all 
other etc. Then SVM models are obtained for each such pair. For N classes N different 
SVMs are trained. For final prediction a jury is formed by all N SVMs.
SVM  algorithms  are  capable  to  solve  large-scale  multidimensional  problems. 
Data containing up to several tens of thousands of samples can be efficiently analyzed by 
SVM.  It  has  been  estimated  that  the  computational  time  for  SVM  training  relates 
approximately with n
2 to the number of training samples (Joachims 1999). 
Applications of the Support Vector Machine in bioinformatics 
SVM for DNA chip analysis 
SVM was successfully employed for analysis of gene expression using microarray 
data. Research in this area has two primary goals. 
First,  given  the  gene  expression  profile  predict  if  it  corresponds  to  certain 
physiological conditions, like classification of cancer versus non-cancer tissues (Furey et 
al. 2000). Using SVM in a combination with a feature selection scheme it was possible to 
identify  small  groups  of  genes,  which  could  serve  as  markers  to  classify  tissue  as 
cancerous (Guyon et al. 2002) . 
The second main direction is to create an alternative to conventional clustering 
methods by grouping genes with similar functions. When applied to gene expression data, 
SVM training begins with a set of genes that have a known common function (“positive 
class”). A separate set of genes that are known not to be members of this functional class 
is also specified (“negative class”). These two sets of genes are combined to form a 
training set, where genes are labeled positively if they are in the functional class and 
negatively if they are not in the functional class. SVM for functional characterization of 
genes was shown to produce more accurate predictions than other mostly unsupervised 
learning methods like self-organizing maps and k-means clustering (Brown et al. 2000). 
Recently this approach was further extended by adding phylogenic information about 
genes and applying different kernel functions (Pavlidis et al. 2002).  
SVM has several mathematical features that that make it an attractive technique 
for gene expression analysis, including its flexibility in choosing the classifier function 
(SVM kernel), sparseness of the solution when dealing with large data sets, and explicit 
identification  of  outliers.  It  also  provides  an  excellent  classification  performance 68
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compared  to  other  methods  like  Parzen  windows,  decision  trees,  and  Fisher  linear 
discriminant (Brown et al. 2000). 
SVM for protein structure prediction 
Recently, SVM was applied for protein fold prediction. Given the amino acid 
sequence of a protein SVM was trained to predict the overall protein fold (Cai et al. 2002; 
Cai  et  al.  2002;  Ding  and  Dubchak  2001).  Proteins  were  described  by  features 
representing amino acid composition, hydrophobicity, normalized van der Waals volume, 
polarity,  polarizability,  and  other  properties.  Performance  of  the  classification  was 
evaluated on classes of protein folds from the SCOP database (Lo Conte et al. 2000). 
Large  classes  of  fold  types  like  all-�,  all-�, �/�  or  �+�  were  predicted  with  a  high 
accuracy  yielding  80-95%  correct  identification  (Cai  et  al.  2002).  Smaller  classes  of 
protein  folds  from  SCOP  were  classified  with  an  accuracy  approaching  50%  correct 
prediction, which still is significantly more accurate than random class label assignment 
which  yields  about  4%.  Compared  to  artificial  neural  network  classifiers,  SVM  was 
shown to produce more accurate predictions. It should be noted that small classes of 
protein folds contain only a small number of samples - about 20 per class -, and still it 
was possible to generate a useful, though not perfect, SVM classifier. 
SVM for prediction of protein-protein interaction 
A  major  post-genomic  scientific  and  technological  pursuit  is  to  describe  the 
functions  of  proteins  encoded  in  a  genome.  One  strategy  is  to  first  identify protein–
protein  interactions  in  a  proteome,  then determine  signaling pathways,  and  finally  to 
statistically  infer  functional  roles  of  individual  proteins.  Currently  huge  amounts  of 
genomic data are available, and protein-protein interaction assays are being developed to 
meet high-throughput standards (Rudert et al. 2000; Mahlknecht et al. 2001). Data-driven 
methods analyzing these experimental data can play a pivotal role for inference of protein 
function.  
SVM was used as one of the methods for predicting protein-protein interaction 
from the knowledge of the amino acid sequences only (Bock and Gough 2001). Features 
representing  local  physico-chemical  properties  of  proteins  were  evaluated.  For  each 
amino acid sequence of a protein–protein complex, feature vectors were assembled from 
encoded representations of tabulated residue properties including charge, hydrophobicity, 
and surface tension. This feature set was motivated by the previous demonstration of 
sequential hydrophilicity profiles as sensitive descriptors of local interaction sites (Hopp 
and Woods 1983). This concept was further extended to integrate charge and surface 
tension, as water molecules influence atomic packing for shape complementarity, and 
mediate  polar  interactions  at  protein–protein  recognition  sites  (Lo  Conte  et  al.  1999; 
Böhm and Schneider 2003). The postulate was that since sequentially-proximal protein 
secondary  structure  elements  are  often  co-located  in  three-dimensional  conformation 
(Levitt and Chothia 1976), the sequential profile of these additional features (charge, 
surface tension) must similarly ‘co-locate’ upon folding. Samples were selected as pairs 
of proteins and these pairs were labeled as interacting or non-interacting, forming the 
positive  and  negative  sets  required  for  SVM  training.  The  method  results  in 69
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approximately 80% correctly predicted interacting pairs, which means that four out of 
five  potential  protein  interactions  were  correctly  estimated  by  the  system  (Bock  and 
Gough 2001).  
Further  extension  of  this  technique  aimed  at  predicting  the  energy  of  ligand-
receptor interactions (Bock and Gough 2002). The results obtained were comparable to 
those of other methods, including molecular dynamics (Böhm 1998; Head et al. 1996; 
Wanga et al. 2002). SVM regression was used to map the feature vector of a receptor-
ligand pair to the value of their interaction energy. The main conclusion of this research 
is that it might become possible to predict binding free energy without direct information 
about the three-dimensional structure of receptor and the ligand with an accuracy that is 
comparable to other computationally more expensive methods. 
Combination of HMM and SVM for sequence analysis 
A core problem in statistical biological sequence analysis is the annotation of new 
protein sequences with structural and functional features. To a certain degree, this can be 
achieved by relating new sequences to proteins for which such structural properties are 
already  known,  i.e.  by  detection  of  protein  homologies.  Several  statistical,  sequence-
based  tools  have  been  developed  for  this  purpose,  including  the  heuristic  alignment 
methods  BLAST  (Altschul  et  al.  1990)  and  FASTA  (Pearson  and  Lipman  1988),  or 
Hidden Markov Models (HMMs) (Krogh et al. 1994). It was shown that methods such as 
PSI-BLAST  (Altschul  et  al.  1997)  and  HMMs,  which  can  be  used  to  construct  a 
statistical model from multiple sequence alignments, perform better than simple pair-wise 
comparison  methods,  but  all  sequence-based  methods  actually  miss  many  important 
remote homologues (Park et al. 1998).
A  new methodology was  developed by  Haussler  and co-workers combining a 
sequence-specific  algorithm  with  the  general  discriminative  statistical  method  SVM 
(Jaakkola et al. 1999). In their approach, HMMs were employed to extract features from 
protein sequences, and these features were subsequently used to train an SVM classifier. 
The main idea of HMM is: given a sequence of a new protein predict its probability to be 
generated by a certain statistical model called “HMM model”. In this case P(X | H) can be 
estimated, where X is a protein sequence and H is the HMM model. The naïve Bayes 
estimation of a log-likelihood classifier can be used to predict whether a new sequence 
belongs to a family of proteins: 
� �
� �
� � � �
�
�
� �
�
�
�
1 0 : : 0 0
1 1 ) , ( ) , (
) ( ) | (
) ( ) | (
log ) (
H X i H H i
i i i i
i i
X X K X X K
H P H X P
H P H X P
X � � � .
Here ) (X �  is a log-likelihood of the ratio of probabilities of sequence X to be 
generated by HMM H1 versus H0: If  ) (X �  is larger than zero then sequence X is more 
likely to be generated by HMM H1 than H0 and vice versa. Here  ) (H P  is the probability 
to observe sequence generated by model H and  ) | ( H X P is the probability to generate 
sequence X by HMM H. H1 represents a model of the sequences under investigation, and 
H0 is a random model. In this method  ) (X �  is interpreted as a decision function and 70
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approximated  in  accordance  to  SVM  theory,  which  means  that  i � are  interpreted  as 
Lagrange multipliers for the sample vectors Xi.
To  be  more  specific,  for  predicting  protein  homology  with  SVM,  ) (X � was 
adopted to represent a discriminative surface like it exists in the SVM implementation. In 
order to do so, a new kernel function, the Fisher kernel, was introduced (Jaakkola et al. 
2000). The Fisher kernel was defined as 
)) ( ) (
2
1
' ' 2 ) ' , (
x x
T
x x U U U U
e X X K
� � �
� �  , 
by introducing gradients over HMM parameters: 
) , | ( 1 � � H X P U X � � .
Here ) , | ( 1 � H X P  is the same as  ) | ( 1 H X P , but HMM parameters are explicitly 
represented by variable � . Gradients are calculated with respect to these parameters. The 
magnitude  of  the  components  of  the  gradients  specifies  the  extent  to  which  each 
parameter  contributes  to  generating  the  query  sequence.  A  detailed  description  of 
parameter  calculation  in  the  context  of  HMMs  along  with  their  relation  to  sufficient 
statistics is described in more detail elsewhere (Jaakkola et al. 1999). The original work 
on  a  family  of  GPCR  indicates  that  a  combination  of  SVM  and  HMM  leads  to  an 
improvement of the characterization of protein families from SCOP. A similar approach 
combining HMM and SVM was also applied for characterization of promoter regions 
(Pavlidis et al. 2001), and characterization of GPCR superfamilies (Karchin et al. 2002).  
SVM for feature selection 
Feature selection plays a pivotal role in molecular informatics. Current screening 
techniques provide us with a large amount of information, which allows formation of 
various  features  for  analyzing  biological  properties.  Often  only  a  surprisingly  small 
number of features is responsible for a certain biological effect, and techniques that will 
allow to find such features are very useful. An application of SVM to feature selection 
was described for identifying splice sites in mRNA precursors (Degroeve et al. 2002). 
Rouzé and co-workers selected 50 nucleotides upstream and 50 nucleotides downstream 
of introns conforming the GT-AG consensus for the positive training set. Each nucleotide 
position was then encoded by a four-digit unary number resulting in 4*(50+50) = 400 
features. A feature represents presence or absence of a particular nucleotide. Almost all 
positives were identified (96%) but only about 30% of predicted positives were correct. 
Nucleotides  responsible  for  defining  splicing  sites  were  then  identified  using  SVM 
feature  selection  approach.  Wrapper-based  feature  selection  was  used,  which  first 
performs classification with all available features and then excludes the most irrelevant 
feature and performs classification again. This procedure was repeated until only a small 
number of relevant features remained. This approach is reported to be generally superior 
to methods that select features prior to classification (Kohavi and John 1994). 71
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A different method based on scaling of parameters of the SVM kernel was applied 
by  Reifman  and  co-workers  to  identify  key  amino  acid  positions  responsible  for  the 
pathology of immunoglobulin-type beta domains (Zavaljevski et al. 2002). Features were 
created based on physico-chemical properties of amino acids. Parameters responsible for 
weighting  amino  acid  properties  at  predefined  positions  were  scaled  to  improve 
classification. For example, features were enhanced at positions that are conserved over 
the protein family, non-conserved features were down-weighted. In addition, automatic 
adaptive scaling was used, which was based on the sensitivity of the classifier function to 
changing of the scaling factors. It was shown that appropriate scaling could significantly 
reduce classification error. 
SVM for predicting protein sub-cellular localization 
As more and more sequences of proteins become available important information 
about protein function can be deduced by predicting their sub-cellular localization. To 
date,  three  conceptually  different  approaches  have  been  proposed:  i)  using  targeting 
signals as `address labels', ii) basing the prediction on the observation that proteins from 
different cellular compartments tend to differ in subtle ways in their overall amino acid 
composition, and iii) using evolutionary relationships to infer the sub-cellular localization 
(Bickmore and Sutherland 2002; Emanuelsson and von Heijne 2001). Recently, SVM 
was trained on a set of features that is capable to capture different types of information 
for sub-cellular localization (Chou and Cai 2002). The method was used to predict the 
following  locations:  chloroplast,  cytoplasm,  cytoskeleton,  endoplasmic  reticulum, 
extracellular  matrix,  Golgi  apparatus,  lysosome,  mitochondria,  nucleus,  peroxisome, 
plasma membrane, and vacuole. The decision was based on amino acid composition and 
functional  comparison  of  the  query  protein  to  a  set  of  proteins  with  well-defined 
structural and functional domain types. This procedure results in a binary vector: the ith
component of this vector is equal to one if both amino acid sequence (based on BLASTP) 
and domain structure (based on HSP (Altschul et al. 1990)) of the query protein and the 
ith protein from the above mentioned set are sufficiently similar. The concept allows for 
incorporation  of  information  about  both  the  amino  acid  sequence  and  evolutionary 
relationships into the feature vector. The SVM classifier yielded 80% correct predictions 
overall, when trained on the proteins from SWISS-PROT (Bairoch and Apweiler 2000). 
Application of Support Vector Machine and Neural Network 
Models for Classification of GPCR Ligands 
Applications  of  SVM  models  in  various  areas  of  bioinformatics  have  shown  certain 
advantages of SVM over other learning algorithms, and first applications of SVM in 
pharmaceutical research have been described (Burbidge et al. 2001; Warmuth et al. 2003; 
Wilton  et  al.  2003;  Trotter  and  Holden  2003).  Since  both  SVM  and  multi-layered 
artificial neural networks (ANN) are capable of solving non-linear classification tasks, 
there is a debate as to which system should be preferred. SVM and ANN were designed 
for similar purposes, so they basically have the same structure of input and output, but the 72
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algorithm for training is significantly different. SVM results should be interpreted in the 
same way as ANN results. The main difference between SVM and ANN is that the SVM 
decision surface depends only on the support vectors, i.e. data points which are close to 
the decision surface. In contrast, in ANN training all data points contribute to the final 
solution. The decision surface constructed by SVM is essentially nonlinear. Nonlinearity 
is introduced by mapping data points to a very high-dimensional space, where a decision 
surface can be found in a form of a hyperplane. The mapping function provides the 
correspondence between the separating hyperplane in a very high-dimensional space and 
a decision surface in the original data space. The exact mapping is determined by the 
particular kernel used for SVM training. ANN approximate a decision function in the 
original data space. The SVM kernel method is particularly appealing because finding a 
decision surface in a form of a linear hyperplane can be algorithmically treated in a 
straightforward manner.  
For demonstration of a typical application, we compared the performance of SVM 
classifiers to neural network-based prediction of GPCR ligands. The classification task 
was  to  find  a  model  separating  small  organic  molecules  which  interact  with  GPCR 
(“class”)  from  compounds  which  were  assumed  not  to  modulate  GPCR  activity 
(“nonclass”). Similar approaches were successfully introduced using neural networks as 
classifying systems some years ago and have become very popular in the field of virtual 
screening  (Ajay  et  al.  1998;  Sadowski  and  Kubinyi  1998;  Schneider  et  al.  2001; 
Schneider and Böhm 2002). 
For  this  study  we  used  the  GPCR  ligands  compiled  in  the  COBRA  database 
(Schneider  and  Schneider  2003).  COBRA  contains  a  large  collection  of  bioactive 
molecules published in the recent scientific literature and was developed to provide sets 
of reference compounds for virtual screening applications and method development. 1645 
GPCR  ligands  (“class”,  label  +1)  and  2862  “nonclass”  (label  -1)  compounds  were 
selected. Molecular descriptors were used to represent the molecules in a form which is 
suitable  for  learning.  In  this  work  we  used  MOE  descriptors  (Molecular  Operating 
Environment, MOE. Chemical Computing Group Inc., Montreal) and CATS descriptors 
(Schneider  et  al.  1999).  These  descriptors  include  various  physico-chemical  and 
geometrical properties of molecules. As a result, each molecule was represented by 407 
descriptors and a class label.  
The neural network model. Conventional two-layered neural networks with a single 
output neuron were used for neural network model development (Figure 2). As a result of 
network training a decision function is chosen from the family of functions represented 
by the network architecture. This function family is defined by the complexity of the 
neural network, i.e. number of hidden layers, number of neurons in these layers, and 
topology of the network. The decision function is determined by choosing appropriate 
weights for the neural network. Optimal weights usually minimize an error function for 
the  particular  network  architecture.  The  error  function  describes  the  deviation  of 
predicted  target  values  from  observed  or  desired  values.  For  our  class/nonclass 
classification problem the target values were 1 for “class” and -1 for “nonclass”, and the 
mean-square-error  (E) served as objective  function  for  training. Standard  two-layered 
neural networks with a single output neuron can be represented by the following equation: 73
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function and g  was a tan-sigmoid transfer function. The ANN model produced values 
in  ]-1,1[,  where a positive value  meant  “class”  and a negative value “nonclass”. For 
weight  optimization  the  Levenberg-Marquardt  method  was  employed  (Hagan  and 
Menhaj  1994;  Foresee  and  Hagan  1997),  as  implemented  in  the  MATLAB  package 
(MATLAB  2002,  The  mathematical  laboratory.  The  MathWorks  GmbH,  D-52064 
Aachen, Germany). 
The  SVM  model. A freely available  SVM-package has been published by Joachims 
(SVM-light package, URL: http://svmlight.joachims.org/) (Joachims 1999), which was 
used to build SVM models. We compared the polynomial kernel  
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The SVM model for GPCR ligand/nonligand classification of a pattern x was: 
� � � � � � �
i
SV
i i b x x K a x SVM , ) ( , where 
i runs only over support vectors. The value of SVM(x) is either positive (“class”) 
or negative (“nonclass”). 
Model evaluation. Classification accuracy was evaluated based on prediction accuracy, 
expressed by the correlation coefficient according to Matthews (Matthews 1975): 
) )( )( )( ( U P O P U N O N
OU NP
cc
� � � �
�
� ,
where P, N, O, U are the number of true positive, true negative, false positive and 
false negative predictions respectively. GPCR ligands were considered as “positive set”, 
the non-GPCR ligands formed the “negative set”. The values of cc can range from –1 to 
1. Perfect prediction gives a correlation coefficient of 1. Different training and test sets 
were selected for 10-fold cross-validation (random 80 + 20 splits) and average values of 
<cc> were calculated.  74
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Results and discussion.  SVM and ANN classification models were developed using 
different  numbers  of  training  samples.  Figure  3  shows  the  dependence  of  the 
classification accuracy as a function of the size of the training subset. It is evident that 
accuracy is gained by larger training sets, irrespective of the type of learning system 
applied. The SVM classifier yielded higher average classification accuracy (<cc> = 0.78) 
than the ANN models tested (<cc> = 0.67). Although ANN classification performance 
increased with the number of hidden neurons it did not reach the accuracy of the SVM 
model. In a previous comparison of SVM to several machine learning methods by Holden 
and co-workers it was demonstrated that an SVM classifier outperformed other standard 
methods, but a specially designed and structurally optimized neural network was again 
superior to the SVM model in a benchmark test (Burbidge et al. 2001). In the present 
study an SVM was optimized with regard to its model parameters and applied to the 
identical  classification  task  (GPCR  ligands vs.  nonligands)  as neural  networks which 
were  not  specifically  optimized.  With  appropriate  structural  optimization  it  might  be 
possible to obtain an ANN architecture showing comparable performance. It is always 
required  to  properly  understand  the  classification  technique  applied  and  optimize  its 
tunable features in order to draw conclusions about strengths and weaknesses of a method 
in comparison to other approaches. 
In a second study, we compared different kernels for SVM training. Figure 4 
shows the dependence of the Matthews correlation coefficient on the type of kernel used 
for  training.  We  compared  the polynomial kernel  with the RBF kernel.  Both kernels 
performed  similarly,  with  slightly  higher  classification  accuracy  yielded  by  the  RBF 
kernel. Again, we wish to stress that this result does not justify conclusions regarding a 
general superiority of the RBF kernel to be drawn, since the accuracy obtained with the 
polynomial kernel was still within the standard deviation margin. The mapping to a high-
dimensional space where the optimal hyperplane is determined is only defined by the 
SVM kernel function. Provided that the dimensionality of this very high-dimensional 
space is sufficiently large, classification accuracy should not depend on the particular 
kernel (Vapnik 1995). In practice, almost every kernel has parameters that should be 
tuned for optimal classification accuracy. Provided that these parameters are optimally 
tuned SVM classification accuracy only slightly depends the particular form of a kernel. 
This  was demonstrated by our  comparison of the polynomial  and RBF kernel in the 
GPCR example (Figure 4). 
In the light of medicinal chemistry it is remarkable that it was possible to obtain a 
prediction  system  for  GPCR  ligands  with  comparably  high  prediction  accuracy 
(approximately 90% correct). Previous attempts were grounded on privileged structures 
(Klabunde  and  Hessler  2002),  receptor-ligand  docking  (Vaidehi  et  al.,  2002), 
phylogenetic  analysis  and  ligand  clustering  (Vassilatis  et  al.  2003),  neural  network 
systems (Manallack et al. 2002), a self-organizing map (Schneider et al. 2001; Schneider 
and Nettekoven 2003), or property-based library design (Balakin et al. 2002). Our new 
tool can now be used for very fast early-phase virtual screening campaigns to collect 
promising  candidates  for  further  evaluation  and  testing.  It  represents  a  useful  virtual 
filtering  technique  for constraining the  size  of  GPCR-targeted libraries  that will help 
speed up the identification of novel GPCR-ligands. 75
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Conclusions
It was demonstrated by a number of independent research teams and the present study 
that irrespective of the particular application a properly designed SVM has the capability 
to  compete  with  and  sometimes  outperform  other  data-driven  methods  including 
supervised  and  unsupervised  learning.  SVM  performs  particularly  well  when  large 
numbers  of  features  are  available,  as  typified  by  gene  chip  analysis  experiments.  A 
particular advantage of SVM is “sparseness of the solution”. This means that an SVM 
classifier depends only on the support vectors and the classifier function is not influenced 
by the whole data set, as it is the case for most neural network systems. It should be kept 
in mind that irrespective of the appeal of the technique, SVM should be considered as 
complementary  to  other  methods.  And  just  like  for  ANN  training,  there  are  model 
parameters  to  be  tuned  for  optimal  SVM  performance.  We  expect  that  in  the  future 
prediction  will  be  increasingly  performed  by  a  plethora  of  classifiers  obtained  by 
different methods, which are combined by a jury decision method. SVM are likely to play 
a role in this game. 
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Legend to the figures 
Figure 1. 
SVM classification. This figure illustrates values of an SVM model obtained during SVM 
training. The task was to separate two classes of objects indicated by squares and circles. 
Squares represent nonclass samples (“negative examples”) and circles are class members 
(“positive  examples”).  0 ) ( ) ( w D � � � x w x  is  the  decision  function  defining  class 
membership according to the SVM classifier. The SVM classifier is represented by the 
separating line (D(x) = 0). The margin is indicated by dotted lines. Support vectors are 
indicated by filled objects (x2, x2, x3, x4). i �  are slack variables for support vectors that 
are not lying on the margin border.  i y  are label-variables equal to 1 for positive examples 
(class membership) and -1 for negative examples (nonclass membership). 
�1 = 1 – D(x1)
y * D(x2) = 1 - �2> 0 
�3 = 1 + D(x3)
y * D(x4) = 1 - �4< 0 
Figure 2. 
Architecture of an artificial feed-forward neural network. Formal neurons are drawn as 
circles, weights are represented by lines connecting the neuron layers. Fan-out neurons 
are drawn in white, sigmoidal units in black, and linear units in gray.
Figure 3. 
Matthews  correlation  coefficients  for  prediction  of  GPCRs  inhibitors.  SVM-based 
prediction  was  compared  to  neuronal  network  performance.  Matthews  correlation 
coefficients for the test samples are plotted versus number of samples used for training. 
Standard deviations are shown as dotted lines. 
Figure 4. 
Matthews  correlation  coefficients  for  comparison  of  different  kernels  used  in  SVM 
training.  Classification  performance  of  SVM  classification  performance  depends  only 
slightly depends on the nature of kernel function, provided that parameters of the kernel 
are optimized during training. Here, GPCR inhibitors were predicted by SVM with an 
RBF and a polynomial kernel. Standard deviations are shown as dotted lines. 81
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Support vector machine (SVM) and artificial neural network (ANN) systems were applied to a drug/nondrug
classification problem as an example of binary decision problems in early-phase virtual compound filtering
and screening. The results indicate that solutions obtained by SVM training seem to be more robust with a
smaller standard error compared to ANN training. Generally, the SVM classifier yielded slightly higher
prediction accuracy than ANN, irrespective of the type of descriptors used for molecule encoding, the size
of the training data sets, and the algorithm employed for neural network training. The performance was
compared using various different descriptor sets and descriptor combinations based on the 120 standard
Ghose-Crippen fragment descriptors, a wide range of 180 different properties and physicochemical descriptors
from the Molecular Operating Environment (MOE) package, and 225 topological pharmacophore (CATS)
descriptors. For the complete set of 525 descriptors cross-validated classification by SVM yielded 82%
correct predictions (Matthews cc ) 0.63), whereas ANN reached 80% correct predictions (Matthews cc )
0.58). Although SVM outperformed the ANN classifiers with regard to overall prediction accuracy, both
methods were shown to complement each other, as the sets of true positives, false positives (overprediction),
true negatives, and false negatives (underprediction) produced by the two classifiers were not identical. The
theory of SVM and ANN training is briefly reviewed.
INTRODUCTION
Early-phase virtual screening and compound library design
often employs filtering routines which are based on binary
classifiers and are meant to eliminate potentially unwanted
molecules from a compound library.1,2 Currently two clas-
sifier systems are most often used in these applications: PLS-
based classifiers3,4 and various types of artificial neural
networks (ANN).5-9 Typically, these systems yield an
average overall accuracy of 80% correct predictions for
binary decision tasks following the “likeness concept” in
virtual screening.2,10 The support vector machine (SVM)
approach was first introduced by Vapnik as a potential
alternative to conventional artificial neural networks.11,12 Its
popularity has grown ever since in various areas of research,
and first applications in molecular informatics and pharma-
ceutical research have been described.13-15 Although SVM
can be applied to multiclass separation problems, its original
implementation solves binary class/nonclass separation prob-
lems. Here we describe application of SVM to the drug/
nondrug classification problem, which employs a class/
nonclass implementation of SVM. Both SVM and ANN
algorithms can be formulated in terms of learning machines.
The standard scenario for classifier development consists of
two stages: training and testing. During first stage the
learning machine is presented with labeled samples, which
are basically n-dimensional vectors with a class membership
label attached. The learning machine generates a classifier
for prediction of the class label of the input coordinates.
During the second stage, the generalization ability of the
model is tested.
Currently various sets of molecular descriptors are avail-
able.16 For application to drug/nondrug classification of
compounds, the molecules are typically represented by
n-dimensional vectors.6,7 In this work, we focused on the
fragment-based Ghose-Crippen (GC) descriptors17-19 which
were used in the original work of Sadowski and Kubinyi
for drug/nondrug classification,7 descriptors provided by the
MOE software package (Molecular Operating Environment.
Chemical Computing Group Inc., Montreal, Canada), and
CATS topological pharmacophores.20 Having defined this
molecular representation, the task of the present study was
to compare the classification ability of standard SVM and
feed-forward ANN on the drug/nondrug data. A www-
based interface for calculating the drug-likeness score of a
molecule using our SVM solution based on the CATS
descriptor was developed and can be found at URL: http://
gecco.org.chemie.uni-frankfurt.de/gecco.html.
DATA AND METHODS
Data Sets. For SVM and ANN training we used the sets
of “drug” and “nondrug” molecules prepared by Kubinyi and
Sadowski.7 From the original data set 9208 molecules could
be processed by our descriptor generation software. The final
working set contained 4998 drugs and 4210 nondrug
molecules. Three sets of descriptors were calculated: counts
of the standard 120 Ghose Crippen descriptors,17-19 180
* Corresponding author phone: +49-69 79829821; fax: +49-69 7982-
9826; e-mail: gisbert.schneider@modlab.de.
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descriptors from MOE (Molecular Operating Environment.
Chemical Computing Group Inc., Montreal, Canada), and
225 topological pharmacophore (CATS) descriptors.20 MOE
descriptors include various 2D and 3D descriptors such as
volume and shape desciptors, atom and bonds counts, Kier-
Hall connectivity and kappa shape indices, adjacency and
distance matrix descriptors, pharmacophore feature descrip-
tors, partial charges, potential energy descriptors, and
conformation-dependent charge descriptors. Before calculat-
ing MOE descriptors, single 3D conformers were generated
by CORINA.21 225 CATS descriptors were calculated
using our own software taking into consideration pairs of
atom types separated by up to 15 bonds (URL: http://
gecco.org.chemie.uni-frankfurt.de/gecco.html).20 All 225 de-
scriptor columns were individually autoscaled. An alternative
would have been block-scaling where each descriptor class
is autoscaled as a whole, which was not applied here.
Support Vector Machine. SVM classifiers are generated
by a two-step procedure: First, the sample data vectors are
mapped (“projected”) to a very high-dimensional space. The
dimension of this space is significantly larger than dimension
of the original data space. Then, the algorithm finds a
hyperplane in this space with the largest margin separating
classes of data. It was shown that classification accuracy
usually depends only weakly on the specific projection,
provided that the target space is sufficiently high dimen-
sional.11 Sometimes it is not possible to find the separating
hyperplane even in a very high-dimensional space. In this
case a tradeoff is introduced between the size of the
separating margin and penalties for every vector which is
within the margin.11 The basic theory of SVM will be briefly
reviewed in the following.
The separating hyperplane is defined as
Here x is a samples vector mapped to a high dimensional
space, and w and w0 are parameters of the hyperplane that
SVM will estimate. Then the margin can be expressed as a
minimal τ for which holds
Without loss of generality we can apply a constraint
τ||w|| ) 1 to w. In this case maximizing τ is equivalent to
minimizing ||w|| and SVM training is becoming the problem
of finding the minimum of a function with the following
constraints:
This problem is solved by introduction of Lagrange
multipliers and minimization of the function
Here Ri are Lagrange multipliers. Differentiating over w
and wi and substituting we obtain
When perfect separation is not possible slack variables
are introduced for sample vectors which are within the
margin, and the optimization problem can be reformulated:
Here �i are slack variables. These variables are not equal
to zero only for those vectors which are within the margin.
Introducing Lagrange multipliers again we finally obtain
This is a quadratic programming (QP) problem for which
several efficient standard methods are known.22 Due to the
very high dimensionality of the QP problem, which typically
arises during SVM training, an extension of the algorithm
for solving QP is used in SVM applications.23
A geometrical illustration of the meaning of slack variables
and Lagrange multipliers is given in Figure 1. Points
classified by SVM can be divided into two groups, support
vectors and nonsupport vectors. Nonsupport vectors are
classified correctly by the hyperplane and are located outside
Figure 1. Principle of SVM classification. The task was to separate
two classes of objects indicated by squares and circles. Squares
represent nonclass samples (“negative examples”, e.g. nondrugs)
and circles are class members (“positive examples”, e.g. drugs).
D(x) is the decision function defining class membership according
to the SVM classifier which is represented by the separating line
(D(x) ) 0). The margin is indicated by dotted lines. Support vectors
are indicated by filled objects (x2, x2, x3, x4). �i are slack variables
for support vectors that are not lying on the margin border. yi are
label-variables equal to 1 for positive examples (class membership)
and -1 for negative examples (nonclass membership). See text for
details.
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the separating margin. Slack variables and Lagrange multi-
pliers for them are equal to zero. Parameters of the
hyperplane do not depend on them, and even if their position
is changed the separating hyperplane and margin will remain
unchanged, provided that these points will stay outside the
margin. Other points are support vectors, and they are the
points which determine the exact position of the hyperplane.
For all support vectors the absolute values of the slack
variables are equal to the distances from these points to the
edge of the separating margin. These distances are defined
in the units of half of the width of the separating margin.
For correctly classified points within the separating margin,
slack variable values are between zero and one. For mis-
classified points within the margin the values of the slack
variables are between one and two. For other misclassified
points they are greater than two.
For points that are lying on the edge of margin, Lagrange
multipliers are between zero and C, and slack variables for
these points are still equal to zero. For all other points, for
which the values of slack variables are larger than zero,
Lagrange multipliers assume the value of C.
Explicit mapping to a very high-dimensional space is not
required if calculation of the scalar product in this high
dimensional space of every two vectors is feasible. This
scalar product can be defined by introducing a kernel
function(x‚x′) ) K(x,x′),24 where x and x′ are vectors in a
low-dimensional space for which a kernel function that
corresponds to a scalar product in a high dimensional space
is defined. Various kernels may be applied.25 In our case,
we used a kernel function of a fifth-order polynomial:
This kernel corresponds to the decision function
where Ri are Lagrange multipliers determined during training
of SVM. The sum is only over support vectors xsV. Lagrange
multipliers for all other points are equal to zero. Parameter
b determines the shift of the hyperplane, and it is also found
during SVM training. Simultaneous scaling of s, r, and b
parameters does not change the decision function. Thus, we
can simplify the kernel by setting r equal to one:
In this case only the kernel parameter s and error tradeoff
C must be tuned. Parameter C is not present explicitly in
this equation; it is set up as a penalty for the misclassification
error before the training of SVM is performed. For tuning
parameters s and C, four-times cross-validation of training
data was applied, and values for s and C that maximize
accuracy were then chosen. Accuracy maximization was
performed by heuristics based gradient descent.26 Basically,
the following procedure was applied. The data set was
divided into two parts, training and validation set. The
validation subset was put aside and used only for estimation
of the performance of the trained classifier. Training data
were divided into four nonoverlapping subsets. The SVM
parameters to be determined were set to reasonable initial
values. Then, the SVM was trained on the training data
excluding one of the four subsets, and the performance of
the obtained SVM classifier was estimated with the excluded
subset. This procedure was repeated for each subset, and an
average performance of the SVM classifier was obtained.
For SVM training we used freely available SVM soft-
ware (SVM-Light package; URL: http://svmlight.joachims.
org/).26,27 A Linux-based LSF (Load Sharing Facility;
Platform Computing GmbH, D-40878 Ratingen, Germany)
cluster was used for determination of the cross-validation
error to reduce calculation time. All calculations were
performed using the MATLAB package (MATLAB 2002,
The mathematical laboratory. The MathWorks GmbH,
D-52064 Aachen, Germany).
ARTIFICIAL NEURAL NETWORK
Conventional two-layered neural networks with a single
output neuron were used for ANN model development
(Figure 2a).26 As a result of network training a decision
function is chosen from the family of functions represented
by the network architecture. This function family is defined
by the complexity of the neural network: number of hidden
layers, number of neurons in these layers, and topology of
the network. The decision function is determined by choosing
appropriate weights for the neural network. Optimal weights
usually minimize an error function for the particular network
architecture. The error function describes the deviation of
predicted target values from observed or desired values. For
our class/nonclass classification problem the target values
were 1 for class (drugs) and -1 for nonclass (nondrugs).
Standard two-layered neural network with a single output
neuron can be represented by the following equation
with the error function E ) ∑k)1
n (y(xk) - yk)2. In this work,
g ˜ is a linear function and g is a tan-sigmoid transfer function.
A second type network architecture containing additional
connections from the input layer to the output layer was
trained to reimplement the original drug/nondrug ANN
developed by Ajay and co-workers (Figure 2b).6
Training of neural network is typically performed on
variations of gradient descent based algorithms,26 trying to
K(x,x′) ) ((x‚x′)s + r)
5
f(x) ) sign(∑
i
RiK(xi
sV, x) + b)
K(x,x′) ) ((x‚x′)s + 1)
5
Figure 2. Architecture of artificial neural networks. Formal neurons
are drawn as circles, weights are represented by lines connecting
the neuron layers. Fan-out neurons are drawn in white, sigmoidal
units in black, and linear units in gray. (a) conventional three-layered
feed-forward system (“architecture I”); (b) network architecture used
by Ajay and co-workers for drug-likeness prediction (“architecture
II”).6
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minimize an error function. To avoid overfitting cross-
validation can be used for finding an earlier point of
training.28 In this work the neural network toolbox from
MATLAB was used. Data were preprocessed identically to
SVM based learning. We applied the following training
algorithms to ANN optimization in their default versions
provided by MATLAB: gradient descent with variable
learning rate,29,30 conjugated gradient descent,30,31 scaled
conjugated gradient descent,32 quasi-Newton algorithm,33
Levenberg-Marquardt (LM),34,35 and automated regulariza-
tion.36 For each optimization ten-times cross-validation was
performed (80+20 splits into training and test data), where
the ANN weights and biases were optimized using the
training data, and prediction accuracy was measured using
test data to determine the number of training epochs, i.e.,
the endpoint of the training process. This was performed to
reduce the risk of overfitting. It should be noted that the
validation data were left untouched.
MODEL VALIDATION
The SVM model for drug/nondrug classification of a
pattern x was
Here, i runs only over support vectors (SV). The value of
SVM(x) is either positive (“drug”) or negative (“nondrug”).
The ANN model for drug/nondrug classification produced
values in ]-1,1[, where a positive value meant “drug” and a
negative value “nondrug”.
Classification accuracy was evaluated based on prediction
accuracy, i.e., percent of test compounds correctly classified,
and the correlation coefficient according to Matthews:37
where P, N, O, and U are the number of true positive, true
negative, false positive, and false negative predictions,
respectively. Drugs were considered as “positive set”, the
nondrug molecules formed the “negative set”. The values
of cc can range from -1 to 1. Perfect prediction gives a
correlation coefficient of 1.
SVM and ANN models were developed using various sizes
of training data to measure the influence of the size of the
training set on the quality of the classification model. The
number of training samples was iteratively diminished:
Starting with an 80+20 random split of all available samples
into training and validation subsets, at each of the following
iterations we diminished the size of the training set to only
80% of the number of samples of the previous iteration. This
allowed us to obtain better sampling for small training sets.
10-times cross-validation was performed, and average values
of prediction accuracy and 〈cc〉 were calculated.
RESULTS AND DISCUSSION
The main aim of this study was to compare SVM and
ANN classifiers in their ability to distinguish between sets
of “drugs” and “nondrugs”. We trained different neural
network topologies, and performance of the best network
was compared to the SVM classifier.
Two types of ANN architecture were considered: standard
feed-forward networks with one hidden layer (“architecture
I”) and a feed-forward network with one hidden layer with
additional direct connections from input neurons to the output
(“architecture II”) (Figure 2). The first type of ANN was
used by Sadowski and Kubinyi in their original work on
drug-likeness prediction;7 the second architecture was em-
ployed by Ajay and co-workers serving the same purpose.6
Using these networks and the GC descriptors in combination
with the Levenberg-Marquardt training method, classifica-
tion accuracy was identical to the original results (on average
80% correct) despite the use of a different training technique
and different training data (Table 1). This observation
substantiates the original findings. Both network types
performed identically considering the error margin (ap-
proximately 80% correct classification). We observed that
for some of the training algorithms a slightly lower standard
deviation of the prediction accuracy was observed for
architecture I (data not shown). Since the additional con-
nections in network architecture II did not contribute to a
greater accuracy of the model, we used only the standard
feed-forward network with one hidden layer containing two
neurons (architecture I) for further analysis.
For each training method and combination of input
variables (descriptors) networks with different numbers of
hidden neurons (2-10 neurons) were trained. Overall, we
did not observe an overall best training algorithm. The
Levenberg-Marquardt method was used for the development
of the final ANN model. Also, we did not observe an
improved classification result when the number of hidden
neurons was larger than two (data not shown). ANN
architecture I with two hidden neurons yielded the overall
best cross-validated prediction result for all descriptors
(GC+MOE+CATS), 80% correct predictions (〈cc〉 ) 0.58).
The rank order of descriptor sets with regard to the overall
classification accuracy yielded was as follows: All > GC
> MOE > CATS (Table 1). It should be stressed that the
differences in classification accuracy are minute for the
descriptors “All”, MOE, and GC and should be regarded as
comparable considering a standard deviation of 1%. The
CATS descriptor led to approximately 5% lower accuracy.
Table 1. Cross-Validated Results of Machine Learninga
% correct Matthews cc
descriptors ANN SVM ANN SVM
GC 79.25 ( 0.66 80.01 ( 0.087 0.567 ( 0.012 0.592 ( 0.002
MOE 77.89 ( 0.74 80.19 ( 0.74 0.537 ( 0.013 0.593 ( 0.016
CATS_225 72.13 ( 0.88 73.90 ( 0.51 0.432 ( 0.013 0.485 ( 0.011
all (GC+MOE+CATS) 80.05 ( 1.02 82.24 ( 0.66 0.579 ( 0.018 0.633 ( 0.010
a Average values and standard deviations are given. The Levenberg-Marquardt training method was used for ANN training.
SVM(x) )∑
i
(aiK(xi
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cc ) NP - OU
�(N + O)(N + U)(P + O)(P + U)
ARTIFICIAL NEURAL NETWORK SYSTEMS J. Chem. Inf. Comput. Sci., Vol. 43, No. 6, 2003 188590
Publications
SVM training resulted in models showing slightly higher
prediction accuracy than the ANN systems (Table 1). A
1-2% gain was observed, independent of the number of
training samples and method used for neural network
training. Figures 3 and 4 illustrate the dependency of the
classification accuracy on the number of sample molecules
used for training. In one experiment only GC descriptors
were used (Figure 3), in a second study the combination of
GC, MOE, and CATS descriptors was employed (Figure 4).
With the GC descriptor the SVM estimator only slightly
outperforms the neural networks (Figure 3). Similar results
were obtained if only MOE or CATS descriptors were used
for training (data not shown). The situation changed when
all descriptors were used. With the complete descriptor set
(525-dimensional) SVM clearly outperforms the neural
network system (Figure 4). These results substantiate earlier
findings that SVM performs better than ANN when large
numbers of features or descriptors are used.12
A general observation was the fact that classification
accuracy significantly improved with an increasing number
of training samples, reaching a plateau in performance
between 2000 and 3000 samples (Figures 3 and 4). The
accuracy curves represent almost ideal learning behavior. It
should be mentioned that the performance plateau observed
does not reflect an inherent clustering of the data set, as
training data subsets were randomly selected from the pool.
The fraction correctly predicted grows from approximately
65% to 80% when the training set is increased by a factor
of ∼250. The combination of MOE, GC, and CATS
descriptors improved classification accuracy by approxi-
mately two percent for SVM and by one percent for ANN
compared to models based on individual descriptors. These
results demonstrate that an optimal ANN training to a large
extent depends on the number of training patterns available
and the type of molecular descriptors used. For instance, for
GC descriptors the best learning algorithm was training with
Figure 3. Average cross-validated prediction accuracy (fraction correct) of SVM and ANN classifiers optimized by various training schemes
for GC descriptors (upper graph: logarithmic scale; lower graph: linear scale).
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automated regularization, but for the combination of GC,
MOE, and CATS descriptors this algorithm was extremely
slow and converged relatively unstable. In contrast, SVM
generally performed more stably compared to ANN, with
only a small increase in computation time for both sets of
descriptors (Figures 3 and 4).
In a previous comparison of SVM to several machine
learning methods by Holden and co-workers it was shown
that an SVM classifier outperformed other standard methods,
but a specially designed and structurally optimized neural
network was again superior to the SVM model in a
benchmark test.13 This observation is supported by the
observation that in the present study the set of molecules
which were correctly classified by both SVM and ANN
(mutual true positives) was 72% on average, and the fraction
incorrectly classified by both systems (mutual false negatives)
was 11%. 10% of the test data were correctly predicted by
SVM but failed by ANN, and 6% were correctly classified
by ANN but not by SVM using the full set of descriptors
(GC+MOE+CATS). Examples of the latter two sets of
molecules are shown in Figure 5. Clearly, the ANN classifier
and the SVM classifier complement each other, and both
methods could be further optimized, for example, by chang-
ing the SVM kernel or by exploring more sophisticated ANN
architectures and concepts.
Fast classifier systems are mainly developed for first-pass
virtual screening, in particular for identification (“flagging”)
of potentially undesired molecules in very large compound
collections.2 Due to robust convergence behavior SVM seems
to be well-suited for solving binary decision problems in
molecular informatics, especially when a large number of
descriptors is available for characterization of molecules. In
this study we have shown that two drug-likeness estimators
can produce complementary predictions. We recommend the
parallel application of both predictive systems for virtual
screening applications. One possibility to combine several
estimators for “drug-likeness” or any other classification task
is to employ a “jury decision”, e.g. calculate an ensemble
Figure 4. Average cross-validated prediction accuracy (fraction correct) of SVM and ANN classifiers optimized by various training schemes
for the combination of GC, MOE, and CATS descriptors (upper graph: logarithmic scale; lower graph: linear scale).
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average.38,39 As more and more different predictors become
available for virtual screening a meaningful combination of
prediction systems that exploits the individual strengths of
the different methods will be pivotal for reliable compound
library filtering.
CONCLUSION
It was demonstrated that the SVM system used in this
study has the capacity to produce higher overall prediction
accuracy than a particular ANN architecture. Based on this
observation we conclude that SVM represents a useful
method for classification tasks in QSAR modeling and virtual
screening, especially when large numbers of input variables
are used. The SVM classifier was shown to complement the
predictions obtained by ANN. The SVM and ANN classifiers
obtained for drug-likeness prediction are comparable in
overall accuracy and produce overlapping, yet not identical
sets of correctly and misclassified compounds. A similar
observation can be made when two ANN models are
compared. Different ANN architectures and training algo-
rithms were shown to lead to different classification results.
Therefore, it might be wise to apply several predictive models
in parallel, irrespective of their nature, i.e., being SVM- or
ANN-based. We wish to stress that our study does not justify
the conclusion that SVM outperforms ANN in general. In
the present work only a standard feed-forward network with
a fixed number of hidden neurons was compared to a
standard SVM implementation. Nevertheless, our results
indicate that solutions obtained by SVM training seem to
be more robust with a smaller standard error compared to
standard ANN training. Irrespective of the outcome of this
study, it is the appropriate choice of training data and
descriptors, and reasonable scaling of input variables that
determines the success or failure of machine learning
systems. Both methods are suited to assess the usefulness
of different descriptor sets for a given classification task,
and they are methods of choice for rapid first-pass filtering
of compound libraries.40 A particular advantage of SVM is
“sparseness of the solution”. This means that an SVM
classifier depends only on the support vectors, and the
classifier function is not influenced by the whole data set,
as it is the case for many neural network systems. Another
characteristic of SVM is the possibility to efficiently deal
with a very large number of features due to the exploitation
of kernel functions, which makes it an attractive technique,
e.g., for gene chip analysis or high-dimensional chemical
spaces. The combination of SVM with a feature selection
routine might provide an efficient tool for extracting chemi-
cally relevant information.
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Artificial neural networks, the support vector machine (SVM), and other machine learning methods for the
classification of molecules are often considered as a “black box”, since the molecular features that are most
relevant for a given classifier are usually not presented in a human-interpretable form. We report on an
SVM-based algorithm for the selection of relevant molecular features from a trained classifier that might be
important for an understanding of ligand-receptor interactions. The original SVM approach was extended
to allow for feature selection. The method was applied to characterize focused libraries of enzyme inhibitors.
A comparison with classical Kolmogorov-Smirnov (KS)-based feature selection was performed. In most of
the applications the SVM method showed sustained classification accuracy, thereby relying on a smaller
number of molecular features than KS-based classifiers. In one case both methods produced comparable
results. Limiting the calculation of descriptors to only the most relevant ones for a certain biological activity
can also be used to speed up high-throughput virtual screening.
INTRODUCTION
Feature selection methods can help determine molecular
descriptors that are important for the characterization of
target-family specific classes of drugs and drug-like mol-
ecules by machine learning systems. Currently large numbers
of descriptors are available for molecule characterization.
Traditional feature selection methods such as forward and
backward selection1 or evolutionary algorithms2 are com-
putationally too expensive to be applied to very large
descriptor sets directly. The most time-consuming step is
retraining of the classifier after every modification of the
set of selected features. This step needs to be reiterated
sufficiently often before the process converges to the final
set of features. Parallelizing computations is usually the only
way to speed up the procedure.
An alternative approach is to select the important features
prior to classifier training. In this case, the classifier needs
to be trained only once for the selected features. Several
techniques are known to implement this concept, e.g.
correlation coefficients,3,4 Fisher discriminant analysis,1 and
Kolmogorov-Smirnov (KS) statistics.5 KS statistics was
shown to be well-suited for feature selection in different
fields of research.6,7 Recently several model-dependent
methods for feature selections were developed,8 where the
classifier is trained prior to feature selection, and features
are selected based on a statistical model of the trained
classifier. These methods have been predicted to outperform
model-independent feature selection algorithms.8
For the present study we developed and applied a support
vector machine (SVM)-based feature selection and compared
it with a KS-based algorithm. An advantage of the SVM-
based classification9 in comparison to other methods, e.g.
multilayered feed-forward neural networks,1 is that the
construction of the surface that separates classes of data
depends only on the support vectors.10 Support vectors are
samples that are lying close to the border that separates two
classes. Using only these samples can help increase the
accuracy of the SVM prediction.11 We extended the same
principle to feature selection. Once an SVM classifier has
been trained with all molecular descriptors, feature selection
is based on the identified support vectors only, disregarding
other samples.
The method was applied to feature selection from SVM
classifiers for kinase inhibitors, factor Xa inhibitors, and
thrombin inhibitors. The approach complements related work
on “drug-likeness” prediction12 and extends it to target- and
target-family specific sets of inhibitors.
DATA AND METHODS
Data Sets. For SVM training and feature selection we used
subsets of the COBRA database, version 2.1.13 Three
different splits of the COBRA collection were used for
evaluation of the feature selection algorithms: 226 kinase
inhibitors and 4479 noninhibitors; 227 factor Xa inhibitors
and 4478 noninhibitors; and 227 factor Xa inhibitors and
195 thrombin inhibitors. The subset of kinase inhibitors
represents a diverse set of molecules in that they are specific
to a family of targets that differ significantly from each other.
On the contrary, factor Xa and thrombin inhibitors are drug
molecules which are specific for a single target. We expected
that factor Xa and thrombin inhibitors should share a certain
degree of similarity due to the similarity of the target binding
sites.
Two sets of descriptors were calculated: 182 descriptors
from MOE (Molecular Operating Environment)14 and 225
topological pharmacophore (CATS) descriptors.15 MOE
descriptors include various 2D and 3D descriptors. 2D
descriptors were physical properties, subdivided surface
areas, atom and bonds counts, Kier-Hall connectivity and
*Corresponding author phone: +49-69 79829821; fax: +49-69 79829826;
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Kappa Shape indices, adjacency and distance matrix descrip-
tors, pharmacophore feature descriptors, and partial charges
descriptors. 3D descriptors were potential energy descriptors;
surface area, volume and shape descriptors; and conforma-
tional dependent charge descriptors. Before calculating MOE
descriptors, single 3D conformers were generated by Co-
rina.16 CATS descriptors were calculated taking into con-
sideration pairs of atom types separated by 0 up to 15 bonds.
All descriptor columns were scaled to have zero mean and
unit standard deviation.
Kolmogorov-Smirnov Statistics. KS-based statistics rep-
resent a model-independent method for feature selection. It
is routinely used for feature selection from different data sets
and features. Its main advantage over other methods is the
independence from the particular statistical model that
generates the data, in contrast to other methods, that perform
well only if the data adopts certain statistics. For instance,
“correlation coefficient”3,4 based feature selection performs
best if the data can be modeled by Gaussian mixtures,1 and
its accuracy drops otherwise. Very often it is impossible to
correctly guess statistical models of the data a priori, which
results in only approximately correct models. If the under-
lying statistics is not known or a Gaussian mixture model is
not appropriate, KS statistics can be a method of choice.
In KS statistics each feature is first tested to have different
statistics for class and nonclass samples. This is done by
merging feature values for class and nonclass and building
two separate cumulative fraction functions, one for class and
one for nonclass. The cumulative fraction function represents
the dependency of the percentage of samples whose feature
values are below a certain threshold, on the position of the
threshold value in the sorted list of feature values. An
example of the cumulative function for the data set {0.08,
0.10, 0.15, 0.17, 0.24, 0.34, 0.38, 0.42, 0.49, 0.50, 0.70, 0.94,
0.95, 1.26, 1.37, 1.55, 1.75, 3.20, 6.98, 50.57} is given in
Figure 1a. The maximum difference D of two cumulative
functions for class and nonclass is then used as a measure
for the significance of a distinguishing feature. An example
of this measure is given in Figure 1b.
A KS statistics test is performed for all available features,
which are then sorted with respect to the KS test results,
and only the most relevant features are considered for further
training.
SVM-Based Feature Selection. Usually feature selection
algorithms are applied prior to the classifier training: A
feature selection algorithm first selects a set of features and
then a classifier is trained based on the features of this subset.
Recently it was demonstrated that feature selection schemes,
where the feature selection algorithm relies on the model
that is created during training, produce better results.8
Accordingly an alternative scheme for feature selection was
suggested: The classifier is first trained using all available
features. Then, the least important features are deleted. The
drawback of this approach is that the trained classifier usually
assumes a certain statistical model for the data, which might
be only approximately correct. Current algorithms for
nonlinear classifier training like artificial neural networks
or SVM estimate a statistical model for the data sufficiently
well to make this approach an alternative to model-
independent feature selection.
The separating surface generated by SVM is given by
Here ai, b, and xi
svare parameters of the SVM, determined
during training. xi
sv are support vectors, which represent a
subset of the training samples that determine the separating
surface. This surface corresponds to the linear separation in
a very high-dimensional space, where data points are mapped
during SVM training.17 This mapping is determined solely
by the kernel function K (x,x′).18 In this high-dimensional
space the separating surface is given by
where
is a normal vector of the separating hyperplane. To estimate
the importance Rf of a feature to the accuracy of the SVM
prediction we calculated a projection of the feature change
in the mapped space to the normal of the SVM plane (Figure
2):
Calculating the derivative we obtain:
Figure 1. (a) Cumulative fraction plot. X denotes a molecular
feature. (b) KS-test comparison. Cumulative fraction plots for two
classes of data are shown by solid and dotted lines. D denotes the
maximum difference of feature X values observed for the two
classes.
Figure 2. SVM-based feature selection. The optimal SVM
hyperplane is shown with examples of class and nonclass samples
(filled circles and squares). In the example support vectors are
indicated by open symbols. For an estimation of the feature
relevance the gradient (shown by arrows) of the feature change is
calculated only for support vectors. (a) relevant features have a
gradient perpendicular to the separating hyperplane; (b) irrelevant
features.
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For estimating the relevance of a feature to classification
we should calculate Rf only in the vicinity of the separating
hyperplane. To achieve it we will sum Rf only over support
vectors, extending the principle of SVM that the position of
the classifying hyperplane depends only on support vectors:
Empirically we observed that data normalization improved
the performance in some cases; therefore, the final formula
that we used to perform feature selection is
Summarizing, Rf was calculated for all features, and those
features with low Rf value were excluded from the features
used for training. It is important to note that Rf depends only
on the support vectors.
For constructing SVM models we used the SVM-light
package.19 A fifth-order polynomial kernel was used in SVM
training: K(x′,x) ) (s(x′‚x) + 1)5. Training parameters s and
C were optimized using a gradient decent-like algorithm to
achieve maximum accuracy of prediction for the validation
set. Parameter C is an internal parameter that is set prior to
SVM training. It defines the tradeoff between the separating
margin and the penalty for incorrect predictions.17
Model Validation. Classification accuracy was evaluated
based on prediction accuracy and the correlation coefficient
according to Matthews20
where P, N, O, and U are the numbers of true positive, true
negative, false positive, and false negative predictions,
respectively. Active molecules with specific activity were
considered as the “positive set”, and the other molecules
formed the “negative set”. The values for cc can range from
-1 to 1. A perfect prediction gives a correlation coefficient
of 1. Different training and test subset were selected, 80%
of samples for the training and 20% for the test. Ten cross-
validations were performed to estimate average and standard
deviation of the accuracy. Prediction accuracy and average
value of 〈cc〉 were calculated for the test subsets.
RESULTS AND DISCUSSION
We compared two methods for feature selection, KS-based
and SVM-based. Both methods were able to effectively select
sets of the most relevant features. Figure 3 shows the
dependency of the classification accuracy and Matthews
correlation coefficient on the number of selected features
for each subset. In all three sample applications the SVM-
based feature selection method outperformed the KS-based
approach, i.e., the classification accuracy remained at a high
level even for small numbers of remaining features. The
prediction accuracy dropped when the number of features
fell between 100 and 200 for the KS-based method. In
contrast, using the SVM-based method for feature selection
we were able to go down to about 40 features with only a
slight reduction in classification accuracy. This indicates
potential advantages of the SVM-based method. Considering
the error margins in the thrombin vs factor Xa classification,
KS-based feature selection may be regarded as comparable
to the SVM approach. This might have a relatively simple
explanation: A large portion of features might be relatively
easily discarded as “irrelevant” for correct classification. In
this case no significant advantage of an SVM-based versus
a KS-based scheme is observed. Still, when the number of
features was below 100 SVM-based feature selection per-
formed better. We wish to stress that a general statement
about the relative usefulness of the two methods is not
possible based on this single study. Also, we cannot fully
exclude that the difference seen in Figure 3 between SVM
and KS might in part result from different levels of parameter
optimization.
Table 1 contains a list of the features which were selected
being the most relevant for subset classification. Table 2
contains average property values calculated for the sets of
inhibitors used in this study.
Both factor Xa and thrombin inhibitors are relatively large
molecules containing characteristic fragments that are specific
for binding to the S1 pocket of the trypsin-like serine
proteases.21 Typically, these fragments are positively charged.
Most of the known faxtor Xa inhibitors exploit the S4 pocket
and S3 “cation recognition pocket” of factor Xa to gain
binding affinity.22 A difference between the two classes of
the molecules might be noted by observing the most relevant
features in more detail. The distance of a positive charge on
the one side and lipophilic, hydrogen-bond donor and
acceptor groups on the other side was suggested being a key
property for a distinction between factor Xa and thrombin
inhibitors by our SVM-based feature selection. This property
is most easily observed by comparing CATS descriptors for
large distances. As expected, these descriptors are found in
the top listed of the ranked features (Table 1a). These features
can be highlighted in the two-dimensional structures of
selective factor Xa inhibitors (Figure 4). Compound 123 and
compound 224,25 have an approximately 3300-fold selectivity
for factor Xa over thrombin and contain the topological
pharmacophores selected by SVM. Structure 2 is a repre-
sentative member of several covalent, peptide-derived bis-
cation factor Xa inhibitors which were used for SVM-
training. It is not surprising, therefore, that the most
“relevant” molecular features according to the SVM classifier
are found in these molecular structures. Structure 1 was not
part of the training data, but some of the high-ranking
features are present in this molecule, too.
Our compilation of kinase inhibitors represents a com-
pound collection containing much broader activities than the
collection of factor Xa and thrombin inhibitors. Looking at
their average molecular weight and lipophilicity (clogP) one
can conclude that they are smaller and more lipophilic than
factor Xa and thrombin inhibitors (Table 2). This might
explain the observation that in the list of top-ranking SVM
features the topological descriptors are less prominent, and
various van der Waals based estimations of surface charges
were selected as “relevant” (Table 1b).
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Factor Xa inhibitors represent a relatively diverse set of
molecules. Nonetheless, by examining their structures it is
possible to assume that they have certain topological similar-
ity. This could be a reason, why various topological
descriptors are found within the first 20 most important
descriptors (Table 1c). Surprisingly simple descriptors, like
the number of aromatic atoms and aromatic bonds are also
at the top of the list. Certainly, these simplistic descriptors
cannot explain selectivity of factor Xa inhibitors, rather the
whole list of “relevant” features must be taken into consid-
eration if one tries to make sense out of a classifier system.
This example demonstrates that feature selection does not
necessarily deliver clear answers.
Although similar approaches were applied to perform
SVM-based feature selection by Guyon and co-workers,26
an advantage of our method is that feature selection was
performed only based on the position of support vectors. It
allows us to discard a large portion of data which is irrelevant
for construction of the separating hyperplane. A potential
additional advantage of our implementation is that classifica-
tion of new molecules is quick and straightforward: com-
putation time needed for a single molecule is approximately
comparable to the time for reading its descriptors. Further
information about computational efficiency of SVM can be
found elsewhere.18 Our results demonstrate that a central idea
of SVM, namely the construction of a separating surface
which is based only on support vectors, results in an efficient
algorithm for feature selection when equipped with a feature
selection scheme. We have successfully applied this algo-
rithm to characterize groups of enzyme inhibitors. The
algorithm was able to select crucial molecular features from
a rather loosely defined compound class (kinase inhibitors)
as well as features that might be relevant for inhibition of a
particular target (factor Xa). It is important to mention that
such feature selection methods do not explain why subsets
can be classified or what the chemical explanation for an
Figure 3. Results of feature selection by SVM- and KS-based algorithms. Matthews correlation coefficient and average classification
accuracy are plotted as a function of the number of selected features. Standard deviations are shown as dotted lines. (a, b) Classification
of kinase inhibitors versus the remainder of the COBRA data set. (c, d) Classification of factor Xa inhibitors versus the remainder of the
COBRA data set. (e, f) Classification of factor Xa versus thrombin inhibitors.
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Table 1. (a) Selected Features of Factor Xa Inhibitors versus Thrombin Inhibitors,a (b) Selected Features of Kinase Inhibitors,b and (c) Selected
Features of Factor Xa Inhibitorsc
feature description
(a)
SMR_VSA4 sum of Vi such that Ri is in (0.39,0.44]
CATS_207 correlation for the distance of 13 bonds between positive and lipophilic atoms
CATS_171 correlation for the distance of 11 bonds between acceptor and acceptor atoms
CATS_153 correlation for the distance of 10 bonds between donor and positive atoms
CATS_120 correlation for the distance of 8 bonds between lipophilic and lipophilic atoms
a_nN number of nitrogen atoms
CATS_91 correlation for the distance of 6 bonds between donor and donor atoms
CATS_63 correlation for the distance of 4 bonds between donor and positive atoms
CATS_57 correlation for the distance of 3 bonds between positive and lipophilic atoms
CATS_50 correlation for the distance of 3 bonds between acceptor and acceptor atoms
CATS_47 correlation for the distance of 3 bonds between donor and acceptor atoms
SMR_VSA5 sum of Vi such that Ri is in (0.44,0.485]
PEOE_FPNEG fractional negative polar van der Waals surface area. This is the sum of the Vi such
that qi is less than -0.2 divided by the total surface area. The Vi were
calculated using a connection table approximation.
PEOE_VSA+3 sum of Vi where qi is in the range [0.15,0.20).
CATS_187 correlation for the distance of 12 bonds between acceptor and positive atoms
CATS_33 correlation for the distance of 2 bonds between donor and positive atoms
Dens mass density: molecular weight divided by van der Waals volume.
PEOE_VSA_PNEG total negative polar van der Waals surface area. This is the sum of the Vi such
that qi is less than -0.2. The Vi were calculated using a
connection table approximation.
PEOE_VSA-1 sum of Vi where qi is in the range [-0.10,-0.05).
(b)
VDistEq If m is the sum of the distance matrix entries, then VdistEq is defined to be
the sum of log2m-pilog2pi/m where pi is the number of distance
matrix entries equal to i. 28
diameter largest value in the distance matrix28
CATS_188 correlation for the distance of 12 bonds between acceptor and negative atoms
SMR_VSA4 sum of Vi such that Ri is in (0.39,0.44].
VSA_other approximation to the sum of VDW surface areas of atoms that are not a
donor, acceptor, positive, negative, or hydrophobe
a_nCL number of chlorine atoms
std_dim1 standard dimension 1: the square root of the largest eigenvalue of the covariance
matrix of the atomic coordinates. A standard dimension is equivalent to
the standard deviation along a principal component axis
FASA_H fractional ASA_H calculated as ASA_H/ASA. Here, ASA•H is the water
accessible surface area of all hydrophobic (|qi|<0.2) atoms and
ASA is the water accessible surface area of all atoms.
Q_VSA_FPOS fractional positive van der Waals surface area. This is the sum of the Vi such
that qi is nonnegative divided by the total surface area. The Vi were
calculated using a connection table approximation.
Q_VSA_FHYD fractional hydrophobic van der Waals surface area. This is the sum of the Visuch
that |qi| is less than or equal to 0.2 divided by the total surface area.
The Vi were calculated using a connection table approximation.
radius If ri is the largest matrix entry in row i of the distance matrix D, then the
radius is defined as the smallest of the ri
28
CATS_192 correlation for the distance of 12 between positive and lipophilic atoms
b_ar number of aromatic bonds
a_aro number of aromatic atoms
CATS_147 correlation for the distance of 9 bonds between donor and lipophilic atoms
a_nF number of fluorine atoms
petitjian value of (diameter-radius)/diameter.28 Here diameter is the largest value in the
distance matrix; radius is defined as follows, if ri is the largest matrix
entry in row i of the distance matrix D, then the radius is defined
as the smallest of the ri
petitjianSC Petitjean graph shape coefficient as defined in ref 28
CATS_200 correlation for the distance of 13 bonds between donor and lipophilic atoms
CATS_186 correlation for the distance of 12 bonds between acceptor and acceptor atoms
(c)
PEOE_VSA+1 sum of Vi where qi is in the range [0.05,0.10).
balabanJ Balaban’s connectivity topological index29
b_ar number of aromatic bonds
a_aro number of aromatic atoms
SLogP_VSA1 sum of Vi such that Li is in (-0.4,-0.2]
wienerPol Wiener polarity number: half the sum of all the distance matrix entries with a
value of 3 as defined in ref 30
vsa_acid approximation to the sum of VDW surface areas of acidic atoms
a_acc number of hydrogen bond acceptor atoms (not counting acidic atoms but counting
atoms that are both hydrogen bond donors and acceptors such as -OH).
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observed biological activity is. They might be suited for
reducing the number of variables used in QSAR studies. It
should be stressed that different feature selection algorithms
tend to select different sets of “relevant” features. Therefore,
the ranked list of features produced by the SVM-based
method need not necessarily be more meaningful than a
selection obtained by other methods, as one might conclude
from the observation that the selected features resulted in a
sustained high level of classification accuracy. It is possible
that certain feature sets represent approximately the same
chemical information, and as long as we only roughly
describe a chemical agent using molecular descriptors, there
will exist several almost equally suited partial solutions to
the same classification task.
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Table 1 (Continued)
feature description
reactive indicator of the presence of reactive groups. A nonzero value indicates that the
molecule contains a reactive group. The table of reactive groups was based
on the Oprea set31 and includes metals, phospho-, N/O/S-N/O/S single
bonds, thiols, acyl halides, Michael acceptors, azides, esters, etc
b_rotR fraction of rotatable bonds: b•rotN divided by b_count. Here b_count is the
number of bonds including implicit hydrogens.
vsa_pol approximation to the sum of VDW surface areas of atoms that are both hydrogen
bond donors and acceptors, such as -OH
vsa_base approximation to the sum of VDW surface areas of basic atoms.
Q_VSA_FPOS fractional positive van der Waals surface area. This is the sum of the Vi such that qi
is nonnegative divided by the total surface area. The Vi were calculated
using a connection table approximation.
Q_VSA_FHYD fractional hydrophobic van der Waals surface area. This is the sum of the Vi such
that |qi| is less than or equal to 0.2 divided by the total surface area.
The Viwere calculated using a connection table approximation.
b_heavy number of bonds between heavy atoms
CATS_91 correlation for the distance of 6 bonds between donor and donor atoms
SLogP_VSA2 sum of Vi such that Li is in (-0.2,0].
Pmi principal moment of inertia.
Zagreb Zagreb index32
Chi1_qC carbon connectivity index (order 1)32
a Calculation of the subdivided surface areas descriptors, like SMR•VSA, PEOE•VSA, was based on an approximate accessible van der Waals
surface area calculation for each atom, Vi, along with some other atomic property pi. The Vi were calculated using a connection table approximation.
Each descriptor in a series was defined to be the sum of the Vi over all atoms i such that pi is in a specified range (a,b]. For SMR•VSA pi is Ri,
which denotes the contribution to Molar Refractivity for atom i. For PEOE•VSA pi is Li, which denotes the contribution to logP(o/w) for atom i.27
b Here, Vi is the van der Waals surface area of atom i (as calculated by a connection table approximation). Ri denotes the contribution to the molar
refractivity of atom i.27 c For definition of Vi, Ri, and L, see Table 1a.
Table 2. Average Property Values of the Three Sets of Inhibitorsa
target MW PSAb/Å2 clogP
factor Xa 490 132 2.9
thrombin 503 140 2.6
kinase 405 89 3.2
a Properties were calculated using MOE.14-32 b PSA: polar surface
area.
Figure 4. Examples of molecular features selected by SVM.
Compounds 1 and 2 are selective factor Xa inhibitors. Two features
are highlighted which were identified by an SVM classifier for
discrimination between factor Xa and thrombin inhibitors. In
structure 1 a positive charge (+) is separated by 10 bonds from a
hydrogen-bond donor (D) site; in structure 2 a positive charge is
separated by 13 bonds from a lipophilic point (L). These two-point
pharmacophore features might be relevant for binding to the factor
Xa active site pocket.
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A software tool was developed for fast combinatorial
library enumeration (SMILIB). Its particular features are
its simplicity to use, high flexibility in constructing
combinatorial libraries and high speed of library construc-
tion. SMILIB offers the possibility to construct very large
combinatorial libraries using the flexible and portable
SMILES format. Libraries are generated at rates of
approximately 30,000 molecules per minute. Combinato-
rial building blocks are attached to scaffolds by means of
linkers rather than to concatenate them directly. This
allows for creation of easily customized libraries using
linkers of different size and chemical nature. A web
interface for a limited web-based version of the software is
available at URL: www.modlab.de. An unlimited binary
version of SMILIB for command line execution on Linux
systems is available from this URL.
Rapid construction of virtual combinatorial products is a
prerequisite for in silico library enumeration and design [1,
2].Ithasbeendemonstratedthatforlibrarydesignpurposes
virtual screening of combinatorial reaction products is
usually preferable to purely educt-based screening and
filtering [3, 4], and several commercially available software
suites offer a possibility for this kind of combinatorial
enumeration. Here we present a freely available software
tool (SMILIB) which was developed to offer a means for
straightforwardlibraryassemblyandmayserveasabasisfor
subsequent virtual screening and filtering of enumerated
combinatoriallibraries.ThemainfeaturesofSMILIBareits
flexibility in constructing combinatorial libraries and high
speed of library construction. SMILIB offers the possibility
to rapidly construct very large combinatorial libraries using
thecompact and portableSMILES format [5].Libraries are
created at rates of approximately 30,000 molecules per
minute on a Linux-based personal computer. A web inter-
faceforSMILIBisavailableatURL:http://www.modlab.de.
For performance reason the number of reaction products is
restricted to 10,000 molecules using the web-interface. An
unlimited binary version for Linux systems is also available
from the URL. The SMILIB binary was compiled using
GNU C Compiler (GCC) 3.2 on SuSE 8.1 Linux running
kernel 2.4.19.
Construction of combinatorial products with SMILIB
follows the concept of ™scaffolds∫, ∫linkers™ and ∫building
blocks™ (Figure 1) [6]. Building blocks are attached to the
scaffold via linker groups.This allows for different chemical
reactions to be considered implicitly by using different
linker types and generic building block collections. It also
simplifies library enumeration since connecting functional
groups may be completely left out in the set of building
blocks. An advantage of this conceptual idea of a combina-
torial library is its simplicity and ease of implementation
yielding very fastcode.Anobvious downside isthe fact that
realisticchemicalreactionscannotbemodeleddeliberately.
For example, ring formation during building block attach-
ment cannot be modeled by SMILIB; or scaffold formation
during the combinatorial reaction.
SMILIB uses basic ANSI C string functions to perform
virtual reactions of building blocks and linkers with
QSAR Comb. Sci. 22 (2003) DOI: 10.1002/qsar.200310008 ¹ 2003 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim 719
Figure 1. Schematic composition of a virtual reaction product.
BB denotes building block, L denotes linker.
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scaffolds. All educts have to be formulated in an enhanced
notation of SMILES: Special labels ™[R1]∫, ™[R2]∫, ™[R3]∫,
etc. and ™[A]∫ were introduced to specify sites of variability
(R) and attachment sites (A) respectively, the latter being
necessary to allow directional concatenation of building
blocks to linkers and linkers to scaffolds (Figure 2). Basic
help for generating SIMLIB compliant SMILES is given
with these examples:
Scaffolds:
[R1]N2CCN([R2])C1�CC�CC�C1C2
[R2]N(C3�C2C�CC�C3)CC12CCN([R1])CC1
[R1]N1CCN([R2])CC1
Linkers:
[A][R1] (™pseudo linker∫)
[A]S(�O)(N[R1])�O
[A]O[R1]
Building blocks:
[A]C
[A]CC1�CC�CC�C1
S(CC[A])C
In order to facilitate flexible library generation each
individual product needs to be explicitly determined by a
reaction scheme. Similar to a connection table, the reaction
scheme determines the constituents of a virtual reaction
product by referring to them by numbers. Each line of the
reaction scheme thus refers to a number-encoded virtual
chemical reaction yielding a desired combinatorial product.
A sample reaction scheme for a complete six-membered
virtual library from one scaffold, two linkers, three building
blocks and one R-group on the scaffold is given by:
1 1 1
1 1 2
1 1 3
1 2 1
1 2 2
1 2 3
Thefirstcolumnspecifiesthescaffoldnumber,thesecond
column determines the linker group, and the third column
specifies the building block. A more detailed guideline of
how to use SMILIB and generate reaction schemes is
available from the web site. A tool for generating the
reaction scheme is also available on this web site.
Reaction products are generated by concatenation of
input SMILES strings using ™unsatisfied∫ ring closures [7].
For example, according to the SMILES convention, either
of the following notations for ethane is valid: ™CC∫ or
™C1.C1∫. Following this scheme, SMILIB uses unsatisfied
ring closures to form chemical bonds between the constit-
uents of a reaction product as shown in Figure 2. The
resulting SMILES look unconventional ± yet they are
perfectly valid. We tested compatibility to the following
programs: CLIFF molecule file converter [8], Molecular
Operating Environment (MOE) [9], ChemDraw molecule
editor [10], and CORINA conformer generator [11].
SMILIB is intended to support molecular designers by
providing a fast means for virtual library generation. Its
principal strength is full or partial library enumeration.
Certainly, even the fastest enumeration method combined
with the largest storage capacity will be limited by the
maximal upper size of the virtual compound library. To
avoid exhaustive library enumeration, a trend in virtual
720 ¹ 2003 WILEY-VCH Verlag GmbH&Co. KGaA, Weinheim QSAR Comb. Sci. 22 (2003)
Figure 2. A virtual reaction along with corresponding SMILES: The building block is connected to a linker having the building block×s
A-group react with the linkers R1-group forming intermediate product and a virtual A-R1 by-product (neglected). The intermediate
product×s A-group then undergoes reaction with the scaffolds R1-group yielding in the final reaction product and a second A-R1 by-
product (also neglected).
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combinatorial library generation and exploration is to
perform a guided search in very large chemical spaces [2].
SMILIB can also be used for this task. In this scenario,
predictive QSAR models, e.g. for ™drug-likeness∫, ™fre-
quent-hitter∫ liability or binding affinity [12, 13], are
coupled to virtual molecule generators like SMILIB, and
only small compound sub-sets are actually assembled in
silico, rather than the complete library. In an iterative
processtheoverallqualityofthesub-setisimproved[14,15].
Several such optimization protocols have been suggested
and successfully applied [16±20], and SMILIB can be used
to support these activities.
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ABSTRACT. Iterative virtual screening cycles using Support Vector Machines (SVM) were
successfully applied to ligand-based searching for novel ligands. The approach offers a rapid
way to identify novel lead structure candidates with minimal experimental effort even in the
absence of receptor-structure information. Virtual screening was performed in two
consecutive cycles. In the first stage, an SVM was trained for prediction of D3 receptor-
selective ligands. Based on the prediction of this virtual filter, twelve compounds were tested
for binding affinity at D2 and D3 receptors. In the second stage, a similarity search was
performed with the most promising candidate molecule from the first round as the query. Four
out of five compounds from the final hit list exhibited nanomolar affinity at the D3 receptor
including a novel scaffold structure. The Ki value of the best molecule was 40 ± 6 nM.109
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Imbalance of the dopaminergic system is involved in various neurological and
neuropsychiatric disorders, e.g. Parkinson’s disease, schizophrenia, and drug abuse.
[1]
Selective attraction of one dopamine receptor subtype could represent an improved
therapeutic approach or at least a good way to evaluate the (patho)physiological functions of
this subtype in the disorder. Here we focused on the dopamine D3 receptor since this subtype
displays in several diseases an important role on neuroregulation and possesses a distinct
localisation in the central nervous system.
[2] As D3 receptors display high sequence identity to
D2 receptors, cross-reactivity is a problem for most compounds used. Although this field of
research has been worked out for decades many lead structures are unsatisfying concerning
selectivity. Since numerous described compounds with diverse structural elements showed
some D3 receptor preference we focused on these elements first by virtual and then by real
screening of the most promising compounds to find new lead candidates for further
optimization.
Virtually screened synthetic compounds from collections of Specs (release January 2004,
Specs, 2628 XH Delft, The Netherlands) and Interbioscreen (IBS) (release February 2004,
Interbioscreen Ltd., 121019 Moscow, Russia) were investigated as potentially selective
ligands at dopamine D3 receptors. We performed this screening by using analogues of BP897
(1), a D3 receptor-preferring partial agonist in clinical development, and related structures as a
starting point (Chart 1). Virtual screening was performed in two stages. In the first stage, we
trained a Support Vector Machine (SVM) on the reference set and constructed a filter for D3
receptor-selective ligands. Based on the prediction of this virtual filter twelve compounds
from the IBS collection were tested for binding affinity at D2 and D3 receptors. In the second
stage, we performed a similarity search with the most promising candidate molecule from the
first round against the Specs collection. The parameters for this similarity search were
extracted from the SVM model of the BP897 analogues. Four out of five compounds
exhibited nanomolar affinity at the D3 receptor including a novel scaffold structure. The Ki
value for the best molecule was 40 ± 6 nM.
Ligand-based virtual screening. As a reference active set we used analogues of BP897 and
related structures.
[3] The compounds from this set possess the following features: i) a
lipophilic amine moiety, i.e. phenylpiperazine in BP897, ii) a spacer, usually a linear
tetramethylene chain, and iii) a hydrophobic residue connected by an amide bond, which has
proven to be favorable for high receptor affinity.
[3] In order to fulfill structural requirements
for high-affinity binding, the basic nitrogen connected to the aryl group through an aliphatic
linker was preserved. For all compounds in this series Ki values of D2 and D3 receptor
affinities were screened in radioligand binding assays as described.
[3]
[Chart 1]
Compounds were encoded by three-point pharmacophore (3PP) fingerprints available from
the MOE software suite.
[4] For the first virtual screening round, an SVM was trained on the
prediction of potential D3 receptor ligands. As “active” compounds we defined molecules
which have measured Ki values below 1 µM for the D2 or D3 receptor (331 out of 395
reference compounds).
[5] For cross-validation this active set was split into four non-
overlapping subsets. During validation we “mimicked” a real screening experiment by
addition of compounds known to bind D2 or D3 receptor to the screening database and
estimated the efficiency with which these compounds were retrieved from the screened
database. For this, we ranked all screening compounds based on the SVM predictions and
optimized SVM parameters, so that compounds that we mixed with the screening data were at
the top of the ranked list.
[6-8] The observed enrichment gave an estimation of what is the
expected percentage of active compounds from the IBS dataset among the top 1% of the110
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ranked compounds. In the cross-validation study 50.6 ± 1.3% of the known active compounds
were retrieved within 1% of the IBS collection -- a result which is significantly above random
screening. The training procedure with parameter optimization lasted less than 30 minutes on
a Linux cluster with 16 CPUs.
Application of “active learning” further increased the enrichment to 91.8 ± 1.2% of
validation actives in the 1% of the ranked IBS collection (for details of the SVM training
procedure and the active learning concept, cf. Supporting Information). This was a
consequence of the more fine-grained compound sampling from the neighborhood of the
known actives in pharmacophore space.
Selection of D3 receptor-specific ligands. We trained a regression SVM for prediction of
the logarithm of the ratio between Ki values for D2 and D3 receptors. The <q
2> of the four-
fold cross-validation was 0.40 ± 0.15. The relatively low <q
2> is explained by the marked
similarity between D2 and D3 receptor binding behavior.
[2] The final prediction system was a
combination of the two virtual filters described above: binary SVM optimized with active
learning, and regression SVM. First, we selected compounds that were similar to the reference
set and then we ranked them according to the predicted log(KiD3 / KiD2) to pick up potential
D3 receptor-selective compounds. The list of the selected molecules obtained was manually
further processed to exclude compounds with potentially reactive groups or poor solubility.
Compounds which are too similar to the reference set were also excluded, in order to identify
compounds with novel scaffolds. Ki measurement followed a similar protocol as for the
BP897 analogues.
[3]
Results and Conclusions. Individual compounds exhibited preferential binding at D3
receptor, although Ki values for most of the molecules are in the micromolar range if any
could be determined at all (cf. Supporting Information). This observation can be explained by
the bias introduced during manual post-selection of molecules. We avoided a pronounced
similarity to BP897-like compounds, which obviously resulted in lowering the D2 and D3
binding activity.
[Chart 2]
In order to further increase D3 receptor affinity we optimized compound 2 using a similarity
searching approach (Chart 2). Molecule 2 was the only ligand found in the first virtual
screening round with an experimental Ki < 2 µM at the D3 receptor, and Ki  2 µM at the D2
receptor. For similarity calculation we employed a modified distance metric for 3PP
fingerprints space, where fingerprints were weighted based on their importance in our SVM
regression model (cf. Supporting Information). This procedure allowed for the selection of
compounds that are similar to 2, focusing on features that were considered being important for
interaction with the receptor. Very similar compounds and compounds with reactive groups
were again manually excluded. The testing results for the selected molecules are given in
Table 2. The chemical structures of the tested molecules are shown in Figure 1, aligned at
their basic nitrogen which is assumed to be essential for this type of G-protein receptor
binding. As can be seen from Table 1, all active compounds possess a common pattern of the
aromatic residue coupled to a potential hydrogen-bond donor and separated by an aryl moiety
from the positively charged amine with an adjacent ring system.
[Table 1]
Although the most active compound in this series 4 shows nanomolar affinity at the D3
receptor accompanied by a 10-fold D3 receptor preference in comparison to its D2 receptor
affinity it must be stressed that 4
[9] and 5 are quite similar to the reference set. By the use of111
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compound libraries one can hardly expect to retrieve totally unknown lead candidates.
Nevertheless, compounds 2, 3, 6, and especially 7 disclose some novel structural features
resulting in first hits as well as promising new leads for dopamine receptor subtype ligands in
this overcrowded area of drug development. Together with the other data obtained from
virtual and real compound screening (cf. Supporting Information) one may extract structural
characteristics which have not or have only rarely been applied to dopamine D3 receptor
ligands. Compounds 6 and 7 already display slight D3 receptor preferences showing the
success of our approach, and give for 7 good hopes for further optimization that is distinct
from well-known structure-activity relationships. For the first time, iterative virtual screening
cycles using SVM were successful applied to entirely ligand-based searching for novel
ligands. The concept offers a rapid way to identify lead structure candidates with minimal
experimental effort even in the absence of receptor-structure information.
[Figure 1]
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Legend to the figure
Figure 1.
Compounds selected for testing based on similarity to compound 2. Structures were aligned
according to the position of the basic nitrogen (dotted line). Three different parts of the
molecules were distinguished: A) an aromatic moiety, B) an aliphatic linker, C) a
hydrophobic part connected through a basic nitrogen.114
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Table 1. Dopamine receptor affinities of compounds from the first virtual screening round
(from IBS catalogue)
Molecule No. Ki (D2) ± SD [nM]
[a] n
[b] Ki (D3) ± SD [nM]
a n
[b]
3 1414±516 2 1408±1068 2
4 554± 97 4 40±6 4
5 417±60 8 139±17 5
6 201±48 8 96±21 7
7 4395±497 6 914±307 6
[a]Ki values (mean value with standard deviation (SD)) were measured in CHO cells stably
expressing hD2s and hD3 receptors by using [³H]spiperone.
[b]Number of experiments.115
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1. Brief description of experimental procedures
Data sets and descriptors. 395 compounds with reported affinity at D2 and D3 receptors
served as the SVM training sets. These compounds were synthesized analogues of BP897 and
related structures reported in literature.
1 Each compound was represented by a fingerprint of
3PP pharmacophores using MOE version 2004.05 (Chemical Computing Group, Montreal).
The individual 3PP pharmacophore was represented as a triangle. We considered all possible
triangles with their vertexes located at atom centers. Presence or absence of a certain triangle
defines the one or zero state of the corresponding bit of the fingerprint. Triangles were
distinguished by the type of atom at vertexes and by the path length of their edges. The vertex
was either donor (D) and planar (Dpl), acceptor (A) and planar (Apl), polar (P), or
hydrophobic (H) and planar (Hpl) as defined by the atom-types implemented in MOE.
4
Lengths of the edges were calculated along the molecular graph, no estimation of the 3D
structure of molecule was performed at this stage.
Binding studies. Human dopamine D2s and dopamine D3 receptors were expressed in stably
transfected Chinese hamster ovary (CHO) cells.
2,3 In brief, radioligand binding screening was
performed on cell membrane preparations in triplicate by using 0.2 nM [³H]spiperone
(Amersham Biosciences, Freiburg, Germany). Nonspecific binding was determined in the
presence of 10 µM BP897. For rapid screening the compounds have been tested at four
concentrations (10 µM, 1 µM, 0.1 µM, and 0.01 µM) in two independent experiments.
Competition binding data were analyzed using the software GraphPad Prism™ (San Diego,
CA, USA), using a non-linear least squares fit. Ki values were calculated from the IC50 values
according to the Cheng-Prusoff equation.
4
(1) Pilla, M., Perachon, S., Sautel, F., Garridol, F., Mann, A., Wermuth, C. G., Schwartz, J. C., Everitt, B. J.,
Sokoloff, P. Nature (London) 1999, 400, 371-375.
(2) Hayes, G., Biden, T. J., Selbie, L. A., Shine, J. Mol. Endocrinol. 1992, 6, 920-926.
(3) Sokoloff, P., Andrieux, M., Besancon, R., Pilon, C., Martres, M. P., Giros, B., Schwartz, J. C. Eur. J.
Pharmacol. 1992, 225, 331-337.
(4) Cheng, Y.C., Prusoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108.
___________________________120
Publications
2. Results of binding studies of the first screening round
Table S1. Dopamine receptor affinities of compounds
from the first virtual screening round (from IBS
catalogue)
a Ki values were measured in CHO cells stably expressing hD2s and
hD3 receptors by using [³H]spiperone (two experiments).
All compounds were aligned according to the basic nitrogen.
No. Chemical Structure Ki (D2)
[µM]
a
Ki (D3)
[µM]
a
S1
N
N
<2 <2
S2
N
O
O
O
O
O 2-6 <2
S3
N
N
2-6 2-6
S4
N
N
>6 2-6
S5
O
N
>6 2-6
S6
O
N
>6 2-6
S7
N N
O
>6 >6
S8
F
O
N
N
O
O
>6 >6
S9
O
O
N N
>6 >6
S10
O2N
N N
O >6 >6
S11
O
N
O >6 >6121
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3. Docking of ligands into a homology model. To get an idea of a potential binding
pose of the found actives, we constructed a homology model of the dopamine D3 receptor.
Docking of the compounds into a homology model of human D3 receptor highlights two
potential hydrogen bonds (Figure S1): one to Ser192, and a second one between the basic
amine and Asp110. It was previously shown that mutation of Ser192 to Ala (S192A) leads to
approximately ten-fold reduced ligand binding to the mutated D3 receptor.
1 The importance of
optimal hydrogen bonding interaction between the hydroxyl group of the well-studied ligand
R-(+)-7-OH-DPAT and Ser192 is also supported by SAR data, which shows that replacement
of the hydroxyl group by a methoxy group in R-(+)-7-OH-DPAT reduces its binding affinity
by 100-fold.
2
A potential hydrogen bonding pattern between the protonated basic amine of the
ligands and Asp110 is also visible in the homology model. It was previously demonstrated
that the basic amine function is important for receptor-ligand interaction for many different
GPCR ligands.
3 For the D2 and D3 receptors the interaction with Asp110 (Asp114 for D2) is a
generally accepted hypothesis.
4
A B
Phe 345
Phe 346
Ser 192
Asp 110
Figure S1. A) Docking of compound 4 into a homology model of the human dopamine D3
receptor. Parts of the predicted binding pocket are shown. Potential hydrogen bonds between the
ligand and Asp110 and Ser192 are indicated by dotted lines. The predicted lipophilic pocket for
part C of the molecule (cf. Figure 1) is represented by a Connolly surface. B) Superposition of
docked structures of compounds 3-6. The overlapping of the basic amine, as well as part C of the
molecules is observed. Potential hydrogen bond acceptors that potentially interact with Asp110
are in close vicinity. Compound 7 is not present in the alignment as it probably adopts a different
mode of binding. (Note: compound numbering according to Table 1 and Figure 1 of the main
manuscript).
Residues corresponding Phe345 and Phe346 were shown to be important for ligand
binding in many different GPCRs.
5 Phe345 of the D3 receptor corresponds to the Phe389 of
D2; its mutation to Ala was shown to abolish the binding of several ligands.
6 Although we
observed these residues to be in contact with the docked ligand in the homology model, we
cannot unambiguously identify face-to-face or face-to-edge aromatic interactions between
rings of these two residues and the aromatic moiety of our compounds. This is easily
explained by the inaccuracy of the constructed homology models due to low sequence identity122
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(28%) between the D3 receptor and the rhodopsin template. We wish to stress that although
the docking experiments were able to propose a common binding mode for several ligands
(Figure S1b), and the model of the binding site is in accordance with receptor mutation
studies, the homology model must be treated with great caution. Unarguably, homology
models have their value in molecular modeling,
7 but we wish to stress that one should
consider our D3 receptor model only as an “idea generator” potentially guiding the following
steps of hit exploration and generation of structure-activity relationships.
Since the compounds selected were taken from public compound collections it is clear
that some of the compounds were already used in other investigations e.g., 4 for adrenergic
and serotonergic receptors (cf. Ref. 9 in main manuscript).
4. SVM training and active learning. For constructing SVM models we used the
SVM-light package.
8 Details of the SVM training protocol can be found elsewhere.
9,10 The
prediction of a trained SVM is given by Eq. 1.
b K f
i
sv
i i + = ) , ( ) ( x x x α , where 5 ) 1 ) (( ) , ( + • = s K y x y x . (1)
The greater f the higher is the probability for a compound to be active. x and y are
molecular fingerprint vectors, x
sv are support vectors, i.e. molecular fingerprints that define
the exact shape of the separating SVM hyperplane. The kernel function K defines the
complexity of the surface that will be constructed. We used a fifth order polynomial kernel for
all SVM models. Kernel parameter s was optimized to achieve improved ranking of
compounds.
10 For active learning, we considered all compounds with Ki < 1 µM for D2 or D3
receptors (331 compounds) as active compounds; they were labeled as “Class” (C). 50,000
“Non-Class” (NC) substances were selected from the IBS collection (~240,000). The NC
compounds were selected for minimal distance to the SVM hyperplane allowing a more fine-
grained re-sampling of the “near-active-compound” space. The resulting filter consisted of
two consecutive SVM models: the first SVM model ranked all available IBS compounds with
respect to the distance to the active reference set, the second SVM model re-orders the most
promising candidates.
SVM training aimed at maximizing the enrichment factor, expressed by the percentage
of active compounds retrieved in the top 1% of a ranked screened database. It was done by
standard four-fold cross-validation.
11
5. Regression SVM model for predicting the 2
3
log D
i
D
i
K
K
ratio. SVM-light was used to
construct the model. The <q
2> value was used as the criterion for optimization (Eq. 2):
( )
( ) 

> < −
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− >= <
i
i
measured
i
measured
i
i
predicted
i
measured
f f
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Here
i
measured f and
i
predicted f are measured and predicted 2
3
log D
i
D
i
K
K
, where > <
i
measured f
is the averaged ratio of measured binding constants. For model optimization four-fold cross-
validation was applied, in which the model was trained on the compounds excluding the
validation subset, and then <q
2> was calculated for the compounds of the validation subset.
Parameters of the SVM were optimized to achieve maximum performance for the four
validation subsets. The final model was trained using all molecules yielding optimized SVM
parameters s (Eq.1) and w epsilon width for the regression tube.
8
6. Compound ranking based on the similarity to the reference compounds. The
selection of the final set of compounds was performed by using a similarity measure, where
the distance between molecules was calculated by Equation 3.
 − =
i
M
i
M
i i w M M L ) ( ) 2 , 1 (
2 1 x x . (3)
Here, L is a distance between molecules M1 and M2;
1 M
i f and
2 M
i f are 3PP
fingerprint bits, and i w are the weights of the features estimated by the SVM model. The
weights wiwere extracted from the SVM model by estimating their influence on the predicted
activity (Eq. 4).
( )
n
f f
w
n
k
k
x pred
k
x pred
i
i i 
=
= = −
=
1
0 1 ) ( ) ( x x
. (4)
The summation is over all active compounds (n = 395) of the reference set. The
) ( 0 , 1
k
x pred i f = x is the prediction of the 2
3
log D
i
D
i
K
K
for compound
k x , where fingerprint i is set to
one or zero.
7. Homology model of the D3 receptor. The transmembrane region of the dopamine
D3 receptor was homology-modeled based on a 2.8 Å resolution rhodopsin crystal structure
(PDB-code 1F88).
12 The sequence alignment for the D3 receptor and rhodopsin was obtained
from the multiple sequence and Hidden Markov model of rhodopsin-like GPCRs from the
PFAM database.
13 For homology modeling, energy minimization and structural analysis of
protein we used MOE software package.
14 The active site of protein was predicted by
analyzing the positions of the following residues, that are known to be important for ligand
binding to D3 receptor: Asp110, Ser192, Phe345, Phe346.
5,15 Compounds were docked into
the proposed active site using the MOE built-in docking routine. For scoring partial charges
from MMFF94s were used.
16 We generated 100 different docked conformations for each
compound. A final conformation of each ligand was manually selected, taking into
consideration mutation data for the D3 receptor.
1,2,5 We selected conformations that possess124
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potential hydrogen bonds to Ser192, and between the positively charged amine of the ligands
and Asp110.
8. Binding studies. CHO-D2S cells, expressing the recombinant human D2(short)
dopamine receptor gene,
17 were grown in Dulbecco’s Modified Medium/Nutrient Mixture
F12 1:1 Mixture supplemented with 2 mM glutamine, 10% foetal bovine serum, and 10
µlml-1 penicillin/streptomycin in an atmosphere of 5% CO2 at 37 °C (Gibco
TM, Karlsruhe,
Germany). Human D3 receptors stably expressed in CHO cells as previously described by
Sokoloff et al.
18 were used. The cell line was cultured in Dulbecco`s Modified Eagle Medium
supplemented with 2 mM glutamine, and 10% dialysied fetal bovine serum, and were grown
in an atmosphere of 5% CO2 at 37 °C (Gibco
TM). Human D2S and D3 receptors expressing cell
lines were grown to confluence. The medium was removed, and the cells were washed with
10 ml PBS buffer (140 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4) at
4 °C. After removing the wash buffer, the cells were scraped from the flasks into 15 ml of ice-
cold media, and centrifuged at 3,000 rpm for 10 min at 4 °C. After centrifugation the medium
was removed and the supernatant resuspended in ice-cold Tris-HCl buffer containing 5 mM
MgCl2, pH 7.4 and disrupted with a Polytron and centrifuged at 20,000 rpm, for 30 min at 4
°C. The pellet was resuspended by sonication in ice-cold Tris-HCl buffer (containing 5 mM
MgCl2, pH 7.4), membrane aliquots were stored at -70 °C. Determination of membrane
protein was carried out by the method of Bradford.
19 Cell membranes containing human D2s
and D3 receptors from CHO cells were thawed, rehomogenized with sonication at 4 °C in
Tris-HCl, pH 7.4 containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 mM MgCl2
(incubation buffer), and incubated with 0.2 nM [³H]spiperone (106 Cimmol
-1 , Amersham
Biosciences, Freiburg, Germany), and drug diluted in incubation buffer. Nonspecific binding
was determined in the presence of 10 µM BP897 (prepared by same of the authors).
Incubations were run at 25 °C for 120 min, and terminated by rapid filtration through
PerkinElmer GF/B glass fibre filters (PerkinElmer Life Sciences, Rodgau, Germany) coated
in 0.3% polyethylenimine (Sigma-Aldrich, Taufkirchen, Germany) using an Inotech cell
harvester (Inotech AG, Dottikon, Switzerland). Unbound radioligand was removed with four
washes of 1 ml of ice-cold 50 mM Tris-HCl buffer, pH 7.4, containing 120 mM NaCl. The
filters were soaked in 8 ml Beta plate scint scintillator and counted using a PerkinElmer
MicroBeta
®Trilux scintillation counter (PerkinElmer Life Sciences). Competition binding
data were analysed by the software GraphPad Prism™ (2000, version 3.02, San Diego, CA,
USA), using non-linear least squares fit. For fast screening the compounds have been tested at
four concentrations (10 µM, 1 µM, 0.1 µM, and 0.01µM) in triplicate carrying out two
binding experiments for human dopamine D2s and for human dopamine D3 receptors. Ki
values were calculated from the IC50 values according to Cheng-Prusoff equation.
20125
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Abstract
Cytochrome P450 2C9 (CYP2C9) is one of the most important phase 1 metabolising enzymes
in humans for many therapeutically relevant pharmaceuticals. Any new chemical candidate
inhibiting this membrane-associated heme protein thus would significantly affect the
metabolism of physiologically important molecules and drugs, resulting in clinically
significant drug-drug interactions. In search for computational tools to identify potential
CYP2C9 inhibitors early in drug discovery, we constructed a filter based on a collection of
1100 structurally diverse molecules tested for CYP2C9 inhibition under identical conditions.
The chemical structures were encoded using several 2D descriptors, followed by the
generation of different statistical models using support vector machines (SVM). This
approach consistently leads to significant and predictive models for regression and
classification of CYP2C9 inhibitors. Their predictive ability was underscored by successfully
applying them to a test set of 238 compounds. Even more important for early drug discovery
phases is the ability of these models to correctly discriminate CYP2C9 inhibitors from
inactive molecules on this enzyme. This filter also allows extracting and visualizing important
ligand substructures and functional groups, which are essential to understand protein-ligand
interactions for CYP2C9. To validate the correct identification of essential functional groups
connected to CYP2C9 affinity, predicted features from the SVM models for some local
structure-activity series in that dataset were analysed in detail. Furthermore the application of
these models to the substrate S-warfarin, which recently has been co-crystallized with
CYP2C9, revealed that the identified substructures are involved in the interaction with the
CYP2C9 inhibitor binding site. For example, the model correctly indicated the aromatic
stacking interactions with Phe114 and Phe476 as well as a hydrogen bond with backbone of
Phe100. Hence, these models consistently provide guidelines for reducing CYP2C9 inhibition
in novel candidate molecules.
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1. Introduction
Mammalian cytochrome P450 proteins are a class of membrane-associated heme containing
proteins that recognize and metabolize a diverse range of xenobiotics such as environmental
molecules, pollutants and drug compounds. The human isoforms CYP1A2, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4 were identified as major drug-metabolizing enzymes.
Those have been reported to contribute to the oxidative metabolism of ~90 % of currently
used pharmaceuticals in clinical application. Cytochrome P450 2C9 (CYP2C9) is one of the
important cytochromes involved in drug metabolism in humans, responsible for ~18 % of all
reactions catalysed by this superfamily (
1). There are several CYP2C9 substrates that belong
to the class of nonsteroidal anti-inflammatory drugs, such as diclofenac (
2,3), ibuprofen (
4),
naproxen (
5), flurbiprofen (
6,
7), piroxicam (
6). CYP2C9 is also involved in the metabolism of
polar acidic drugs (
8), progesterone and anticoagulants with a coumarin substructure like S-
warfarin. Any interference of novel drug candidates with these known pathways of CYP
metabolism thus might cause undesirable drug-drug interactions upon clinical development
and co-medication during a therapy.
Until recently, the molecular basis of drug binding to human CYP2C9 and other human
cytochromes has been derived from X-ray structures of bacterial CYPs with ligands (
9,10,11,12).
Then the structure of rabbit CYP2C5 provided additional insights of key residues located
within the putative ligand and substrate-binding site (
13). Following these studies, Williams et
al. determined the X-ray structure of human CYP2C9 in the absence and presence of the
substrate S-warfarin (PDB 1OG2, 1OG5 (
14)). CYP2C9 was identified as a two-domain
protein with the typical fold characteristics of the CYP450 family. The heme is located
between helices I and L, the iron ion is pentacoordinated with Cys435 as single ligand. This
structure reveals unexpected interactions of warfarin to the CYP2C9 binding site and
highlights an additional binding area close to the heme pocket.
The structure of a different construct of human CYP2C9 in complex with flurbiprofen has
been determined to a resolution of 2.0 Å by X-ray crystallography by Wester et al. (PDB code
1R9O (
7)). Interestingly in this structure a distinct conformation of the helix B to helix C
region allows Asp108 to form hydrogen bonds with Asp293 and Asn289 and to interact
directly with the carboxylate of flurbiprofen. Obviously these essential interactions are
responsible to position the substrate for regioselective oxidation in the CYP2C9 binding site
and they account for the preference of this CYP isoform for anionic nonsteroidal anti-
inflammatory drugs (
7). This region adopts a different conformation in the CYP2C9 structure130
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from Williams and does not orient Arg108 towards the substrate binding site (
14). Several
other X-ray crystal structures of important mammalian and human cytochromes have
appeared in the meanwhile, which provide additional structural details on important protein-
ligand interactions in this protein family (
15,16,17,18,19).
Any reliable prediction of CYP2C9 inhibition would greatly increase the efficiency in earlier
drug discovery phases. There has been a constant development in understanding interaction
features in the active site of CYP2C9 using different approaches. Some studies have involved
overlapped CYP substrates to identify a binding template (
20,21). Others have used tienilic acid
derivatives (
22), phenytoin analogs and bis-triazole antifungals (
23) to establish the structure-
activity-relationship (SAR) for rationalizing known substrate and inhibitor specificity of
CYP2C9. NMR and molecular modelling have also been combined to assist in defining the
positioning of substrates in the CYP2C9 active site (
3). Site-directed mutagenesis indicated
the importance of the I-helix residues Ser286 and Asn289 for specificity for the substrates
diclofenac and ibuprofen (
24 ) in agreement to interactions revealed in the CYP2C9-
flurbiprofen X-ray structure (
7). This X-ray structure 1R9O also confirmed the observations of
a CYP2C9 preference for small acidic lipophilic compounds in an “anionic binding site”
(
21,22,25), while in the 1OG5 binding site no basic amino acids being able to interact with
substrates or inhibitors could be identified. In addition numerous hydrophobic residues are
lining the CYP2C9 active site from the analysis of both CYP2C9 X-ray structures.
Based on these findings, numerous approaches employing a variety of 3D-QSAR methods
have been useful for developing predictive models and understanding binding site
requirements for CYP2C9 (
26,27,28,29,30), although these models are consistently based on small
training data sets of diverse molecules.
Recent advances in synthetic methodology have expanded the diversity of chemically
accessible structures, leading to an increasing number of high-quality compounds for lead
identification and optimization in drug discovery. As the application of filter criteria was
shown to increase the quality of newly synthesized candidates (
31), our interest was to develop
a fast and reliable filter for this “antitarget” as complement to existing virtual screening and
compound optimization tools focussed on affinity toward the desired molecular target. The
filter should be based on internal experimental assay results from a wide range of compounds
tested under identical conditions. The purpose of such a filter differs from classical QSAR
approaches such that larger numbers of structures are passed through this and related models
focussed for target affinity and ADME properties in virtual screening.131
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In this study we applied support vector machines (SVM) as statistical approach for
constructing a structure-activity model for a large and diverse set of compounds tested for
CYP2C9 inhibition under identical experimental conditions. This algorithm was invented by
Vapnik to derive a classifier for a data set of actives and inactives for a given experimental
observation (
32). It then was successfully applied in different research areas (
33) including bio-
and chemoinformatics (
34). In some examples, SVM outperformed other learning machines,
for instance, ANN (artificial neuronal networks (
35)), while the general utility of any statistical
approach depends on many factors like data set, descriptors, size and others. The final quality
of any model, however, can only be assessed from application to external test sets. Another
important criterion is the ability to understand structural reasons for compound inhibition,
which might be useful for subsequent lead optimization.
For the present data set, the use of molecular descriptors requiring information about the
inhibitors’ three-dimensional (3D) structure and their putative alignment was prevented due to
its diversity including many chemotypes from internal drug discovery programs.
Consequently two different sets of two-dimensional (2D) descriptors known to capture
relevant information for protein-ligand interactions have been employed.
First, three-point pharmacophoric fingerprints (3PP) have been used. Each bit in this
fingerprint encodes the presence or absence of a particular pharmacophoric triangle with
certain distance requirements in a molecule (
36). Molecules are represented as collections of
pharmacophoric points separated by topological distances (i.e. bonds). This description results
in a total of ~10
5 bits per molecule. One advantage of SVM versus other methods is its ability
to work with large number of features (
37). Furthermore there might be several possible
binding modes and thus different acceptable pharmacophores for affinity within the CYP2C9
substrate and inhibitor binding pocket. It was not possible in this data set to decide a priori,
which chemotype is engaged in which orientation within the CYP2C9 binding pocket. SVM
was earlier shown to be intrinsically able to deal with larger numbers of descriptors in a
vector and to correctly analyse data sets with multiple binding modes (
38). In addition to
standard binary classification, SVM regression models were built to incorporate consistent
IC50 values for our datasets. These models then allowed visualization of important features for
receptor ligand interactions on selected SAR series and compounds from this data set. The
most important features for binding of S-warfarin to CYP2C9 could be derived from applying
the models, which are in good agreement to its recent X-ray crystal structure in CYP2C9 (
14).
Subsequently, a collection of different descriptor types was used. This descriptor collection
encompasses substructure keys following the MACCS key definitions (
39), topological132
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pharmacophores based on CATS descriptors (
40), computed pKa values for basic and acidic
groups from ACD/Labs (
41) and surface based and related descriptors computed using
QikProp (
42). This collection, named CMQA, has been useful for deriving significant
statistical models in other internal projects.
These models were further validated by predicting test sets of 238 diverse compounds and a
library of compounds focussed towards G-protein coupled receptors (GPCRs), for which
experimental data under similar conditions were available. This CYP2C9 prediction model
shows sufficient performance and thus can be used early in drug discovery to identify
molecules with potential drug-drug interaction problems involving this isoform.
2. Results and Discussion
2.1. Statistical Models using SVM and PLS for CYP2C9 Inhibition
2.1.1. SVM Regression Models using 3PP Descriptors
The resulting models derived using the training set of 1100 compounds followed by validation
using 238 compounds as test set are presented in table 1. This table summarizes six models
differing by descriptors (3PP, CMQA), statistical methods (SVM, PLS (
43)) and the SVM
approach (classification, regression). The original data set, consisting of 1338 molecules from
multiple chemical series and internal projects, was divided into a training set of 1100
compounds and a test set of 238 compounds using statistical design applying a maximum
diversity approach (
44).
(Table 1)
First, the SVM regression approach using 3PP fingerprints was applied to build a model for
CYP2C9 affinity prediction for the training set of 1100 compounds (table 1a). Internal
parameters for the SVM were optimized using four-fold cross-validation (leave-25%-out
approach, see Experimental Section). In addition, this approach allows visualization of the
inhibitor functional groups that were predicted by SVM to be important for binding to
CYP2C9. A significant model with a q
2value (crossvalidated r
2from four-fold-crossvalidation)
of 0.34 and an r
2 of 0.81 resulted, which correctly predicted the external test set of 238
compounds (predictive r
2 0.63).
After successful prediction of the external set based on the SVM model derived on 1100
compounds, both data sets were merged and analysed again, resulting in a second SVM model
for a total of 1338 molecules (table 1b). The q
2 value of 0.43 for this combined training set is
larger than the q
2(cv) for 1100 compounds alone due to increased information in this133
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collection. As the original split into training and test sets was done using statistical design,
some features are obviously not any longer represented in the training set. However, the final
assessment about model quality and usefulness was done based on its application to the test
set and the predicted r
2 for this set, which was not used to derive the model (table 1a).
2.1.2. SVM Regression Models using 2D Descriptors
In order to check that relevant information to describe the biological affinity against CYP2C9
was captured by 3PP-fingerprint descriptors, an additional SVM model was generated using a
total of 339 CMQA descriptors (table 1c). These descriptors encompass structural keys
following the MACCS definition (
39), CATS pharmacophore correlation over 2D molecular
graph (
40), pKa values from ACD/Labs (
41) and QikProp derived descriptors (
42). Due to the
smaller number of CMQA descriptors (339 versus ~10
5 3PP fingerprints), a non-linear SVM
model performed better on predicting the test set than the corresponding linear SVM model,
respectively. In contrast, it was observed for 3PP fingerprints that the linear SVM model
resulted in a more predictive model (non-linear SVM results not shown).
This application of non-linear SVM is only meaningful, if the dimensionality of the descriptor
space is below a few thousands, like for the CMQA descriptors. Contrastingly for higher
dimensionality descriptor spaces, linear SVM model are expected to perform better, as
observed for 3PP fingerprints (results not shown). This could partially be attributed to
additional noise introduced by non-linear mixing of descriptors relevant and irrelevant to the
correct regression (
45).
When comparing these results versus training a SVM model using 3PP fingerprints (table 1a
versus 1c), this regression model exhibited similar quality: the predictive r
2 was only slightly
higher with 0.68 in comparison to 0.63 for 3PP fingerprints, respectively. Although the
crossvalidated q
2 of the training set derived using four-fold crossvalidation was significantly
larger for the non-linear SVM with CMQA descriptors, this can be explained by a different
splitting for the cross-validation of the training set in a and c (Table 1), as this splitting is
performed on a random basis prior to each model generation and validation. However, one of
the significant advantages of the 3PP fingerprint based SVM model over CMQA is the ability
to map fingerprints back to the functional groups of the molecules and thus provide a visual
analysis of the relevant features linked to activity. For most CMQA descriptors such a
mapping is less obvious.134
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2.1.3. Comparison to PLS Regression Models
To compare the performance of SVM with other standard regression techniques, another
model was built using CMQA descriptors and PLS (Partial Least Squares) regression to
predict CYP2C9 inhibition (table 1d). All descriptors were autoscaled and columns without
variance were rejected for analysis. A 6 component PLS model results with a q
2 value of
0.338 for 1100 compounds (leave-one-out crossvalidation) and a conventional r
2 value of
0.475. When applying this model to the test set of 238 molecules, a predictive r
2 value of 0.55
resulted, which indicates significantly lower predictivity than the predictive r
2 value of 0.68
obtained for the SVM model in table 1c, respectively.
2.1.4. SVM Classification Models
In addition to these regression based SVM models, a SVM classification model was
developed as binary filter to estimate whether a compound is able to inhibit CYP2C9. In this
case, prior to the SVM training the experimental IC50 values were assigned to zero for
inactive compounds (IC50 >10 µM) and one for actives (IC50 < 10 µM). The results of the
SVM training are shown in table 1e and f for the training set of 1100 compounds and the
combined data set of 1338 molecules, respectively. A total of 85 % of the compounds from
the test set with 238 molecules was correctly classified as active or inactive by this SVM
classifier from table 1e. For the SVM classifier trained with the combined data set, the overall
accuracy could only be monitored using four-fold-crossvalidation. Here, 73% of the
compounds in all validation subsets were correctly classified, depending on the initial splitting
for internal model validation (table 1f).
2.1.5. Analysis of SVM and PLS Models
Figure 1 shows the graphs of predicted pIC50 values (y-axis) versus experimental data on the
x-axis for models a, c and d from table 1. Figures 1a, b, c and d indicate the fit of predicted
versus experimental pIC50values for linear and non-linear SVM models a and c and both the
training set of 1100 compounds (figure 1a, c) and the prediction for the test set of 238
compounds (figure 1b, d). Figures 1e and f provide the same information for PLS model using
CMQA descriptors (table 1d). One characteristic feature of SVM training is that SVM does
not attempt to adjust the pIC50 prediction, if the residual between predicted and
experimentally measured pIC50values is less than the tube width parameter of the SVM (
46).
This allows SVM to compensate for inaccuracies in the experimental data for this collection
of pIC50 values, which might occur especially in the case of high throughput screening data.135
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The results in Figures 1a and c show that most of the predicted pIC50 values are localized
within the tube width close to the experimental pIC50 value. This reduces the number of
outliers for SVM training in comparison to PLS, as seen by comparing figures 1a, c and d.
This width parameter is also optimized in crossvalidation by maximizing the q
2 for the
randomly chosen validation subsets within the training sets.
(Figure 1)
Most outliers are localized in three characteristic regions of these graphs: inactive compounds,
very active compounds (IC50 > 0.4 µM, upper right circle) and compounds with IC50 values >
10 µM (lower left circle). Outliers with experimental IC50 values of 10 µM and higher are
related in most cases to insufficient solubility at assay concentrations, as estimated from
QikProp solubility predictions (
51). As a consequence it cannot be excluded that SVM
correctly estimates their IC50 values, but experimental values are misleading. A similar
observation has been made for some compounds with experimental IC50 values higher as 2
µM, where solubility was experimentally determined as limiting factor to obtain a more
accurate value. Predictions using all models produce consistently lower pIC50 values in
agreement with this solubility limit. In contrast, some compounds with high experimental
affinity to CYP2C9 were predicted only moderately active; on the other hand some of the
inactive compounds were predicted to have binding activity for CYP2C9. This might be a
consequence of the complexity of inhibitor interactions with CYP2C9. Furthermore the
presented model does not explicitly account for entropic effects upon ligand binding. It is also
known that some of the CYP2C9 ligands have at least two binding modes (
14,7). The
assumption of a consistent binding site area, which is occupied by this very diverse data set,
might also be an oversimplification, as the binding site is relatively large and thus offers
several possibilities for protein-ligand binding. Furthermore, the binding of inhibitors to
CYP2C9 could additionally be affected by geometrical requirements in the substrate–access
channel (
47). Hence, the experimental binding affinities might be affected by multiple
mechanisms and observations in such a diverse data set.
2.1.5. Additional Validation Studies
As additional validation the model 1c (table 1c) was applied to predict compounds from
another external dataset published by Afzelius et al. (
29). For these compounds the binding
affinities were reported as Ki instead of IC50 values. Moreover, the assay conditions differ to
those used in our study (
29). Hence, in order to compare the SVM filter for this dataset, the
compounds were only classified as active (IC50< 10 µM) or inactive (IC50>10 µM) and SVM136
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predictions were compared with known CYP2C9 affinity for this set. In fact, a total of 75 %
compounds from this series was correctly classified (table 1c, Accuracy test).
Another more strict validation of the three most relevant models from our study was carried
out by an outlier analysis, as presented in table 2. This analysis was performed the original
test set with 238 compounds encompassing 95 actives (40 %) and 143 inactives (60 %), plus a
second external set consisting of 344 representative members from a GPCR–targeted library
on a limited number of scaffolds (see Experimental Section). This second set contains 147
actives (43 %) and 197 inactives (57 %). As mentioned above, the experimental biological
affinities for these two sets were obtained under identical conditions. For interpretation, the
compounds were classified based on an affinity threshold, namely smaller or larger affinities
than an IC50 value of 10 µM.
(Table 2)
All models were useful to discriminate compounds active as CYP2C9 inhibitors from inactive
compounds, as seen from inspecting table 2. The performance on the GPCR-targeted library
compounds in general was slightly worse in comparison to the 238 compound test set.
Consistently all models are characterized by a relatively small number of false positives in
comparison to false negatives. For model a) using SVM and 3PP fingerprints, 6 and 5 % false
positives were found for the test set and the GPCR compounds, while 16 and 24 % false
negatives were classified, respectively. Furthermore a predictive r
2 value of 0.362 for the test
set derived from representative compounds of the GPCR targeted library was calculated, now
taking the actual predicted values into account. These success rates are comparable for model
b) using SVM and CMQA descriptors. Here, 6 and 1 % false positives were obtained, while
18 and 28 % false negatives were found for the test and GPCR set, respectively. Here the best
predictive r
2 value of 0.45 for the GPCR targeted library compounds were obtained with this
non-linear SVM model and CMQA descriptors. Finally the PLS model d) resulted in 3 and 5
% false positives, while 22 and 26 % false negatives were obtained. A predictive r
2 value of
0.412 for representative GPCR compounds was obtained with this model.
Hence, these models are collectively able to identify true CYP2C9 inhibitors with a relatively
low rate of wrong classifications (false positives). As this scenario is the primary application
of any virtual screening filter for CYP2C9 inhibition complementary to target binding
affinities, all these models are useful to rank appropriate compounds during early phases in
drug discovery projects. The success rates for identification of inactive compounds are
slightly lower, which requires additional experimental testing for those compounds passing
the initial filter and shown to be interesting in terms of affinity at the desired target .137
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2.2. Visualization of Important Functionalities for CYP2C9 Affinity
Subsequently the SVM models were applied to identify ligand features linked to CYP2C9
inhibition. To this end, the influence of every atom to the model was estimated by summing
up contributions from 3PP features including this atom as vertex (cf. Experimental Section,
Pharmacophore Visualization). The following section provides a chemical interpretation of
this model on the basis of important features for selected inhibitors.
Two similar CYP2C9 inhibitors 1 and 2 with different IC50 values (4.4 and 30 µM) are
displayed in figure 2. The SVM model 1a based on 1100 compounds and 3PP fingerprints
(see table 1a) correctly predicts the CYP2C9 binding affinity for 1 (pIC50 2.36 / 2.52 predicted)
and 2 (1.52 / 1.78), respectively. Interestingly, the substitution of chlorine against fluorine in 1
is correctly predicted to reduce affinity to CYP2C9. Furthermore, the replacement of the
aliphatic side chain in 1 to a compact and less hydrophobic group is also responsible for a
lower affinity to CYP2C9. Similar observations are made from feature visualization using two
related inhibitors 3 and 4 with significantly higher CYP2C9 binding affinity. For 3 an
experimental pIC50 value of 3.13 is observed, while 2.56 is predicted; for 4 the experimental
pIC50 value is 3.00 in comparison to the prediction of 2.23 (Figure 2). Again the SVM model
correctly predicts a higher binding affinity of both compounds to CYP2C9; in particular the
ranking of 3 and 4 is correctly reproduced. The increased binding affinity in 3 in particular is
related to the significant influence of hydrophobic interactions resulting from the biaryl
substructure (see Figure 2c).
(Figure 2)
(Figure 3)
However, binding affinities for 1 and 2 were slightly overestimated, but slightly
underestimated for 3 and 4. Thus, the most active inhibitor 3 was docked into the CYP2C9
binding site taken from the PDB structure 1OG5 using flexible docking in QXP (
48). The most
likely binding mode is shown in Figure 3 with the 3 imidazole nitrogen in close contact to the
CYP2C9 heme iron, suggesting a pivotal role for protein-ligand recognition in this series. For
compounds 1 and 2, any direct binding interaction to heme is less likely due to additional
methyl groups attached to the imidazole, which might result in lower CYP2C9 affinity.
However, these additional methyl groups indicating sterically unfavourable regions were not
considered during construction of the SVM model: no pharmacophoric point was assigned to
these methyl groups according to the PATTY classification scheme (
49) used to compute the
3PP descriptors. Hence, SVM did not consider any negative influence of those methyl groups,138
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which led to an overestimation of the binding affinity for 1 and 2, while the lack of this
feature results in the underestimation for 3 and 4. Other inhibitors with important
contributions of the imidazole to CYP2C9 binding affinity are displayed in figure 4. Again the
aromatic rings of 5-7 are likely to adopt an orientation similar to those compounds shown
from Figure 2 in complex with CYP2C9.
(Figure 4)
(Figure 5)
As the active site of the cytochrome CYP2C9 is large and capable to accommodate even
several ligands (
14), this might result in uncertainties in determining binding modes by
docking. In the absence of any experimental structure information of a CYP2C9 inhibitor
bound to this enzyme, we analysed the X-ray structure of the CYP2C9 substrate S-warfarin
(PDB code 1OG5), an anti-coagulant drug with a Ki value of 20µM (
14). Figure 5a indicates
key interaction points of S-warfarin with CYP2C9, namely the aromatic stacking between
Phe114, Phe476 and the corresponding aromatic rings of S-warfarin. In addition, two
hydrogen bonds between Phe100, Ala103 and the ligand are essential for substrate binding in
this region of the binding pocket. 3PP-fingerprints were then calculated based only on the
connection graph of the molecule and standard PATTY atomic features (see figure 5c). The
sphere diameter close to the atomic features of S-warfarin indicate their relative importance
for protein-ligand interactions, estimated as average importance of 3PP triangles that include
this feature as a vertex. In fact, three out of four essential interactions are correctly identified
(Figure 5c, Table 1b); namely the two aromatic interactions with Phe114 and Phe476 and the
hydrogen bond to the Phe100 amide nitrogen.
We have noticed that mainly hydrophobic (H) and hydrophobic planar (Hpl, aromatic) features
were considered by SVM as important for the interaction with CYP2C9, which is consistent
with general assumptions on essential requirements for CYP2C9 inhibition. However, it
should be noted that the presented model were derived to identify CYP2C9 inhibitors, while
information about substrates cannot be expected, when connected with weak binding affinities.
Figure 6 shows two other examples of feature visualization using model 1b for Miconazole
(Ki = 6 µM) and the inactive Acebutalol (
30). Again, mainly hydrophobic features are
highlighted by SVM model in good agreement to other reports (
50).
(Figure 6)
(Figure 7)
Finally the SVM model allows analysing features positively or negatively contributing to
CYP2C9 affinity, as exemplified using molecules shown in figure 7. The same SVM model as139
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before was used analysis (Table 1,b). Green and blue spheres highlight the resulting
summations separated by positive or negative contribution: green spheres indicate features
that are favourable for interaction with CYP2C9 and blue refer to detrimental features. As the
same atom can be a part of different 3PP features it is often observed that the same functional
group is predicted to confirm positively and negatively to the interaction with CYP2C9. In
this case one tendency significantly dominates.
The only difference between 11 and 12 in Figure 7 is the presence of a hydrophobic
cyclopropyl group, which is predicted to positively influence CYP2C9 affinity in agreement
with experimental data. Again the IC50 values are correctly estimated by SVM model (11:
IC50 = 1.0 µM, measured pIC50 = 3.0, predicted p IC50 = 2.8; 12: IC50 = 30.0 µM, measured
pIC50 = 2.3, predicted pIC50 = 2.4). Features with negative influence to CYP2C9 affinity are
less important, as seen from the diameters of corresponding spheres.
When comparing 12 and 13, the influence of negative features is significantly larger. First, the
replacement of the amide by an ester (see arrow in Figure 7.b,c) changes a planar donor to
planar polar group, which results in a strong negative feature in this part of the molecule.
Adding the hydrophobic methyl group adjacent to the aromatic ring (see arrow Figure 7c)
results in another negative feature. Furthermore almost all negative features increase their
importance, while almost all positive features decrease their size and importance in 13 in
comparison to 12. This change is also observed for features whose atoms did not change
between 12 and 13. It is attributed to the fact that the negative planar and hydrophobic groups
in 13 correspond to a vertex of a negative 3PP feature. As every 3PP feature corresponds to a
triangle, the two other vertexes are also negative features and are responsible for the overall
increase of negative features in 13. Hence, this feature visualisation allows for a reasonable
chemical interpretation and is in good agreement to the observed ligand SAR trends for
CYP2C9 inhibition.
3. Conclusions
The application of SVM as statistical approach allows generating a significant virtual
screening filter to identify CYP2C9 inhibitors early in drug discovery. It provides an efficient
way to construct significant QSAR models for a large compound set consisting of 1100
structurally diverse molecules tested for CYP2C9 inhibition under identical assay conditions
without obvious molecular alignment. Two significant models for classification and affinity
prediction of CYP2C9 inhibitors have been obtained; those are collectively useful to select140
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and rank novel compounds during early phases of drug discovery based on their potential to
interact with this important cytochrome. Success rates for the identification of inactive
compounds are slightly lower compared to those for active compounds. Hence, additional
experimental testing is suggested for those compounds, which passed the initial filter, have
been synthesized and showed favourable affinity for the desirable biological target.
It is possible to extract and visualize relevant chemical features that are either favourable or
detrimental for binding affinity to CYP2C9. This contribution of chemical features to affinity
is consistent with known structure-activity trends for some chemotypes and with protein-
ligand interactions from the X-ray structure of the substrate S-warfarin with CYP2C9. Hence
the constructed models might help to identify compounds with a potential liability early in the
drug discovery phase and provide some guidelines to understand structural reasons for their
interaction with CYP2C9.
4. Experimental Section
4.1. Data sets and descriptors
For a total of 1338 compounds from different chemotypes and internal drug discovery
programs at Aventis, IC50 values for CYP2C9 inhibition were determined using a globally
harmonized protocol employing human recombinant CYP2C9 with 7-MFC (7-Methoxy-4-
trifluoromethyl-coumarin) as substrate. Inhibition constants were obtained in the range
between 0.4 µM and 50 µM; higher or lower values were assigned to threshold values. All
IC50 values were converted to pIC50 values using the relationship 1/(log(IC50)*1000). The
quality of some data points was limited by low solubility. Solubility was estimated by
prediction of aqueous solubility from QikProp (QPlogS (
42,51)). Any interpretation in those
cases was consequently done with care.
In general, all molecules were treated as neutral. Counter ions and salts were removed.
Canonical 3D structures required for global QikProp descriptors were generated using the
program Corina (
52,53). This data set, which encompasses multiple chemical series from
internal projects, was divided into a training set of 1100 representative structures and 238
molecules as test set using statistical design. To this end, 2D fingerprints were computed
using the program UNITY (
54 ) and used for compound selection using a maximum
dissimilarity approach (
44,55,56).141
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For constructing a classification models, the activity of the molecules was mapped to 0 and 1
depending on the experimental IC50 value. Compound with an IC50 value of 10 µM or higher
were marked inactive, compounds with lower IC50 values were marked active otherwise.
Every compound was represented by a fingerprint of three-point pharmacophores (3PP),
derived from their 2D structure using the standard MOE fingerprint implementation (
36) or by
a collection of substructure, topological pharmacophore and physicochemical descriptors (see
below). The individual 3PP fingerprint is a triangle of atoms with specific pharmacophore
properties assigned to them (
57). We consider all possible triangles with their vertexes located
at the atom centres of a molecule. Presence or absence of a certain triangle defines the “1”
(i.e., bit is set) or “0” state of the corresponding bit in the fingerprint. We distinguished
triangles by the type of atom at vertexes and by the length of their edges. The vertex can be
either donor (D), acceptor (A), polar (P), donor and planar (Dpl), acceptor and planar (Apl),
hydrophobic (H) and hydrophobic and planar (Hpl) as defined by the atom-type implemented
in the software suite MOE, version 2004.03. Lengths of the edges were calculated along the
molecular graph, so no estimation of the 3D structure of molecule was performed.
The second descriptor collection (CMQA) encompasses 163 substructure keys implemented
in Sybyl/SLN following the MACCS key definitions (
39), 150 topological pharmacophore
descriptors implemented in Sybyl based on the CATS pharmacophore correlation over 2D
molecular graph (
40), computed pKa values for basic and acidic groups derived from
ACD/Labs (
41) and a collection of surface based descriptors computed using QikProp (
42).
This collection was useful in other projects for deriving significant statistical models for
multiple properties. Those descriptors were analysed using PLS (partial least squares) (
43), as
implemented in Sybyl, and SVM (see below). PLS allows deriving a linear relationship for
highly underdetermined matrices. Again, crossvalidation (
58) is used to check for consistency
and predictivity of the resulting models.
To additionally validate the resulting statistical models, another dataset analysed by Afzelius
et al. was used (
29,30). For this collection of compounds with 34 active and 49 inactive
molecules, Ki values for CYP2C9 inhibition have been measured using a CYP2C9 assay at
AstraZeneca (
29). However, we classified those compounds as active or inactive to compare
these results with our model based on a different biological assay. Another internal dataset
comprised 344 representative samples from a focussed library for GPCR targets on a limited
number of chemotypes. IC50 values were determined using the same protocol as for the main
reference set of 1100 training and 238 test set compounds.142
Publications
16
Flexible docking of selected compounds into the CYP2C9 binding site from the PDB file
1OG5 was done using the Monte-Carlo based mcdock algorithm implemented in QXP version
2.0 (
48) starting from different input poses to achieve convergence to a most likely binding
pose. Selected protein side chains at the inhibitor binding site were treated as flexible based
on the comparative analysis of other public CYP2C9 X-ray structures.
4.2. Support Vector Machine
Two different algorithms for regression and classification are in general available for training
of the support vector machine. In both cases SVM constructs a surface in the n-dimensional
space that in case of classification separates active from inactive compounds and in case of
regression predicts the pIC50 value (
37). Here n is the number of parameters that were used to
describe a molecule. Prior to construction of the hyperplane the data is mapped to a very high-
dimensional space, where this surface is found in a form of a plane. This plane is then mapped
backed to the original space. The result of the SVM training for both classification and
regression can be given by the following equation (Eq. 1).
b K f
i
sv
i i + = ) , ( ) ( x x x α , where ) , ( y x K is a kernel function (1)
For building a classification model, f(x) gives prediction of the value related to the probability
of the molecule to be active, i.e. the greater the value of f, the higher is the probability for this
molecule to be active. For the SVM regression case, f(x) corresponds to the pIC50 value to be
predicted. The sum in equation (1) runs over the employed support vectors as part of the
training set. x and y represent vectors of molecular features, x
sv are support vectors, i.e.
vectors that define the exact shape of the separating hyperplane. Parameters ai and b were
determined during SVM training as described (
35). For constructing SVM models, the SVM-
light package was used (
37). The kernel function K defines the complexity of the surface that
will be constructed. Different standard kernels can be used during SVM training (
46).
We used the following kernel functions:
) ( ) , ( y x y x • = K , for 3PP fingerprints (2)143
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While a large number of 10
5 different 3PP fingerprints were used to describe individual
molecules, only a small portion of them was relevant for deriving the final models. It was
unlikely that the use of a non-linear kernel in this case would significantly improve prediction
results. In contrast, the use of a non-linear kernel function resulted in significantly lower
prediction quality (results not shown), most likely due to the introduction of noise by
considering non-linear dependency of relevant and irrelevant features together. For the final
models with CMQA descriptors condensing structural and physicochemical information, we
used a fifth-order polynomial kernel for SVM instead:
5 ) 1 ) (( ) , ( + • = s K y x y x (3)
This fifth order polynomial kernel is known to construct a surface to predict sufficiently
complex non-linear dependencies. (
32) Kernel parameter s was optimized to achieve better
ranking of compounds as described.(
35)
4.3. Pharmacophore Visualization
Potential pharmacophore models of the inhibitors were visualized by showing to which extent
certain atom is important for favourable or unfavourable protein-ligand interactions. The
importance Ri of each 3PP feature was calculated based on the change of the SVM prediction
for a molecule with this feature removed (Eq. 4).
)) 0 ( ( )) 1 ( ( = − = = i i i F f F f R x x . (4)
Here x is a fingerprint representation of a molecule with presence or absence of feature Fi.
Then, each atom contributing to feature Fi received the weight Ri. The importance of every
atom was estimated as an averaged sum of the 3PP features, which included this atom as one
of the vertexes.
When considering separately negatively and positively contributing features, summation was
done independently for corresponding contributing 3PP features. It allows independent
visualization of features favourable and unfavourable for the interaction with CYP2C9.144
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Figure Legends
Figure 1. Graph of predicted versus experimental pIC50 values for three statistical models
with splitting into training and test subsets. a) and b) graphs for training and test subsets for
linear SVM model based on 3PP fingerprints. c) and d) same graphs for non-linear SVM with
5-order polynomial kernel and CMQA descriptors. e) and f) PLS models with CMQA
descriptors and similar splitting into training and test subsets.
Figure 2. Interpretation of the chemical features predicted by SVM to be important for
interaction with CYP2C9. The diameter of a sphere near the feature indicates its relative
importance for the final model (green favourable to interaction, blue unfavourable). Larger
spheres indicate features with higher importance. a) IC50 = 4.4 µM, pIC50 = 2.36, predicted
pIC50 = 2.52. b) less active as 1; IC50 = 30 µM, pIC50 = 1.52, predicted pIC50 = 1.78. Arrows
mark chemical groups that according to SVM contribute to the different affinity of these
compounds to CYP2C9. The replacement of chlorine by fluorine at the aromatic ring was
predicted to reduce CYP2C9 affinity. The same effect is observed, when a bulkier group
replaces the lipophilic substituent of compound 1. c) IC50 = 0.74 µM, pIC50 = 3.13, predicted
pIC50 = 2.56. d) IC50 = 1.0 µM, pIC50 = 3.00, predicted pIC50 = 3.13.
Figure 3. Docking of the compound 3 (IC50 0.74 µM) into the active site of CYP2C9. The
pivotal role of the imidazole ring of this compound is obvious due to the interaction with the
heme.
Figure 4. Related compounds similar to 1-4. For these compounds the imidazole ring is also
crucial for the interaction with CYP2C9. Their aromatic rings can adopt similar
conformations as assumed for 1-4 in complex with CYP2C9. a) IC50 = 0.74 µM, pIC50 = 3.13,
predicted pIC50 = 2.56. b) IC50 = 0.74 µM, pIC50 = 3.13, predicted pIC50 = 2.56. c) IC50 = 0.74
µM, pIC50 = 3.13, predicted pIC50 = 2.56.
Figure 5. X-ray crystal structure of S-warfarin in complex with CYP2C9 in comparison to
features contributing to the final SVM model. a) Protein-ligand interactions between the
binding site of CYP2C9 and S-warfarin from the X-ray crystal structure (PDB code 1OG5) b)
Chemical formula of S-warfarin. c) Indication of the relative importance of S-warfarin
features to CYP2C9 interaction. Larger spheres indicate features with higher relative
importance.
Figure 6. Molecular features important for inhibition of CYP2C9 for miconazole (a) (Ki = 6
µM) and acebutalol (b) (inactive), as estimated from analysis of the SVM model.146
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Figure 7. Molecular features important for inhibition of CYP2C9. Features favourable for
CYP2C9 inhibition are indicated by green spheres, features detrimental for affinity are
indicated as blue spheres. The size of the sphere indicates its relative importance. a)
Compound 11 IC50 = 1.0 µM, pIC50 = 3.0, predicted pIC50 = 2.8. b) Compound 12 IC50 = 5.0
µM, pIC50 = 2.3, predicted pIC50 = 2.4. c) Compound 13 IC50 = 30.0 µM, pIC50 = 1.52,
predicted pIC50 = 1.68.147
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Table 2. Performance of individual statistical models on outliers. Number of false positive
and false negatives for test data set (238 compounds) and GPCR-targeted library. Prior to
analysis the all compounds were mapped to active (IC50 < 10 µM) or inactive (IC50 > 10 µM)
based on measured IC50values.
Model Test 238
false pos.
[d]
Test 238
false neg.
[d]
GPCR
false pos.
[e]
GPCR
false neg.
[e]
GPCR
fitted <q
2>
[f]
SVM 3PP
(linear regr.)
[a]
14 (6 %) 38 (16 %) 18 (5 %) 84 (24 %) 0.362
SVM CMQA
(nonlin. regr.)
[b]
14 (6 %) 44 (18 %) 2 (1 %) 98 (28 %) 0.452
PLS CMQA
[c] 7 (3 %) 52 (22 %) 18 (5 %) 91 (26 %) 0.412
[a], [b] and [c] models correspond to models a, c and d from Table 1. [d] This set is the same
set (238 compounds) that was used as a test set for models a, c and d from Table 1. [e] 334
compounds from GPCR–targeted library, IC50 for them were measured at slightly different
conditions as for the Aventis dataset of 1338 compounds that we used most of the time. [f] The
predicted pIC50 for GPCR –targeted library from all three models was linearly fit to the
measured pIC50 to compensate for the assay differences in measuring IC50 for GPCR-targeted
library and 1100 training compounds of these three models.150
Publications
24
Figure 2.
a)
b)
Apl
Hpl
Hpl
P
H
H
H
H
Hpl
Hpl
Apl P
H
H
H
H H
H
H
N
N
F
OH
N
N
Cl
OH
1
2151
Publications
Apl
Hpl
Hpl
Hpl A
Hpl
Hpl
Apl
Hpl
c)
d)
Apl
H
Hpl
Hpl P
Hpl
Hpl
O
N
N
N
N
HO
N
N
Cl
3
4152
Publications
Figure 3153
Publications
27
Figure 4
N
N
CF3
S
O O
N
N
S
O O
Cl Cl
CO2Me
N
N
N
S
O O
CO2Me
Cl Cl
5 6 7154
Publications
O O
OH
O
Phe 476
Phe 114
Phe 100
Ala 103
Heme
Figure 5
a) b)
c)
Hpl
Hpl
Hpl
Ppl
H
Apl
Apl
8155
Publications
29
Figure 6
a)
b)
9
O
Cl
Cl
Cl
Cl
N
N
10
Hpl
Hpl
Hpl
Apl
H
H
A
H
H
H H
P
P
Hpl
Apl
Apl
H
H
Dpl
H
H
O
N H
O
NH
O
OH
NH156
Publications
F
i
g
u
r
e
7
.
a
)
b
)
N
H
2
O
O
M
e
O
C
l
C
l
O
N
H
N
N
N
H
O
O
M
e
O
C
l
C
l
O
N
H
N
N
H
H
H
p
l
H
H
p
l
A
p
l
D
p
l
H
A
p
l
D
p
l
H
H
p
l
A
p
l
H
H
H
p
l
H
H
p
l
A
p
l
D
p
l
A
p
l
D
p
l
H
H
p
l
A
p
l
1
1
1
2157
Publications
3
1
c
)
H
H
H
p
l
H
H
p
l
A
p
l
P
p
l
H
A
p
l
D
p
l
H
H
p
l
A
p
l
H
H
H
p
l
H
H
p
l
A
p
l
P
p
l
H
A
p
l
D
p
l
H
H
p
l
A
p
l
H
1
3
O
M
e
O
C
l
C
l
O
N
H
N
N
O
M
e158
Publications
References
1 Smith, D.A.; Ackland, M.J.; Jones, B.C. Properties of cytochrome P450 isoenzymes and
their substrates. Part 1: Active site characteristics. Drug Disc. Today 1997, 2, 406-414.
2 Transon, C.; Leemann, T.; Vogt, N.; Dayer P. In vivo inhibition profile of cytochrome
P450tb (CYP2C9) by (()-fluvastatin. Clin. Pharmacol. Ther. 1995, 58, 412-417.
3 Poli-Scaife, S.; Attias, R.; Dansette, P.M.; Mansuy, D. The substrate binding site of human
liver cytochrome P4502C9: An NMR study. Biochemistry 1997, 36, 12672 12682.
4 Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and stereoselective
metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharm. 1997, 54, 33-41.
5 Miners, J. O.; Coulter, S.; Tukey, R. H.; Veronese, M. E.; Birkett, D. J. Cytochromes P450,
1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.
Biochem. Pharmacol. 1996, 51, 1003-1008.
6 Tracy, T. S.; Marra, C.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Studies of 4'-
hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
Biochem. Pharmacol. 1996, 52, 1305-1309.
7 Wester, M.R.; Yano, J.K.; Schoch, G.A.; Yang, C.; Griffin, K.J.; Stout, C.D.; Johnson, E.F.
The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å
resolution. J. Biol. Chem. 2004, 279, 35630-35637.
8 Hall, S.D.; Hamman, M.A.; Rettie A.E.; Wienkers, L.C.; Trager W.F.; VandenBranden M
and Wrighton S.A. Relationships between the levels of cytochrome P4502C9 and its
prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 1994, 22,
975-977.
9 Li, H.; Poulos, T.L. Conformational dynamics in cytochrome P450-substrate interactions.
Biochimie 1996, 78, 695-699.
10 Li, H.; Poulos, T.L. The structure of the cytochrome P450 BM-3 haem domain complexed
with the fatty acid substrate, palmitoleic acid. Nature Struct. Biol. 1997, 4, 140-146.
11 Schlichting, I.; Jung, C.; Schulze H. Crystal structure of cytochrome P-450cam complexed
with the (1S)-camphor enantiomer. FEBS Lett. 1997, 415, 253-257.
12 Podust, L.M.; Poulos, T.L.; Waterman, M.R. Crystal structure of cytochrome P450 14α-
sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole
inhibitors. Proc. Natl. Acad Sci. U.S.A. 2001, 98, 3068-3073.
13 Williams, P.A.; Cosme, J.; Sridhar, V.; Johnson, E.F.; McRee, D.E. Mammalian
microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding
and functional diversity. Mol. Cell. 2000, 5, 121-131.
14 Williams, P.A.; Cosme, J.; Ward, A.; Angove, H.C.; Vinkovic, D.M.; Jhoti, H. Crystal
structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, 464-468.
15 Scott, E.E.; He, Y.A.; Wester. M.R.; White, M.A.; Chin, C.C.; Halpert, J.R.; Johnson, E.F.;
Stout, C.D. An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution.
Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13196-13201.
16 Scott, E.E.; White, M.A.; He, Y.A.; Johnson, E.F.; Stout, C.D.; Halpert, J.R. Structure of
Mammalian Cytochrome P450 2B4 Complexed with 4-(4-Chlorophenyl)imidazole at 1.9-Å
resolution. J. Biol. Chem. 2004, 279, 27294-27301.
17 Schoch, G.A.; Yano, J.K.; Wester, M.R.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. Structure
of Human Microsomal Cytochrome P450 2C8. J. Biol. Chem. 2004, 279, 9497-9503.159
Publications
33
18 Yano, J.K.; Wester, M.R.; Schoch, G.A.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. The
Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray
Crystallography to 2.05-Å Resolution. J. Biol. Chem. 2004, 279, 38091-38094.
19 Williams, P.A.; Cosme, J.; Vinkovic, D.M.; Ward, A.; Angove, H.C.; Day, P.J.; Vonrhein,
C.; Tickle, I.J.; Jhoti, H. Crystal Structures of Human Cytochrome P450 3A4 Bound to
Metyrapone and Progesterone. Science 2004, 305, 683-686.
20 Jones, B.C.; Hawksworth, G.; Horne, V.A.; Newlands, A.; Tute, M.; Smith, D.A. Putative
active site model for CYP2C9 (tolbutamide hydroxylase). Br. J. Clin. Pharmacol. 1993, 34,
143-144.
21 Jones, B.C.; Hawksworth, G.; Horne, V.A.; Newlands, A.; Morsman, J.; Tute, M.S.; Smith,
D. A. Putative active site template model for cytochrome P450 2C9 (tolbutamide
hydroxylase). Drug Metab. Dispos. 1996, 24, 260-266.
22 Mancy, A.; Broto, P.; Dijols, S.; Dansette, P.M.; Mansuy, D. The substrate binding site of
human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and
molecular modelling. Biochemistry 1995, 34, 10365-10375.
23 Morsman J.M.; Smith D.A.; Jones B.C. and Hawksworth G.M. (1995) Role of hydrogen-
bonding in substrate structure-activity relationships for CYP2C9. In Proceedings of the 4th
International ISSX Meeting; Seattle, Washington, USA, 1995; pp. 259-261.
24 Klose, T.S.; Ibeanu, G.C.; Ghanayem, B.I.; Pedersen, L.G.; Li, L.; Hall, S.D.; Goldstein,
J.A. Identification of residues 286 and 289 as critical for conferring substrate specificity of
human CYP2C9 for diclofenac and ibuprofen. Arch. Biochem. Biophys. 1998, 357, 240-248.
25 De Groot, M.J.; Alex, A.A.; Jones, B.C. Development of a combined protein and
pharmacophore model for cytochrome P450 2C9. J. Med. Chem. 2002, 45, 1983-1993.
26 Jones, J.P.; He, M.X.; Trager, W.F.; Rettie, A.E.; Three-Dimensional Quantitative
Structure-Activity Relationship For Inhibitors of Cytochrome P450 2C9. Drug Metab. Dispos.
1996, 24, 1-6.
27 Rao S.; Aoyama R.; Schrag, M.; Trager, W.F.; Rettie, A.; Jones, J.P. A Refined 3-
Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug
Interactions. J. Med. Chem. 2000, 43, 2789-2796.
28 Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J.S.; Ring, B.J.; Wikel, J.H.; Wrighton, S.A.
Three and four dimensional-quantitative structure-activity relationship (3D/4D-QSAR)
analyses of CYP2C9 inhibitors. Drug Metab. Dispos. 2000, 28, 994-1002.
29 Afzelius, L.; Masimirembwa, C.M.; Karlén, A.; Andersson T.B.; Afzelius, I.; Discriminant
and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using
alignment independent GRIND descriptors. J. Comp. Aided Mol. Des. 2002, 16, 443-458.
30 Afzelius, L.; Afzelius, I.; Masimirembwa, C.M.; Karlén, A.; Andersson T.B.; Mecucci, S.;
Baroni, M.; Cruciani, G. Conformer- and Alignment-Independent Model for Predicting
Structurally Diverse Competitive CYP2C9 Inhibitors. J. Med. Chem. 2004, 47, 907-914.
31 Zuegge, J.; Fechner, U.; Roche, O.; Parrott, N.J.; Engkvist, O.; Schneider, G. A fast virtual
screening filter for cytochrome P450 3A4 inhibition liability of compound libraries. Quant.
Struct.-Act. Relat. 2002, 21, 249-256.
32 Cortes C, Vapnik V. 1995. Support-Vector Networks. Machine Learning, 20:273-297.
33 Cristianini N, Shawe-Taylor J. 2000. An Introduction to Support Vector Machines and
Other Kernel-based Learning Methods. Cambridge: Cambridge University Press.
34 Byvatov E., Schneider G. SVM applications in bioinformatics. Appl. Bioinformatics. 2003;
2(2):67-77.
35 Byvatov, E.; Fechner, U.; Sadowski, J.; Schneider, G. Comparison of Support Vector
Machine and Artificial Neural Network Systems for Drug/Nondrug Classification. J. Chem.
Inf. Comput. Sci. 2003, 43, 1882-1889.160
Publications
34
36 MOE 2004.03, CCG, 1010 Sherbrooke St. West, Suite 910, Montreal, Quebec, H3A 2R7,
Canada.
37 T. Joachims, Making large-Scale SVM Learning Practical. Advances in Kernel Methods -
Support Vector Learning, B. Schölkopf and C. Burges and A. Smola (ed.), MIT-Press, 1999
38 Byvatov, E.; Schneider, G. Support Vector Machine based Feature Selection for
Characterization of Focused Compound Collections. J. Chem. Inf. Comput. Sci. 2004, 44,
993-999.
39 Internal implemented in Sybyl / SLN (Version 6.9, Tripos Inc., 1699 S. Hanley Road, St.
Louis, MO 63144, USA.) following the documentation in ISIS/Base 2.1.3., Molecular Design
Ltd, 14600 Catalina Street, San Leandro, CA 94577, USA.
40 a) Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. „Scaffold-hopping“ by topological
pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 1999,
38, 2894-2896.
b) Internal implementation in Sybyl (Version 6.9, Tripos Inc., 1699 S. Hanley Road, St. Louis,
MO 63144, USA.)
41 ACD/logD Suite, ACD/Labs, 33 Richmond St. West, Suite 605, Toronta, ON MSH 2L3,
Canada.
42 a) Duffy, E.M.; Jorgensen, W.L. Prediction of Properties from Simulations: Free Energies
of Solvation in Hexadecane, Octanol, and Water. J. Am. Chem. Soc. 2000, 122, 2878-2888.
b) QikProp Version 2.0, Schrödinger, Inc. 1500 S.W. First Avenue, Suite 1180, Portland OR
97201, USA.
43 a) Wold, S.; Albano, C.; Dunn, W.J.; Edlund, U.; Esbenson, K.; Geladi, P.; Hellberg, S.;
Lindberg, W.; Sjöström, M. In Chemometrics: Mathematics and Statistics in Chemistry;
Kowalski, B., Ed., Reidel, Dortrecht, The Netherlands, 1984, pp 17-95.
b) Dunn, W.J.; Wold, S.; Edlund, U.; Hellberg, S.; Gasteiger, J. Multivariate Structure-
Activity Relationship Between Data from a Battery of Biological Tests and an Ensemble of
Structure Descriptors: The PLS Method. Quant. Struct.-Act. Relat. 1984, 3, 31-137.
c) Geladi, P. Notes on the History and Nature of Partial Least Squares (PLS) Modelling. J.
Chemom. 1988, 2, 231-246.
44 Pötter, T.; Matter, H. Random or Rational Design ? Evaluation of Diverse Compound
Subsets from Chemical Structure Databases. J. Med. Chem. 1998, 41, 478-488.
45 R. O. Duda, P. E. Hart, D. G. Stork, Pattern Classification, Wiley-Interscience, New York,
2000.
46 Burges CJC. 1998. A Tutorial on Support Vector Machines for Pattern Recognition. Data
Mining and Knowledge Discovery, 2:121-167.
47 Lewis, D.F.V. On the recognition of mammalian microsomal cytochrome P450 substrates
and their characteristics: towards the prediction of human P450 substrate specificity and
metabolism. Biochem. Pharmacol. 2000, 60, 293-306.
48 McMartin, C.; Bohacek, R.S. QXP: powerful, rapid computer algorithms for structure-
based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
49 Bush, B.L.; Sheridan, R.P. PATTY: A Programmable Atom Typer and Language for
Automatic Classification of Atoms in Molecular Databases. J. Chem. Info. Comp. Sci. 1993,
33, 756-762.
50 Lewis, D.F.V. Quantitative structure activity relationships (QSARs) for substrates of
human cytochromes P450 CYP2 family enzymes. Toxicology in Vitro 2004, 18, 89-97.
51 Jorgensen, W.L.; Duffy, E.M. Prediction of drug solubility from Monte Carlo simulations.
Bioorg. Med. Chem. Lett. 2000, 10, 1155-1158.
52 Sadowski, J.; Rudolph, C.; Gasteiger, J. The generation of 3D models of host-guest
complexes. Anal Chim Acta 1992, 265, 233-241.161
Publications
35
53 Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of automatic three-dimensional model
builders using 639 X-ray structures. J. Chem. Inf. Comp. Sci. 1994, 34, 1000-1008.
54 UNITY Version 4.4, Tripos Inc., 1699 S. Hanley Road, St. Louis, MO 63144, USA.
55 Lajiness, M.; Johnson, M.A.; Maggiora, G.M. Implementing Drug Screening Programs
using Molecular Similarity Methods. In: QSAR: Quantitative Structure-Activity Relationships
in Drug Design; Fauchere, J.L., Ed.; Alan R. Liss Inc.: New York, USA, 1989; pp 173-176.
56 Taylor, R. Simulation Analysis of Experimental Design Strategies for Screening Random
Compounds as Potential New Drugs and Agrochemicals. J. Chem. Inf. Comput. Sci. 1995, 35,
59-67.
57 Sheridan, R.P., Miller, M.D., Underwood, D.J., Kearsley, S.K. Chemical Similarity Using
Geometric Atom Pair Descriptors. J. Chem. Inf. Comput. Sci. 1996, 128-136.
58 a) Wold, S. Cross-Validatory Estimation of the Number of Component in Factor and
Principal Component Models. Technometrics 1978, 4, 397-405.
b) Diaconis, P.; Efron, B. Computer-Intensive Methods for Statistics. Sci. Am. 1984,116, 96-
117.
c) Cramer, R.D.; Bunce, J.D.; Patterson, D.E. Crossvalidation, Bootstrapping and Partial
Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant.-
Struct.-Act. Relat. 1988, 7, 18-25.162
Publications
7.7 Extraction and visualization of pharmacophore
models by SVM
Byvatov E., Franke L., Werz O., Steinhilber D., Schneider G.
J Med Chem submitted163
Publications
Byvatov et al. 1
Extraction and visualization of pharmacophore models
using Support-Vector-Machines
Evgeny Byvatov
1, Lutz Franke
1, Oliver Werz
2, Dieter Steinhilber
2, Gisbert Schneider
1,*
1Johann Wolfgang Goethe-Universität
Institut für Organische Chemie und Chemische Biologie
Marie-Curie-Str. 11
D-60439 Frankfurt, Germany
2Johann Wolfgang Goethe-Universität
Institut für Pharmazeutische Chemie
Marie-Curie-Str. 9
D-60439 Frankfurt, Germany
* send all correspondence to:
Prof. Dr. Gisbert Schneider, Institut für Organische Chemie und Chemische Biologie, Marie-
Curie-Str. 11, D-60439 Frankfurt, Germany
Tel: +49 (0)69 79829821
Fax: +49 (0)69 79829826
Email: gisbert.schneider@modlab.de
SUBMITTED FOR THE JANSSEN MEMORIAL ISSUE164
Publications
Byvatov et al. 2
Abstract
In this article we constructed pharmacophore models for cyclooxygenase 2 (COX-2)
and thrombin inhibitors. These models resulted from Support Vector Machine (SVM)
training. They were further evaluated by estimating enrichment factors obtained from virtual
screening of a database containing ~2.7×10
6 commercially available compounds. 50-90%
percent of the known active compounds were listed within the first 0.1% of the ranked
database. It is shown that different binding modes, interchangeability of functionally
equivalent features and the possibility to fuse features from different ligands are represented
within the models. For this study the molecules were encoded by topological three-point
pharmacophores. In order to check the validity of the constructed SVM models we developed
a method for feature extraction and visualization using SVM. As a result, features were
weighted according to their importance for COX-2 and thrombin inhibition. Well known
thrombin and COX-2 pharmacophore points were recognized by the machine learning system.
Different binding modes for thrombin were correctly predicted by SVM. Finally several
prospective COX-2 inhibitors were tested in vitro and shown to be active. Their docked
structures with the visualized SVM pharmacophore confirm the identification of relevant
features.
Key words
Classification / Enrichment factor / Thrombin / Cyclooxygenase / Prediction / SVM / Virtual
screening165
Publications
Byvatov et al. 3
Introduction
A pharmacophore represents the 3D or 2D arrangements of structural or chemical features of
a drug (small organic compounds, peptides, etc.) that may be essential for interacting with the
receptor for optimum binding.
1 These pharmacophores can be used in different ways in drug
design programs: i) as a query tool in virtual screening to identify potential new compounds
from 3D databases of “drug-like” molecules with patentable structures different from those
already discovered; ii) to predict the activities of a set of new compounds yet to be
synthesized; iii) to understand the possible mechanism of action; (4) to extract potential
privileged structures.
2,3 Currently several algorithms are known that construct pharmacophore
models from a set of available active compounds employing potential pharmacophore points
(PPP), e.g., CATALYST,
4 DISCO,
5 GASP,
6 or field-based approaches.
7,8 The performance of
these methods usually relies on the quality of the initial three-dimensional (3D) alignment of
compounds. This influence of the initial alignment on the quality of the resulting
pharmacophore model can be modulated by considering multiple ligand conformations and
applying “fuzzy” pharmacophore point definitions.
9,10 Here we present a complementary
method for pharmacophore identification that is grounded on the topological three-point
pharmacophore (3PP) concept.
10 The general idea was to avoid a strict dependency of the
pharmacophore model on a 3D alignment. Each molecule was represented as a binary vector,
where each feature corresponds to the presence or absence of a particular pharmacophore
triangle.
11 Such feature vectors were used for construction of a classifier predicting molecules
to have certain biological activity. Subsequent visualization of the features with respect to
their contribution to the model allowed us to create reasonable pharmacophore models.
Support Vector Machines (SVM) were used for both classification and feature extraction.
12-14
For the present study compounds were represented by fingerprints that contained ~10
4
potential 3PP triangles, and we expected SVM to efficiently discriminate between important
and unimportant features and construct reliable and chemically interpretable pharmacophores.
This approach was motivated by the fact that SVM classifiers have been shown to be well-
suited for first-pass virtual screnning purposes.
15-17 Two test cases were selected to evaluate
our new approach, namely the development of SVM classifiers for cyclooxygenase 2 (COX-
2) and thrombin inhibitors.
Data and Methods
Data sets and features
Two subsets of the COBRA database were used for SVM training: thrombin and COX-2
inhibitors.
18 We used these subsets as a reference for ranking ~2.7 million compounds that are
commercially available from different companies. Every compound was represented by a
fingerprint of 3PP pharmacophores using MOE.
19 The individual 3PP pharmacophore is a
triangle. We consider all possible triangles with their vertexes located at the atom centers of a
molecule. Presence or absence of a certain triangle defines one or zero state of the
corresponding bit in the fingerprint. We distinguished triangles by the type of atom at vertexes
and by the length of their edges. The vertex can be either donor (D), acceptor (A), polar (P),
donor and planar (D=), acceptor and planar (A=), hydrophobic (H) and hydrophobic and
planar (H=) as defined by the atom-type implemented in the software suite MOE, version
2004.05.
19 Lengths of the edges were calculated along the molecular graph, so no estimation
of the 3D structure of molecule was performed.166
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Support Vector Machine
The SVM constructs a surface in the n-dimensional space that separates active from inactive
compounds.
20 Here n is the number of 3PP that were used to describe a molecule. Prior to
construction of the separating surface the data is mapped to a very high-dimensional space,
where separating surface is found in a form of a hyperplane. This hyperplane is then mapped
backed to the original space.
21 The result of the SVM training can be given by the following
equation (Eq. 1).
b K f
i
sv
i i + = ) , ( ) ( x x x α , where 5 ) 1 ) (( ) , ( + • = s K y x y x (1)
Here, f(x) gives the prediction of the molecule to be active, i.e. the greater the value of
f the higher is the predicted probability to be active. x and y are molecular fingerprint vectors,
x
sv are support vectors, i.e. molecular fingerprints that define the exact shape of the separating
hyperplane. The kernel function K defines the complexity of the surface that will be
constructed. Different standard kernels can be used during SVM training.
20 We used a fifth
order polynomial for all SVM models. Kernel parameter s was optimized to achieve better
ranking of compounds as described.
15,16
For database screening, we sorted all available compounds with respect to predicted f.
The sum in Equation (1) is over support vectors, they are part of the raining set. As can be
seen the ranking function depends only on the support vectors. Parameters ai and b were
determined during SVM training as described.
22 For constructing SVM models we used the
SVM-light package.
23
Training of the SVM and “Active Learning” Optimization
During SVM training we tried to optimize the percentage of active compounds found within
the top 0.1% percent of the screening database. In order to achieve this we used a standard
four-fold cross-validation procedure.
24 The reference dataset of active compounds was
divided into four parts. Each part in turn was mixed with the ~2.7×10
6 screening compounds.
The rest of the set of known actives and the newly created set of molecules to be screened
were used as training sets and were assigned “class” (known inhibitors) and “nonclass” (all
other molecules) labels for SVM training. After the training the nonclass compounds were
sorted with respect to the f value computed by the SVM classifier. Molecules with higher f
value are expected to be similar to the active compounds. The parameters of SVM were
optimized to achieve a maximum number of “mixed” (i.e. reference molecules that were
added to the pool of screening compounds) active molecules within 0.1% of the ranked data.
We should note that during SVM training “mixed” active compounds were marked as
nonclass molecules, so that validation subsets were not used in training.
The SVM parameters were tuned to have maximum average accuracy of prediction
over all four validation sets. Then the final SVM training was performed using all available
actives (“class”) and all ~2.7×10
6 compounds with unknown activity as a “nonclass”. The
resulting ranking of these compounds by the trained SVM was used to cherry-pick molecules
for in vitro activity testing.
It is computationally very expensive to train an SVM with all available ~2.7×10
6
compounds. To overcome this limitation, SVM training was performed in two steps: first an
SVM was trained with a randomly selected subset containing only 10
5 compounds from the
screening database. In this case the region near the active compounds might be insufficiently
sampled. We therefore used the “active learning” approach to focus on this “relevant” area of
descriptor space.
24 After obtaining the first ranked list of the compounds the SVM training167
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procedure was repeated, now with a sample set consisting of the top-ranking ~10
5
compounds. By this a more fine-tuned SVM classifier was obtained.
Pharmacophore Visualization
Potential pharmacophore models of the inhibitors were visualized by highlighting atoms that
contribute to the most important features. The importance Ri of each 3PP feature was
calculated based on the change of SVM prediction for a molecule when this feature is
removed (Eq. 2).
)) 0 ( ( )) 1 ( ( = − = = i i i F f F f R x x . (2)
Here x is a fingerprint representation of a molecule with presence or absence of
feature Fi. Then, each atom contributing to feature Fi received the weight Ri. However, it is
reasonable to assume that the importance of atoms in a 3PP differs. In order to take this into
account the importance of every atom in the reference set of actives was estimated (Figure 1).
The individual weight w of an atom was estimated as the average weight of all 3PP triangles
that contain this atom as a vertex. Averaging was done twice, i) over the triangles of each
molecule (Figure 1d), and finally ii) over the whole set of actives.
Visualization contrast was enhanced by diminishing the weights w of the atoms in
every 3PP except for the most important one by w
n. We choose n = 10 empirically, as it
produces the best visualization of the core pharmacophore, i.e. the weight of the most
important atom remains equals 1 and all other weights diminished.
[Figure 1]
NH2
O
OH
3
3
2 2
(2+3=5)
Ri = 3
Rj = 2
a) b) c) d)
Figure 1. Calculation of atom weights for feature visualization. The two-dimesnional
molecular structure (a) is converted to the molecular graph representation (b). Then
topological 3PP triangles are assigned (the length of each edge is calculated as the number of
bonds in the molecular graph connecting the two vertices along the shortest path) (c), and the
importance Ri of each triangle is determined by Equation 2. Individual atoms are weighted
proportional to the sum of the Ri values of contributing 3PP features (d).
Selection and Testing of Potential COX-2 Inhibitors
From the SVM-ranked list of the commercially available compounds 13 molecules were
cherry-picked for in vitro activity testing. We excluded compounds that contain reactive
groups and potentially insolvable molecules by visual inspection. Only compounds available
from Specs (Delft, The Netherlands; www.specs.net) were considered (Scheme 1). A COX-2
inhibition assay was performed to evaluate compound activity with diclofenac 14 as a positive
control:
26 MM6 cells were grown with or without transforming growth factor beta (TGFß) and168
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calcitriol for 96 hrs as described.
27 Six hrs prior harvest, lipopolysaccharide (100 ng/ml) was
added. Cells were harvested, washed twice, re-suspended in PGC buffer (phosphate buffered
saline at pH 7.4 containing 1 mg/ml glucose and 1 mM CaCl2) (5 × 10
6 cells/ml) and
incubated with arachidonic acid (30 µM) for 15 min at 37°C. Cells were centrifuged (300 × g,
5 min, 4°C) and the amount of 6-keto PGF1α released was assessed by ELISA using a
monoclonal antibody against 6-keto PGF1α according to the protocol described by Yamamoto
and coworkers.
28,29 For the ELISA, the monoclonal antibody (0.2 µg/200 µl) was coated to
microtiter plates via a goat anti-mouse-IgG antibody. 6-keto PGF1α (15 µg) was linked to
bacterial β-galactosidase (0.5 mg, Calbiochem), and the enzyme activity bound to the
antibody was determined in an ELISA reader at OD550 nm (reference wavelength: 630 nm)
using chlorophenol-red-β-D-galactopyranoside (CPRG, Roche Diagnostics GmbH) as
substrate.
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Scheme 1. Compounds 1-13 were cherry picked by virtual screening and tested for COX-2
inhibition. Reference compounds diclofenac 14, celecoxib 15, rofecoxib 16.
Docking of COX2 inhibitors
For docking of compounds into the COX-2 active site cavity MOE software was used.
19 The
complex of COX-2 with a selective inhibitor Sc-558 (PDB-identifier: 1CX2) served as
reference. Only one of the four identical domains of the COX-2 complex was considered.
Prior to docking hydrogen atoms were added to the protein complex and its structure was
energy minimized keeping positions of all atoms fixed except for the added hydrogens. Partial
charges of the atoms were calculated using MMFF estimation.
30 Docking was performed
using MOE molecular dynamics approximation and Tabu search as described.
31 The results
were evaluated by comparison with the binding mode of the reference inhibitor SC-558.169
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Results and Discussion
SVM classifiers were trained to predict thrombin and COX-2 inhibitors. The accuracy of the
predictions was assessed by retrospective database screening. In the case of the COX-2
classifier, 81 ± 6 % of the reference compounds were retrieved within the first 0.1% of the
ranked database in a cross-validation study. The retrieval of thrombin ligands was less
accurate, yielding 55 ± 14 % of the reference compounds from the first 0.45% of the ranked
database. The small standard deviations in both cases indicate robust prediction models. With
further optimization by active learning we achieve the rate, 81 ± 6 % of the reference
compounds in 0.0031% of the ranked database for COX2 inhibitors and 55 ± 14 % of the
reference compounds from the first 0.083% of the ranked database for Thrombin ligands. This
difference in performance might be explained not only by differences of the two reference
sets and SVM classifier shortcomings, but also by the structural diversity of chemotype-
families that are present in the screening database.
32 Overall, we concluded that the two SVM
classifiers might be useful for generating focused libraries with significant enrichment of
actives compared to a random selection of compounds.
In order to further validate the constructed SVM models we visualized their most
important pharmacophore features. For COX-2 inhibitors a well-known pharmacophore
pattern was highlighted: a constellation of aromatic rings with a sulfonamide group attached
to one of them (Figure 2).
33 It is important to note that the oxygen atoms of sulfonamide were
marked as important for COX-2 inhibition. Sulfonyl and sulfonamide groups are generally
present in COX-2 specific inhibitors.
33 They are known to interact with Arg-513 in the
hydrophilic pocket of the COX-2 active site.
34 Still only the oxygen atoms were marked as
relevant for this interaction in our model and not NH2 group. (Figure 2). This confirms that
SVM is able to extract appropriate pharmacophore points from the set of all potential
pharmacophore points present in a molecule.
N
N F3C
S NH2
O
O
planar
hydrophobe
H-bond
acceptor
[Figure 2]
Figure 2. Essential pharmacophore points (shaded circles) identified by SVM for the COX-2
selective inhibitor celecoxib 15. The size of the pharmacophore points reflect their relative
contribution (weight) to the SVM classifier.
The COX-2 pharmacophore pattern is relatively simple, and most of the active
molecules contain a relatively small number of features. In contrast, thrombin inhibitors
represent more complex molecules, and their pharmacophore pattern contains more
interaction points.
35,36 Figure 3 shows suggested thrombin pharmacophore points extracted by
the corresponding SVM classifier for one of the compounds that were selected from the
screening database. We can clearly see the guanidinium moiety potentially binding to Asp189
at the bottom of the specificity pocket P1 of thrombin.
37 It is interesting to note that not all
atoms of the arginine side-chain are considered important by SVM. This is exactly what one
would expect, as several arginine-analogues have been identified that bind in the same or a
similar mode to the P1 pocket.
38 We conclude that the SVM classifier correctly captured a170
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pharmacophore motif reflecting the preferred molecular fragments binding to the thrombin
P1-pocket. It was probably achieved by selecting 3PP feature triangles with amines at the
vertexes and relatively long edges which correspond to the arginine side chain. H-bonding to
the Gly216 backbone was also accurately predicted as one of the crucial interaction sites
(Figure 3d). An interesting property of the SVM model is illustrated by analyzing another
compound that was predicted to be potential thrombin inhibitor. Structure 19 represents a
pattern of pharmacophore features that might correspond to a different binding mode than that
of NAPAP-inhibitors. The binding modes of NAPAP 17 and argatroban
41 20 are shown in
Figure 4. It seems reasonable to assume that compound 19 might adopt an argatroban-like
binding mode. The guanidium group has the potential to form hydrogen-bonds with Asp189,
and binding to Gly216 could be similar as for argatroban. This assumption is supported by the
SVM model which considers the essential pharmacophore points as most important (Figure
4). From this entirely theoretical consideration we concluded that both binding patterns,
argatroban-like and NAPAP-like, were contained in the SVM model resulting in an
interpretable prediction of functional groups that might form key interactions with the target
enzyme.
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[Figure 3]
Figure 3. a) Most important interactions between NAPAP
39 17 and thrombin (adapted from
ref. 40); b) structure of a NAPAP-like compound 18 that was predicted to be a potential
thrombin inhibitor by the SVM classifier; with all potential pharmacophore points (c), and the
corresponding weights assigned by the SVM feature extraction procedure (d). The crucial
pharmacophore pattern of the NAPAP-thrombin complex were automatically identified by the
feature extraction method.171
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Figure 4. Complex of NAPAP 17 (green; PDB identifier: 1DWD) and agartroban 20
(magenta; PDB identifier: 1DWC) with thrombin. The ligands were superimposed according
to the emzyme coordinates. Molecule 19 represents a predicted thrombin inhibitor.
Pharmacophore features are highlighted that were considered “important” by the SVM
classifier.
As a first practical validation of our prediction results and the validity of the SVM
approach we tested potential COX-2 inhibitors in an in vitro binding study. We chose this
application for the simple reason that the SVM model of COX-2 inhibitors was more accurate
than our thrombin classifier. Structures 1-13 were tested for COX-2 inhibition with diclofenac
14 as positive reference. We selected a set of compounds which contain both known motifs of
COX-2 ligands, and potentially novel architectures in order to find potentially new
chemotypes (Scheme 1). Compounds 4, 5, and 7 exibited activity in the binding assay (Figure
5). Docking of 5 into the active site pocket of COX-2 essentially revealed a similar binding
mode to SC-558,
42 a selective COX-2 inhibitor (Figure 5). Although the compounds are less
active as diclofenac they might be further improved and used to obtain potential lead
structures. A promising observation is the strong similarity between compounds 5 and 7 and
the known COX-2 inhibitors celecoxib 15 and rofecoxib 16.
43,44 Certainly, selectivity of
COX-2 over COX-1 inhibition should be investigated and considered for future designs.
Again, for this task our SVM approach could be used to develop an additional COX-1
classifier and employed for i) cherry-picking COX-2 selective inhibitors, and ii) identification
of enzyme subtype-specific pharmacophore points. Irrespective of the outcome of such
experiments, this study demonstrated that SVM pharmacophore models can be employed for
identification of promising candidates for subsequent activity testing, and visualized
pharmacophore patterns coincided with known binding models of thrombin and COX-2
inhibitors. The SVM classifiers produced a quantitative ranking of substructural elements
which can be used as a guidedance for further hit and lead structure profiling. It was shown172
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that machine-learning methods can be used in virtual screening and be analyzed in a human-
interpretable way that results in a set of rules for designing novel molecules.
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[Figure 5]
Figure 4. a) Results of the COX-2 binding assay. Diclofenac 14 served as a positive control.
Structures 4, 5, and 7 exibited slight activity. AA: arachidonic acid. b) Superposition of the
coordinates of SC-558 (blue; from PDB entry 1CX2) and compound 5 (red) which was
docked into the COX-2 active site. The two molecules have essentially the same binding
mode.
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Abstract
In this work we illustrate application of the active learning concept to the virtual
screening of the very large datasets that contain typically a few millions of molecules. In
comparison to the screening without active learning the efficiency of the virtual screening
improves approximately several ten-folds. To illustrate the general applicability of the
methods we applied to the selection of compounds that have various biological activities.
We considered molecules that have binding activity to the following targets: ACE
(angiotensin converting enzyme), COX2 (cyclooxygenase 2), CRF (corticotropin
releasing factor) antagonists, DPP (dipeptidylpeptidase) IV, HIV (human
immunodeficiency virus) protease, hormones , NK (neurokinin receptors), PPAR
(peroxisome proliferator-activated receptor), thrombin, GPCR and matrix
metalloproteinase. Active learning did not perform equally well for all these compounds.
In the discussion we tried to explain it by discussing pharmacophore models for the
above listed group of molecules.178
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Introduction
During lead based drug design new compounds are selected from the very large
dataset of available compounds based on the similarity to the original reference set of the
active compounds. This reference set of active compounds consists of the molecules that
have been tested to have the biological activity of interest. The aim of the similarity
search is to pick up compounds which are sufficiently similar to the active set to still
preserve biological activity, but on the other hand different enough to have different,
better ADME profile, Marcush structure,[] different from patent defended compounds or
different cross-reactivity profile. In other words we should try to find “new” chemical
molecules that have desired biological activity. For this purpose definition of the
similarity measure and activity region in the chemical space are playing a crucial role in
virtual screening.
Similarity might be defined differently through various heuristics or by training
learning machine. In the latter case learning machine predicts similarity of the molecule
at question to the reference set of active molecules. We expect this to be more exact than
heuristic definition of the similarity since it defines similarity measure by maximizing
correct prediction of similar compounds during training of the learning machine.
1 The
learning machine itself is trained for the class/nonclass binary classification. Here, the
class is all active molecules, and non-class is a sample set from available compounds for
which biological activity is not known. This is a classical approach to lead based drug
design. Here we suggest its improvement by application of active learning.
The efficiency of the lead based drug design can be significantly improved if the
training set can be selected from molecules laying close to the reference set; it will allows
better sampling of the important region of the chemical space at the border of the set of
active compounds. We achieved this better sampling by application of the active learning.
The learning machine, in our case SVM, was trained twice, once with randomly selected
non-class training set and then with the non-class set selected from the molecules within
the margin near the active/inactive separating hyperplane constructed during first training
of the SVM.
Active Learning was applied to the twelve subsets from COBRA [] database
which includes ligands for several popular target for drug design: ACE (angiotensin
converting enzyme),[] CRF (corticotropin releasing factor) antagonists,[] DPP
(dipeptidylpeptidase) IV,[] HIV (human immunodeficiency virus) protease,[] hormones, []
NK (neurokinin receptors),[] PPAR (peroxisome proliferator-activated receptor),[]
thrombin, GPCR and matrix metalloproteinase.[]
Twelve subsets from COBRA database cover large variety of possible sets of
active molecules. For instance, GPCR inhibitors include very different molecules that
interact with a large number of targets; on the other hand CRF inhibitors have only a few
targets. Some classes are relatively big, there is 118 NK inhibitors, 211 hormone
inhibitors; others are smaller there is only 44 ACE inhibitors. Significant differences
between types of active reference sets allow us to validate active learning strategy in
different conditions.179
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Datasets and Methods
Datasets
As a reference set of active compounds we used 44 ACE (angiotensin converting
enzyme), 94 COX2 (cyclooxygenase-2), 63 CRF (corticotropin releasing factor)
antagonists, 25 DPP (dipeptidylpeptidase) IV, 58 HIV (human immunodeficiency virus)
protease, 211 hormones , 118 NK (neurokinin receptors), 35 PPAR (peroxisome
proliferator-activated receptor), 188 thrombin, 1642 GPCR and 77 matrix
metalloproteinase ligands from COBRA database.[] Our screening collection –
compounds that we virtually screened - contained ~ 2.6*10
6 compounds: 117948
compounds from ASDI,
2 896444 compounds from Ambinter,
3 305765 from Asinex,
4
71488 from ChemStar,
5 335559 from Chembridge,
6 108872 from Chemdiv,
7 83492 from
I.F.Lab,
8 76742 from Maybridge,
9 104854 from Otava,
10 230358 form Specs,
11 4333
form Aurora,
12 271670 form IBS.
13
Each compound was represented by a fingerprint of 3PP pharmacophores using
MOE version 2004.05.
14 The individual 3PP pharmacophore is a triangle. We considered
all possible triangles with their vertexes located at atom centers. Presence or absence of a
certain triangle defines the one or zero state of the corresponding bit of the fingerprint.
Triangles were distinguished by the type of atom at vertexes and by the path length of
their edges. The vertex can be either donor (D) and planar (Dpl), acceptor (A) and planar
(Apl), polar (P), or hydrophobic (H) and planar (Hpl) as defined by the atom-types
implemented in MOE.
15 Lengths of the edges were calculated along the molecular graph,
no estimation of the 3D structure of molecule was performed at this stage.
Support Vector Machine
For constructing SVM models we used the SVM-light package.
16 The detail
description of the SVM theory can be found elsewhere.
17 The prediction of a trained
SVM is given by the following equation (Eq. 1):
b K f
i
sv
i i + = ) , ( ) ( x x x α , where 5 ) 1 ) (( ) , ( + • = s K y x y x . (1)
The greater f the higher is the probability for a compound to be active. x and y are
molecular fingerprint vectors, x
sv are support vectors, i.e. molecular fingerprints that
define the exact shape of the separating SVM hyperplane. The kernel function K defines
the complexity of the surface that will be constructed. We used a fifth order polynomial
kernel for all SVM models. Kernel parameter s was optimized to achieve improved
ranking of compounds.
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SVM for enrichment optimization
Binary classification described above cannot be directly applied to the selection of
compounds for the lead based drug design due to the fact that in SVM training we are
trying to construct hyperplane that separates active compound from the inactive ones. But
our aim is to construct the ranking criterion that ranks our screening collection in
accordance to the similarity to the reference set of active molecules. To certain extent180
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SVM model fulfills this requirement. If this SVM model was constructed by trying
separate active compounds and the screening collection, then distance to the separating
hyperplane might be the measure for predicting activity of the query molecule. If we take
a query compound and wish to check its similarity to the reference set, we might first
evaluate its position with respect to the separation plane of the SVM model. The closer
the molecule to the separating surface the larger is its probability to be active.
In order to directly optimize the efficiency of ranking we have optimized the
percentage of active molecules found within first 0.1% of the ranked non-class subset.
The parameters of SVM are normally tuned by cross-validation.
19 During cross-
validation we tried to bring the percentage of active molecules in the first 0.1% percent of
the data to the maximum. Namely, the active set of compounds was divided into four
non-overlapping subgroups. Every such subgroup was consequentially removed from the
active set, and the rest of the molecules formed four class subsets, the removed subgroups
were consequently mixed with the screening collection, forming four non-class subsets.
These pairs of class and non-class subsets were used as a training pairs for four SVM.
After training non-class subsets were used as validation sets: we ranked compounds from
these sets with respect to the distances to the corresponding SVM planes and check how
many ‘mixed’, known actives were found within first 0.1% of the data. As it has been
described above, these active molecules have been mixed with our screening collection
prior to the training. It allowed us to validate how efficient our trained SVM in defining
chemical space where active molecules were laying: the more “hidden” actives, active
molecules that were marked as belonging to the non-class subsets, are found in the first
0.1% of the ranked screening collection the better SVM was trained. Parameters for SVM
were optimized to produce maximal average actives in 0.1% of the ranked compounds in
four validation sets.
After optimizing SVM parameters by cross-validation we trained final SVM
model using as class all active molecules and as non-class all compounds from the
screening collection. We trained SVM with parameters determined during cross-
validation. Then we ranked screening collection with respect to the distances of
molecules to the separating hyperplane of the obtained SVM model. We would expect
new active molecules to be in the top of this list.
The logic behind it is simple. Let us assume that our screening set contains some
active molecules. During SVM training these active molecules were labeled as non-class.
It exactly mimics cross-validation optimization at training, where part of the active
molecules was mixed with the non-class compounds. Recalling, that we are now training
SVM with parameters optimized to predict these non-class actives to lay in the top of the
ranking list we were concluding that our trained SVM was optimal.
Active Learning
As we have briefly described above, the idea of active learning is to sample better
the important chemical space near the margin separating active compounds from
compounds to be screened. After the training of the SVM with the randomly selected
non-class set we need to decide which molecules should be picked up for the next
focused non-class data set. From the theory of SVM it is known that only vectors that are
lying within the separating margin created by SVM are responsible for the position of this
hyperplane.
20 It means that moving vectors that are not within the separating margin does
not influence its position unless they appeared to move into the margin.181
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We have checked all compounds that need to be screened for their position
relative to the margin, created by SVM trained with the random non-class data set. For
the subsequent training only compounds that are lying within the SVM margin were
taken. It is done because only these compounds should influence and probably modify the
position of the new separating hyperplane according to the SVM theory.
Explicitly we are taking to the second sample set only compounds whose vectors
fulfill the condition:
1 ) ( − ≤ x f , where 1 ) , ( ) ( ≤ + = b K f
i
sv
i i x x x α and 5 ) 1 ) (( ) , ( + • = s K y x y x (2)
These are potential support vectors.
Results and Discussion
Our results indicate that active learning might be very useful in virtual screening:
for some targets active learning improves efficiency of screening 10-20 times, for the
majority of the targets efficiency improves several fold, for one set no improvement was
observed (Table 1). This might be explained by the assortment of features considered
during selection of the two non-class subsets. During selection of the first non-class set
molecules were picked up from all over the available chemical space and SVM was
concentrating on features that distinguish active molecules from other molecules in
general. During selection of the second non-class set, molecules were picked up relatively
close to the reference set of active compounds: this area was sampled more intensively,
which allowed grasping the structure of the chemical space there better. An example of
this procedure is shown in Figure 1. When the first non-class set was collected it might
happen that no compounds were taken from the “near hyperplane” subspace Figure 1. In
this case separating surface might be constructed in a way that all compounds from the
“near hyperplane” subspace were predicted to be active. This error might be easily
corrected provided that the area in the border region was sampled better. That was
achieved during second screening. It was very unlikely that we had picked up only a few
samples from this “near hyperplane” region, because we were picking up samples
directly from there. This is clearly illustrated in Figure 1. “Near hyperplane” region is
significantly better represented in the second non-class set, although the sizes of the first
and second non-class sets could be comparable.
Several factors influence the efficiency of the active learning. The most important
to our opinion is the size and diversity of the active training set. If active set is relatively
small and very diverse then rough estimation of separating surface from the random non-
class sample set and more precise estimation from the focused second non-class sample
set produce similar results. It happens due to the fact that extensive sampling of the
chemical space of the screening collection in the neighborhood of the active set is
compensated by insufficient sampling of the space of the active compounds.
Here we illustrate results of active learning by observing top ranked compounds
before and after its application. On Figure 2 and 3 we show top ranked compounds for
Thrombin inhibitors and HIV protease inhibitors before and after application of active
learning. For the Thrombin inhibitors compounds in Figure 2a and b fulfill Thrombin
pharmacophore, but the compounds after second selection looks significantly better. They
are smaller and more ‘drug-like’. The same applies to the HIV inhibitor prospective
compounds. A of lot features that unlikely to be present in a prospective compounds are182
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observed only after the first ranking. The molecules are too large and might bind
unspecific ally.
The success of the active learning might be also explained differently. Let us
assume that active set of compounds contains certain well defined Feature A. Trying to
extend Feature A by adding others active features when separating first non-class subset
from the active subset will not improve the classification accuracy. It happens because
considering feature A alone is sufficient to distinguish active molecules from the random
set: probability of observing feature A in a non-class sample set is very low and adding
extra active set specific feature simply will not improve the classification of the training
set. On the other hand when we are considering focused second non-class subset
observing feature A is not that rare. In this case its presence is not an absolute criterion
for the molecule to be active and looking at other features can be very useful. This is
done during second SVM training with the more focused non-class data set.
Probably the same principle of feature extension can be applied to COX2
inhibitors. Here the obvious key feature is “micky mouse”-like structure Figure 4. This
substructure is present in most of the COX2 inhibitors. During first screening the part of
the “micky mouse”-like feature could be used as a criterion to predict active molecules.
During the second screening this feature could be extended to the complete “micky
mouse”-like substructure.
In a few cases active learning failed to improve classification accuracy. For the
DPP-IV inhibitors active learning strategy did not improve the quality of prediction. We
might assume that although DPP-IV inhibitors are very diverse almost all compounds
share very small number of distinctive features. It would be obvious for SVM to consider
these features as specific for DPP-IV targeted molecules. With random non-class sample
set from screening compounds the weight of these feature will be extremely high. If
ignoring these very specific features DPP-IV compounds are very diverse and probably
concentrating on the available compounds that has these feature will not help to find
other DPP-IV specific features. It might be a probable explanation of the failure of the
active learning for this set.
More difficult is to analyze the performance of active learning for the set of MMP
inhibitors. Molecules from this set are extremely diverse. By looking at the molecules it
difficult to find feature specific for this type of compounds. But we believe that the same
principle that leads to success of application of active learning for ACE and COX2
inhibitors can be applied here. By definition SVM model is probabilistic model with a lot
of fuzzy features that can be considered. Probably instead of picking up single, set
specific feature, a probabilistic model was constructed. And when the second focused set
of sample compounds was selected probabilistic model was fine tuned by extending
features that constitutes it.
The aim of lead based drug design is identification of the new compound that has
the same biological activity but structure significantly different from the structures of the
active reference set. In order to obtain such structures we should go down in the ranked
list of available compounds. These compounds fulfill SVM model only to certain extent.
After selecting and testing new structure it would be very useful to include their activity
measured data into the new training set. That might be further extension of the active
learning strategy.
In this paper we have demonstrated that active learning optimization might be
very useful for lead-based drug design.183
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Legends to figures
Table 1. Enrichment factors for different classes of target molecules.
In this Table the enrichment factors for different targets with and without application of
the active learning concept is shown. It demonstrates that we need to screen on average
ten-fold less compounds to collect the same number of active, if Active learning concept
is applied. Here part of the active set was mixed with the screened database, and then
later used as blind validation for estimation of the number of actives it the top ranked
compounds.
Table 2. Number of the violations of the Lipinsky “rule of five” within 40 top
ranked compounds before and after application of Active learning. For the 40 top
ranked compounds from the screening collection number of violations of the Lypinsky
“rule of five” was counted. Calculations were performed for the prospective ligands to
Thrombin and HIV protease.
Figure 1. Active learning concept illustration
Figure 2. Top ranked prospective Thrombin inhibitors. The IDs and the suppliers of
compounds are given below.
a) Prior to application of Active Learning. 1 - 17000000771 (ASDI), 2 –
17000000792 (ASDI), 3 - STOCK1N-05985 (IBS), 4 - STOCK1N-09898 (IBS),
5 - STOCK1N-31574 (IBS)
b) After application of Active learning. 1 - STOCK1N-18090(IBS), 2 - STOCK1N-
05985, 3 – 0125160218(Otava), 4 - F1111-0007(I.F.Lab), 5 - A1354/0061103
(Ambinter)
Figure 3. Top ranked prospective HIV-reverse-transcriptase inhibitors. The IDs and
the suppliers of compounds are given below.
a) Prior to application of Active Learning. 1 - STOCK1N-03364 (IBS), 2 -
STOCK1N-39006 (IBS), 3 - STOCK1N-04177 (IBS), 4 – 5103028 (Chembridge),
5 – 17000000771 (ASDI)
b) After application of Active learning. 1 - K784-690 (ChemDiv), 2 - CHS_0158841
(ChemStar), 3 - STOCK1N-37906 (IBS), 4 - STOCK1N-23631 (IBS), 5 -
BAS_0380378 (Asinex)
Figure 4. COX2-inhibor pharmacophore
This figure shows graph of chemical features which are typical for COX2 inhibitors.
.184
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Table 1
Name Enrichment (before Active learning) Enrichment (after Active learning)
ACE 61.36% ± 8.6% of act. in top 0.2% 61.36% ± 8.6% of act. in top 0.0092% (21.6 times)
COX2 80.75% ± 5.92% of act. in top 0.1% 80.75% ± 5.92% of act. in top 0.0031% (32.1 times)
CRF_Antag. 82.6% ± 5.77% of act. in top 0.1% 82.6% ± 5.77% of act. in top 0.012% (7.9 times)
DPP-IV 88.69% ± 14.1% of act. in top 0.1% No improvement
HIV_Protease 98.33% ± 3.3% of act. in top 0.45% 98.33% ± 3.3% of act. in top 0.027% (16.6 times)
Hormone 73.46% ± 1.35% of act. in top 0.1% 73.46% ± 1.35% of act. in top 0.032% (3.06 times)
NK 85.5% ± 7.04% of act. in top 0.1% 85.5% ± 7.04% of act. in top 0.030% (3.23 times)
PPAR 71.51% ± 14.04% of act. in top 0.1% 71.51% ± 14.04% of act. in top 0.031% (3.25 times)
Thrombin 54.78% ± 13.9% of act. in top 0.45% 54.78% ± 13.9% of act. in top 0.083% (5.4 times)
GPCR 46% ± 8.1% of act. in top 0.45% No improvement
MMP 90% ± 9.2% of act. in top 0.1% 90% ± 9.2% of act. in top 0.0044% (22.7 times)185
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Table 2.
Number of violations of the “rule of five” Ligands to Screening
< 0 < 1 < 2 < 3
Prior to Active learning 4 24 32 40 Thrombin
After Active learning 13 27 37 40
Prior to Active learning 5 14 25 38 HIV
protease After Active learning 9 27 39 40186
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Figure 1.
Active Compounds
Active learning
enriched set from
available
compounds
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Figure 3
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